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ABSTRACT 
The acute effects of exercise on appetite, ad libitum energy intake and gut hormone responses 
have received much attention over the past two decades. The experiments in this thesis have 
contributed to this research by examining appetite, acylated ghrelin, peptide-YY (PYY), 
leptin and ad libitum energy intake responses to two consecutive days of moderate-high 
intensity running. To achieve this 15 individuals aged 21 (2) y, with a BMI of 23.0 (1.9) 
kg·m
-2
 were recruited. Additionally, appetite, acylated ghrelin, PYY, glucagon-like peptide-1 
(GLP-1), and ad libitum energy intake responses to an acute bout of moderate intensity 
treadmill exercise were compared in lean and overweight/obese (ow/ob) males and females. 
Two separate cohorts of individuals were recruited; 22 lean individuals and 25 ow/ob 
individuals (aged 38 (15) and 45 (12) y, with a BMI of 22 (2) and 29 (3) kg·m
-2
, for lean and 
ow/ob individuals, respectively). 
In Chapter 4, two consecutive days of 60 min treadmill running at 70% V̇O2 peak did not 
produce compensatory changes in appetite or energy intake over two days. There were no 
main effects of trial for acylated ghrelin or leptin. However a main effect of trial for PYY 
indicated higher concentrations on the exercise than control trial. A meta-analysis was 
completed in Chapter 5, suggesting further research in the effects of acute exercise on 
appetite regulatory hormones in individuals who are ow/ob was necessary. In Chapter 6, 60 
min of treadmill exercise at 60% V̇O2 peak did not alter appetite sensations or energy intake 
in the 7 h after exercise in lean and ow/ob males and females. There were no main effects of 
sex, BMI or trial for acylated ghrelin; however, PYY and GLP-1 concentrations were higher 
in exercise than control trials. 
This thesis has demonstrated that over two days, high volume exercise does not stimulate 
compensatory appetite regulatory changes, in lean healthy males. In the short term, lean and 
ow/ob males and females respond similarly to acute exercise, showing no alterations in 
appetite or food intake responses, whilst PYY and GLP-1 concentrations are higher in 
exercise than control trials. 
Key words: exercise, appetite, energy intake, energy balance, compensations, acylated 
ghrelin, peptide-YY, glucagon-like peptide-1, hormones.  
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CHAPTER I 
Introduction 
Obesity is defined as an abnormal or excessive accumulation of fat, which may impair health 
(WHO 2016). Body mass index (BMI), a product of weight in kilograms divided by height in 
metres squared, is commonly used to stratify body size. Specifically, those with a BMI equal 
to or greater than 25 kg·m
-2
 are classified as overweight, and those with a BMI more than or 
equal to 30 kg·m
-2 
are classified as obese. In 2014, it was estimated that there were more than 
1.9 billion overweight adults worldwide, of whom 600 million were obese (WHO 2016). 
Overweight and obesity negatively impacts morbidity, disability and quality of life. In 
particular, increased BMI increases the risk of cardiovascular disease, type 2 diabetes, 
musculoskeletal disorders (i.e. osteoarthritis) and some cancers (including endometrial, breast, 
ovarian, prostate, liver, gallbladder, kidney, and colon (Bray 2004)). 
Within the UK, the issue of overweight and obesity is just as pervasive. In 2014, 
approximately a quarter of adults were classified as obese, with estimations expecting this to 
rise to over 50% of the population by 2050 (HSCIC 2015). Obesity is thought to cost the 
UK’s wider economy £47 billion a year, second only to the costs of smoking. Notably, there 
are direct costs to the NHS for treating overweight and obesity, costs to produce and supply 
obesity medication, provision of social care and the impact of obesity attributed sick days 
(Public Health England 2015). 
Obesity is a result of sustained positive energy balance, whereby energy consumed outweighs 
that expended in metabolic processes and physical activity, over time. The soaring prevalence 
in overweight and obesity is a repercussion of recent population wide behavioural changes; 
for example, ease of access to energy dense foods, increased physical inactivity through the 
sedentary nature of work and transportation and increased urbanisation (WHO 2016). 
Physiologically, energy balance and body weight are controlled by a plethora of gut, adipose 
and pancreatic derived substrates. These can be subdivided into those that regulate energy 
intake and energy metabolism on an acute or chronic basis (Murphy & Bloom 2006). 
Specifically, over the long-term, insulin and leptin suppress appetite and increase energy 
expenditure. Whilst, gut hormones including ghrelin, peptide-YY (PYY) and glucagon-like 
peptide-1 (GLP-1), regulate energy intake on a meal-to-meal basis. Ghrelin, is appropriately 
dubbed the ‘hunger hormone’, a unique peptide responsible for appetite stimulation and is 
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consequently thought to initiate a bout of eating. Conversely, PYY and GLP-1 are satiety 
hormones, concentrations rise in response to feeding, causing an individual to feel full and 
stop eating. These physiological mechanisms responsible for controlling appetite are 
dysfunctional in obese individuals, increasing susceptibility to over-eating and generation of 
a positive energy balance. Particularly, circulating concentrations of acylated ghrelin are not 
as effectively suppressed after meals and postprandial concentrations of PYY and GLP-1 are 
attenuated in comparison to lean individuals (Batterham et al. 2006; le Roux et al. 2006; 
Morpurgo et al. 2003). The feelings of reduced fullness and satisfaction associated with these 
hormone patterns, promotes food consumption and consequently the generation of a positive 
energy balance in this population. 
These findings initiated research into drug treatments that could imitate the body’s own 
regulatory signals and pathways (Field et al. 2009). To date, these have been largely 
unsuccessful due to efficacy and safety concerns. The only safe obesity drug recognised and 
prescribed in England, Orlistat, had a net cost of £15.3 million in 2014 (Baker & Bate 2016). 
Clearly, this outgoing cost is not sustainable, and as obesity is largely preventable, the 
identification of a more natural, effective and cheaper resolution to the overweight and 
obesity epidemic would be favourable. As a result, the government has begun to implement 
initiatives to encourage healthy food choices and regular physical activity. Current UK 
physical activity guidelines state individuals should aim to complete 150 min of moderate 
intensity exercise (Department of Health 2011). However, despite the government’s best 
efforts, only 67% of men and 55% of women were reported to meet these guidelines in 2012 
(Health Survey for England, 2012). The ACSM position stand furthers these guidelines, 
suggesting that 150 min of moderate intensity exercise is only enough to prevent weight gain 
(Donnelly et al. 2009). To help achieve modest weight loss, the position stand recommends 
that individuals complete 150-250 min of moderate intensity exercise per week. It is 
suggested that further increasing activity (>250 min per week) can result in clinically 
significant weight loss. 
On the other hand, an energy deficit to help induce weight loss can also be achieved by 
energy restriction (i.e. dieting). “Fad” diets have risen in popularity concurrently with the 
overweight and obesity epidemic. In particular, low calorie, low carbohydrate, low fat and 
high protein diets have all received attention in recent years. Indeed, it has been reported that 
following such diets can lead to weight loss in the short term (Dansinger et al. 2005). 
However, it is often reported that dieting alone is unsuccessful in the long run, with weight 
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regain occurring in the majority of individuals (Lowe 2015). Conversely, others regard 
increased physical activity as the most valuable behaviour change to prevent and manage 
overweight and obesity. The associated health benefits of exercise (i.e. reduced risk of 
developing cardiovascular disease, type 2 diabetes, dementia and some cancers (King et al. 
2008; Shaw et al. 2006)) has led to public health authorities advising the population to 
increase physical activity. Exercise training studies have shown that by increasing physical 
activity, weight loss can be achieved (Garrow & Summerbell 1995; Shaw et al. 2006; Wing 
1999). However, in many cases the degree of weight loss achieved with exercise is less than 
predicted, perhaps a result of compensatory appetite responses (Church et al. 2009; King et al. 
2008). Total weight loss is often used as an indicator of weight management; however, this 
can be misleading. For example, during an exercise training programme it might be expected 
for fat mass to be reduced and fat free mass to be increased. Consequently, total body weight 
may remain stable or even increase. However, in caloric restriction both fat and fat free mass 
could be reduced, showing a drop in total weight. In this example, using total weight as a 
measure of effectiveness would suggest that exercise training is less effective for weight 
management. Instead, body composition measures could be more informative as an indicator 
for weight management. It is likely that both diet and exercise need to be considered to 
accomplish and sustain successful weight loss and management. Public health authorities and 
the advertising industry should work hand in hand to help individuals make lifestyle changes 
towards ‘healthier choices’, particularly, choosing low sugar options and increasing physical 
activity. 
The emphasis on increasing physical activity to help prevent weight gain and induce weight 
loss has sparked research into exploring the mechanisms controlling appetite, energy balance 
and exercise. To date, training studies lasting 4-12 months have found exercise to be 
unsuccessful for long-term weight loss (Hopkins et al. 2014; King et al. 2007; Wing 1999). 
This was explained by compensatory increases in appetite and food intake. On the contrary, 
compensatory responses are not seen after acute exercise, with no influence on energy intake 
(Schubert et al. 2013). It is possible that the compensatory responses of subjective appetite 
sensations and ad libitum energy intake to exercise occur over a longer duration than 
previously examined in acute laboratory studies i.e. over more than 24 h. However, extending 
this observation period up to 34 h, has still failed to show any alterations in ad libitum energy 
intake despite latent increases in hunger and motivation to eat after exercise (Beaulieu et al. 
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2015; Heden et al. 2013). Further research is required to extend upon these initial findings, to 
ascertain when compensation begins and to better understand the regulatory mechanisms. 
With this is mind, the importance of exercise, appetite and weight management is not 
restricted to those who are overweight or obese. This also bears great significance to elite 
athletes seeking optimal body weight for performance. Matching an athlete’s energy needs 
will not only help to maintain body weight required for competition, but also optimise 
training effects. Where energy intake is not adequate, muscle mass may be reduced, 
sensations of fatigue increased and as a result performance can suffer (Brouns 1992). It is 
therefore important to understand how the appetite regulatory system responds to an elite 
athlete’s training regime, in particular repeated bouts of intense exercise, so that energy 
intake and body composition can be tightly regulated. 
Subjective appetite perceptions, appetite regulatory hormone and ad libitum energy intake 
responses to acute exercise have mainly been examined in lean active males. Considering the 
implications that appetite responses to exercise have on the wider population, especially in 
individuals who are overweight and obese, research has begun to broaden to determine if the 
favourable effects of acute exercise on appetite translate into those who suffer from impaired 
appetite regulation. The findings in these initial studies have been divided, and further study 
is required to determine the efficacy of exercise in appetite regulation in this population. 
Similarly, there is little work examining the responses of appetite perceptions, appetite 
regulatory hormone and ad libitum energy intake in females. This is likely due to the 
difficulties associated with controlling for the menstrual cycle. In particular, changes in the 
concentration of progesterone and estradiol could lead to females increasing their energy 
intake and/or energy expenditure during certain phases of the menstrual cycle. If sex-based 
differences in appetite regulatory responses to exercise were found, the prescription of 
physical activity and dietary based recommendations given by health authorities would need 
to be adapted to ensure the efficacy of weight loss and maintenance regimes. 
Therefore, the aims of this thesis are threefold; 
 To investigate the effect of a single bout of exercise on appetite regulatory hormone 
responses in lean vs. overweight/obese (ow/ob) males and females 
 To investigate the effect of a single bout of exercise on subjective appetite perceptions 
and ad libitum energy intake responses in lean vs. ow/ob males and females 
5 
 To further examine where compensatory appetite regulatory hormone, subjective 
appetite perceptions and ad libitum energy intake responses begin after a bout of acute 
exercise. 
It was hypothesised that in the hours after a bout of acute treadmill exercise, males and 
females who are lean and ow/ob would express similar appetite perceptions, energy intake 
and appetite regulatory responses. It was also hypothesised that two consecutive days of 
treadmill running, in lean healthy males, would generate a compensatory increase in appetite 
perceptions, energy intake and acylated ghrelin on the second day of exercise. Simultaneous 
compensatory decreases in circulating PYY and leptin would also be seen.  
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CHAPTER II 
Literature Review 
2.1. Introduction 
This literature review will discuss the effects of acute exercise on subjective appetite 
perceptions, energy intake and appetite regulatory hormones in both lean and ow/ob 
individuals. The review will initially describe the components of energy balance and look at 
the gastrointestinal regulation of appetite and energy intake. Particular attention will be given 
to ghrelin, PYY, GLP-1 and leptin due to the significant attention they have received for their 
role in the hormonal regulation of appetite. Thereafter, the acute effects of exercise on 
subjective appetite perceptions, energy intake and appetite regulatory hormones in lean and 
ow/ob individuals will be examined.  
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2.2. Energy balance 
Energy balance describes the relationship between energy intake and energy expenditure. The 
human body conforms to the first law of thermodynamics, which states that energy cannot be 
created or destroyed. When a positive imbalance exists between energy intake and utilisation, 
excess energy can be stored. On the other hand, when a negative imbalance exists between 
energy intake and utilisation, energy stores will be utilised. If either is sustained over time, 
this will lead to an alteration in body composition. To help recognise what is required to lose 
or maintain weight, it is important to understand the components of energy balance. 
Energy intake describes the chemical energy consumed from food and beverages, specifically, 
carbohydrate, fat, protein and to a lesser extent alcohol (Hall et al. 2012). The energy 
densities of these macronutrients are 4 kcal·g
-1
 (17 kJ·g
-1
) for carbohydrate and protein, and 9 
kcal·g
-1
 (38 kJ·g
-1
) for fat (Hall et al. 2012). This energy is used to fuel metabolic processes, 
but when consumed in excess of that required will be stored. 
Rate of energy expenditure is highly variable, showing fluctuations across 24 h periods, and 
across a lifetime. Total energy expenditure is made up of resting energy expenditure (REE), 
dietary induced thermogenesis (DIT) and activity energy expenditure (AEE). REE is the 
largest component of energy expenditure, and accounts for approximately two-thirds of total 
energy expenditure (Hall et al. 2012). Specifically, this describes the energy required to keep 
the body functioning at rest, and includes processes such as breathing, control of body 
temperature and cell growth. There are huge variations in REE between individuals, dictated 
by body size and composition (Johnstone et al. 2005). On the other hand, DIT is the smallest 
contributor to total energy expenditure. This is the energy used to digest and absorb food and 
beverages. Again, DIT is varied between and within individuals. The macronutrient 
composition of ingested food and drink impacts the degree of energy required to digest and 
absorb these. Specifically, for isocaloric amounts of protein, carbohydrate and fat, protein 
utilises the most energy whilst fat utilises the least. Finally, AEE describes the energy 
required for physical activity, and is determined by body movement and body size. AEE is 
largely determined by an individuals want or wish to exercise, and consequently varies 
largely between individuals. 
When an individual consumes more energy than that required for these obligatory processes 
and AEE, over time, obesity develops. Conversely, to induce weight loss, a negative energy 
balance must be maintained.  
8 
2.3. Gastrointestinal regulation of appetite and energy intake 
2.3.1. Ghrelin 
2.3.1.1. Discovery 
In 1999, Kojima and colleagues identified ghrelin as the endogenous ligand for the growth 
hormone secretagogue receptor (GHS-R). The name ghrelin is derived from ‘ghre’, the Proto-
Indo-European root of the word ‘grow’, characterising its role in the release of growth 
hormone. 
2.3.1.2. Structure, production and regulation of secretion 
Ghrelin is a 28 amino acid peptide, formed by the cleavage of preproghrelin, a larger 
precursor molecule (Kojima et al. 1999). Ghrelin is predominantly synthesised in the 
enteroendocrine X/A cells or “ghrelin cells” found in the mucosal layer of the stomach 
(Kojima & Kangawa 2005). These cells are also found within the intestine, but at lower 
concentrations to that in the stomach, with their presence continuing to decrease from the 
duodenum to the colon (Ariyasu et al. 2001; Kojima & Kangawa 2005; Peeters 2005). 
There are two forms of ghrelin found within the circulation; acylated and desacylated. In its 
acylated form, the serine 3 residue is n-octanoylated. Here octanic acid is bound to the third 
amino acid residue (serine) via an ester bond (Figure 2.1 (Sato et al. 2012)). This process is 
catalysed by the enzyme ghrelin O-acyltransferase (GOAT), and allows ghrelin to cross the 
blood brain barrier and act on receptors in the brain (Yang et al. 2008). In particular, acylated 
ghrelin binds to and activates the growth hormone secretagogue receptor (GHSR-1a) 
stimulating hormone secretion, anabolic effects, gastric and cardiovascular function (Kojima 
& Kangawa 2005). The n-octanolyation at serine 3 is essential for ghrelin to bind to 
GHSR-1a and to activate this receptor (Kojima et al. 1999). For this reason, desacylated 
ghrelin was initially considered to be inactive. However, recent evidence suggests 
desacylated ghrelin can increase insulin sensitivity, improve glucose metabolism and inhibit 
lipid metabolism in humans (Delhanty et al. 2012). In some cases, desacylated ghrelin has 
been shown to antagonise the effects of acylated ghrelin (Broglio et al. 2004). 
In human plasma, normal concentrations of acylated ghrelin are 34-67 pg·mL
-1
 and 337-
506 pg·mL
-1 
for total ghrelin (acylated and desacylated ghrelin (Kojima & Kangawa 2005)). 
It is thought that ~90% of ghrelin in the circulation is desacylated because; there is a high 
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ghrelin to GOAT ratio within ghrelin secreting cells (Yang et al. 2008), and esterases present 
in the circulation breakdown the ester bond needed for acylation (Satou et al. 2010). The 
disproportional concentrations of acylated and desacylated ghrelin in the circulation could 
mean measuring total ghrelin may mask any effects caused by the acylated form. 
 
 
 
 
 
 
 
 
Figure 2.1. The structure of acylated ghrelin. Adapted from Sato et al. 2012. 
Feeding is considered the most important factor in the regulation of ghrelin secretion. Plasma 
concentrations rise pre-prandially and fall after a meal (Cummings et al. 2001). This diurnal 
pattern and correlation with sensations of hunger has led to the suggestion that ghrelin plays a 
role in meal initiation (Cummings et al. 2001; Cummings et al. 2004). 
The mechanisms behind the release of ghrelin in response to meals are unclear (Hosoda et al. 
2006; Yin et al. 2009). Nutrient sensing appears to play a role, as the calorie and 
macronutrient content of a meal influences ghrelin secretion into the circulation (Callahan et 
al. 2004; Koliaki et al. 2010; Leidy & Williams 2006). Carbohydrates cause the highest 
degree of ghrelin suppression, with fats and protein being less effective (Erdmann et al. 2004; 
Monteleone et al. 2003). Despite this, protein is considered to be the most satiating 
macronutrient, as it generates a prolonged suppression of ghrelin in the postprandial state 
compared to balanced and high fat meals (Al Awar et al. 2005). Prolonging ghrelin 
suppression could increase time between meals by sustaining lower sensations of hunger and 
consequently reduce energy intake. Lipids appear to be the least effective macronutrient at 
postprandial ghrelin suppression, with consumption of high fat meals causing smaller 
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decreases in post-prandial ghrelin concentrations compared to high carbohydrate or high 
protein meals (Foster-Schubert et al. 2008; Monteleone et al. 2003; Tentolouris et al. 2004). 
Several mechanisms have been proposed to explain why macronutrients differ in their 
effectiveness at suppressing ghrelin after a meal. Foster-Schubert and colleagues (2008) 
suggested that the rapid decreases seen in acylated ghrelin concentrations after high 
carbohydrate feeding could be caused by the fast gastric emptying rates associated with these 
meals. Furthermore, the shorter lived suppression of acylated ghrelin caused by 
carbohydrates could be due to the rapid breakdown and reabsorption of these molecules. 
Insulin may also contribute to the ghrelin response (Foster-Schubert et al. 2008; Yin et 
al. 2009). The pattern of ghrelin secretion is reciprocal to that of insulin, which is seen to be 
low before a meal and rises postprandially (Cummings et al. 2001). The poor ability for lipids 
to stimulate insulin secretion could explain the attenuated ghrelin profile in response to fat 
consumption (Foster-Schubert et al. 2008). The effects of gastric distension on circulating 
ghrelin concentrations have been dismissed. Comparing water ingestion to oral glucose 
administration showed that water alone could not alter ghrelin concentrations. This implies 
that mechanical distension of the stomach does not stimulate ghrelin release (Sato et al. 2012; 
Shiiya et al. 2002). 
2.3.1.3. Physiological functions and mechanisms of action 
Ghrelin is commonly known for its unique characteristic as an orexigenic hormone, 
stimulating appetite when circulating concentrations are high (Druce et al. 2006; Wren 
2001a). However, ghrelin has many other physiological functions that affect both the central 
and peripheral systems (Figure 2.2). In particular, ghrelin influences hormone secretion, 
anabolic reactions, gastric and cardiovascular function. Ghrelin is responsible for stimulating 
the release of growth hormone from the anterior pituitary by binding to GHRS-1a (Kojima et 
al. 1999). Ghrelin has also been shown to increase glucose concentrations and decrease 
insulin concentrations within the blood (Broglio 2001; Delhanty & van der Lely 2011). 
Anabolic effects include stimulating adiposity and increasing appetite (Wynne et al. 2005b). 
Cardiovascular functions include increasing cardiac index and stroke volume, raising cardiac 
output, and decreasing mean and diastolic blood pressure (Hosoda et al. 2006; Nagaya et al. 
2001). In addition, ghrelin alters gastric functions by increasing gastric acid secretion and 
stimulating gastric mobility and gastric emptying (Hosoda et al. 2006; Levin et al. 2006). 
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Figure 2.2. Physiological functions of ghrelin (adapted from Davenport et al. 2015). VTA, 
ventral tegmental area; GI tract, gastrointestinal tract. 
Centrally, ghrelin is found within the hypothalamus (Kojima & Kangawa 2005). In particular 
ghrelin is found within the arcuate nucleus (ARC) (Kojima et al. 1999), a region of the brain 
responsible for appetite control. Ghrelin causes its orexigenic effects by stimulating 
neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the hypothalamus. This 
causes the release of NPY and AgRP which increases appetite (Sato et al. 2012). 
2.3.1.4. Acute energy regulation 
Ghrelin infusion studies have been conducted in both rodents and humans in an attempt to 
understand its role in stimulating appetite. Intracerebroventricular and intraperitoneal infusion 
of ghrelin in rats caused dose dependent increases in food intake, weight gain and adiposity 
(Nakazato et al. 2001; Shintani et al. 2001; Tschöp et al. 2000; Wren et al. 2000; Wren et al. 
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2001b). Decreased fat utilisation was also observed, potentially contributing to the increase in 
adiposity (Tschöp et al. 2000). Similarly, ghrelin infusion in humans, sufficient to generate 
supra-physiological concentrations of circulating ghrelin, increased hunger and energy intake 
in a dose dependent manner (Akamizu et al. 2004; Druce et al. 2006; Huda et al. 2009; Neary 
et al. 2004; Wren 2001a; Wynne et al. 2005b). In normal weight males and females 
intravenous infusion of ghrelin (5 pmol·kg·min
-1
, causing supra-physiological concentrations) 
for 75 min increased energy intake by 20% at an ad libitum buffet meal whereas obese 
individuals showed an increase of 70% (Druce et al. 2005). This suggests ghrelin is an 
appetite stimulator and ghrelin antagonists may be useful in therapeutic treatments for obesity. 
2.3.1.5. Chronic energy regulation 
Ghrelin also seems to influence long-term body weight. In rats, repeated 
intracerebroventricular infusion of ghrelin causes hyperphagia and adiposity (Tschöp et al. 
2000; Wren et al. 2001b). Whereas, ghrelin deficient rats show a slower rate of weight gain 
when fed a high fat diet compared to those administered ghrelin (Wortley et al. 2005). 
Similarly, GHS-R null mice are resistant to diet induced obesity (Zigman et al. 2005). 
In humans, circulating ghrelin concentrations are negatively correlated with BMI (Shiiya et al. 
2002). Obese individuals express lower mean total plasma ghrelin and acylated ghrelin 
concentrations compared to their lean counterparts (Huda et al. 2009; Marzullo et al. 2008; 
Shiiya et al. 2002; Tschöp et al. 2001; Vendrell et al. 2004), whilst those with anorexia 
nervosa and bulimia nervosa show significantly higher circulating ghrelin concentrations 
(Otto et al. 2001; Shiiya et al. 2002; Tanaka et al. 2002; Tolle et al. 2003). Together these 
findings support the notion of ghrelin playing a role in chronic energy regulation, however it 
cannot be assumed that ghrelin is a mechanism for weight gain. In fact, ghrelin may make 
weight loss and its maintenance more difficult. After both diet and exercise induced weight 
loss, overweight and obese individuals have shown increased ghrelin concentrations 
(Cummings et al. 2002; Foster-Schubert et al. 2005; Hansen et al. 2002; Leidy et al. 2004), a 
finding associated with increased hunger and energy intake. 
2.3.1.6. Differences between lean and obese individuals 
Obese individuals express lower basal concentrations of circulating total and acylated ghrelin 
in comparison to their lean counterparts (le Roux et al. 2005; Marzullo et al. 2008; Shiiya et 
al. 2002; Tschöp et al. 2001). It is important to understand ghrelin’s sensitivity to body size 
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as it could be a factor in the pathogenesis of obesity. It has been suggested that obese 
individuals exhibit lower basal concentrations of ghrelin as a compensatory response to 
prevent further weight gain (Koliaki et al. 2010). As obesity is associated with insulin 
resistance and hyperinsulinemia, it could be this that causes the reduced circulating 
concentrations of ghrelin in obese individuals (McLaughlin et al. 2004; Tschöp et al. 2001). 
In obese individuals, the suppression of ghrelin after a meal is blunted (le Roux et al. 2005; 
Tentolouris et al. 2004). It is possible that this contributes to positive energy balance; failing 
to suppress appetite after a meal could consequently encourage further energy intake (Koliaki 
et al. 2010). Although expressing reduced circulating ghrelin concentrations, Druce and 
colleagues (2005) found obese individuals to remain sensitive to the effects of ghrelin. Both 
low (1 pmol·kg·min
-1
) and high (5 pmol·kg·min
-1
) dose ghrelin infusion caused increased 
energy intake in obese individuals. This implies that ghrelin receptor antagonists could be 
useful appetite reducing agents. 
2.3.1.7. Ghrelin as a remedy for obesity? 
Surgery is an effective method for the treatment of obesity; however, it is very impractical to 
implement on a large scale. Consequently, circulating hormones identified in the regulation 
of appetite have been targeted for the development of anti-obesity treatments. There was 
doubt over the effectiveness of targeting ghrelin in the treatment of obesity as obese 
individuals already express lower circulating concentrations of ghrelin than lean individuals. 
However, as obese individuals remain sensitive to the effects of ghrelin (Druce et al. 2005), 
research into ghrelin as a therapy continues. 
Several approaches have been used to target the ghrelin system to ameliorate obesity; 
antagonizing the ghrelin receptor, neutralizing circulating ghrelin and preventing production 
of ghrelin. It was hoped pre-prandial hunger could be suppressed by antagonizing ghrelin 
receptors (GHS-R1a) causing decreased circulating ghrelin concentrations. In obese rats, this 
treatment reduced body weight and improved glucose tolerance (Esler et al. 2007; Rudolph et 
al. 2007). However, no clinical trial has shown these to be successful as an obesity treatment 
in humans (Patterson et al. 2011). This would suggest that although ghrelin receptor 
antagonists are effective in rodent models, these have failed at later stages of 
testing/development. 
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By ‘neutralizing’ circulating ghrelin it was hoped the strength of the hunger signal could be 
reduced, restricting ghrelin from reaching and acting on receptors present in the brain 
(Patterson et al. 2011). In rats, this was achieved through an ‘anti-ghrelin’ vaccine, which 
initiated the development of antibodies against ghrelin (Zorrilla et al. 2006). Over 12 weeks 
of vaccination, the rats showed reduced weight gain, resulting from decreased feeding 
efficiency (body weight gained per unit energy intake). Again, when this vaccine was trialled 
in humans it was found to be ineffective (Cytos, 2006). 
Ghrelin needs to be acylated at the serine 3 residue in order for it to bind to its receptor, GHS-
R1a. GOAT is responsible for the acylation process (Gutierrez et al. 2008; Yang et al. 2008). 
In rats, GOAT inhibitors prevented acylated ghrelin production. When administered for a 
month, the rats showed reduced weight gain and fat mass in response to a high fat diet. Acute 
administration resulted in improved glucose tolerance and increased glucose stimulated 
insulin release. The rats used in this study were normal weight; consequently, these findings 
cannot be generalized to obese rats. The effectiveness of this treatment could also be limited 
by the already suppressed ghrelin concentrations observed in obese individuals. 
To date, results in humans have been discouraging (Cytos, 2006; Patterson et al. 2011). 
However, if a successful GOAT inhibitor can be replicated in humans, it could prove useful 
for treatment of obesity and type 2 diabetes.  
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2.3.2. PYY 
2.3.2.1. Discovery 
Peptide-YY was first isolated from upper small intestinal porcine tissues in 1980 (Tatemoto 
& Mutt 1980). PYY was given its name due to the presence of tyrosine (Y) residues at both 
ends of the molecule (Tatemoto 1982). 
2.3.2.2. Structure, production and regulation of secretion 
Peptide-YY is a 36 amino acid peptide, found in two forms in the circulation; PYY1-36 and 
PYY3-36. PYY3-36 is a truncated, 34 amino acid peptide produced from the cleavage of 
tyrosine and proline at the N terminal of PYY1-36. This reaction is catalysed by the enzyme 
dipeptidyl peptidase IV (DPP-IV (Mentlein et al. 1993)). The majority of PYY found in the 
circulation is PYY3-36 (Batterham et al. 2006), which is synthesised and released from 
endocrine L cells (Batterham et al. 2002; le Roux & Bloom 2005). L cells are present 
throughout the gut but are most abundant in the distal segments of the intestine, in particular 
the ilium and colon (Adrian et al. 1985). The surface of the L cell is partly exposed to the 
lumen of the intestine, allowing it to sense nutrients and other substances in the intestine. L 
cells are responsible for the secretion of both PYY and GLP-1, and circulating concentrations 
of these increase almost immediately after eating. The secretion of these hormones occurs 
before the nutrients will have reached the ilium, indicating that nutrient sensing by L cells is 
not the only mechanism to cause secretion of these hormones (le Roux & Bloom 2005). 
The structure of PYY is altered when the N terminal is truncated. Consequently PYY3-36 is 
only capable of binding to Y2 receptors whereas PYY1-36 can bind to all forms of the Y 
receptor (Karra et al. 2009). Consequently, PYY3-36 has a higher affinity for binding to Y2 
receptors; this difference in receptor preference is thought to be necessary for modulating its 
function. 
2.3.2.3. Physiological functions and mechanisms of action 
Peptide-YY acts as a satiety hormone; its release suppresses appetite after a meal and 
postpones the initiation of the next meal (Neary & Batterham 2009). In rodents, the infusion 
of PYY has been found to decrease food intake and body weight (Batterham et al. 2002; 
Challis et al. 2003; Chelikani et al. 2005; Martin et al. 2004; Pittner et al. 2004). Similarly, in 
humans a 90 min infusion of PYY (0.8 pmol·kg·min
-1 
and 2 nmol·kg
-1
) caused reduced 
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hunger and food intake, further implicating its role as a satiety hormone (Batterham et al. 
2002; Batterham et al. 2003). 
As well as acting as a satiety hormone, PYY also influences energy expenditure and fuel 
partitioning. In rodents, chronic administration of PYY3-36 resulted in a greater rate of fat 
oxidation (Adam & Westerterp-Plantenga 2004; van den Hoek et al. 2007). Similarly, in 
humans, peripheral administration of PYY3-36, adequate to generate supra-physiological 
circulating concentrations of PYY3-36, increased energy expenditure and fat oxidation (Sloth 
et al. 2007). Further to this, a negative correlation has been found between fasting PYY 
concentrations and 24 h respiratory quotient (Guo et al. 2006). Together these findings 
suggest that PYY could help regulate and induce weight loss by reducing food intake and 
increasing energy expenditure. 
Peptide-YY3-36 causes its satiety functions by acting on Y2 receptors in the ARC (Batterham 
et al. 2002). In particular, PYY3-36 modulates neuronal activity within the hypothalamus, 
brainstem, mid brain and areas of the brain related with reward and processing (Batterham et 
al. 2007). PYY is also thought to promote satiety through the ‘ileal brake reflex’ (Figure 2.3), 
whereby proximal intestine and gastric motor activity are inhibited slowing large amounts of 
nutrients reaching the distal intestine (Hussain & Bloom 2013). 
 
 
 
 
 
 
 
 
 
Figure 2.3. A diagram to show how the ileal brake mechanism influences hunger, food intake 
and the gastrointestinal tract. Adapted from Maljaars 2007. 
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Peripheral infusion of PYY has been shown to delay gastric emptying and inhibit secretions 
from the stomach, pancreas and gall bladder (Adrian et al. 1986). In addition to these effects 
on digestive function, PYY plays a role in vasoconstriction, with PYY infusion increasing 
both systolic and diastolic blood pressure (Adrian et al. 1986). 
2.3.2.4. Acute energy regulation 
Peptide-YY concentrations are decreased pre-prandially and are shown to increase after 
feeding, suggesting it has a role in satiety signalling (Karra et al. 2009). After a meal, plasma 
concentrations of PYY increase within 15 min and peak at approximately 60 min, staying 
elevated for 6 h (Adrian et al. 1985; Batterham & Bloom 2003). The amount of PYY released 
from the gut, and the peak concentration after a meal is proportional to calorie intake and 
macronutrient content of the meal (Adrian et al. 1985). Specifically, in humans, high protein 
meals are associated with larger postprandial increases in PYY (Batterham et al. 2006), 
potentially distinguishing PYY’s role in making protein a highly satiating macronutrient. 
The anoeretic effects of PYY were confirmed using infusion studies to induce physiological 
(Batterham et al. 2002) and supra-physiological (Batterham et al. 2003; Degen et al. 2005) 
concentrations in humans. When normal weight males and females were infused with PYY3-
36 for 90 min (0.8 pmol·kg·min
-1
) ad libitum energy intake was suppressed 2 h after the 
infusion and this was maintained for a total of 12 h (Batterham et al. 2002). 
2.3.2.5. Chronic energy regulation 
In humans, there is a negative correlation between circulating concentrations of PYY and 
markers of adiposity, including BMI, body fat percentage and waist circumference 
(Batterham et al. 2003; Guo et al. 2006; le Roux et al. 2006). This suggests that PYY could 
play a role in the long-term regulation of energy balance, consequently influencing body 
weight. 
In rodents, the administration of PYY3-36 can attenuate weight gain (Batterham et al. 2002; 
Pittner et al. 2004). Furthermore, the absence of PYY in rodents can cause hyerphagia and 
obesity (Batterham et al. 2006). Here, PYY coding was deleted and daily cumulative food 
intake increased. This resulted in an increase of body fat and leptin levels. After weight gain, 
the PYY null mice were administered PYY3-36. These mice were hypersensitive to the 
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anorexigenic effects of PYY3-36, and obesity within these rats was reversed. The findings here 
suggest obesity was caused by a loss of PYY, implicating its role in chronic energy regulation. 
It has also been suggested that PYY may beneficially affect metabolism by altering energy 
expenditure, thermogenesis and fuel partitioning (Boey et al. 2008; Guo et al. 2006; Sloth et 
al. 2007). Rodent studies have demonstrated that chronic administration of PYY3-36 results in 
a favoured fat oxidation, and that those that overexpress PYY have increased basal 
temperatures (Adams et al. 2006; van den Hoek et al. 2007). Similarly, in humans it has been 
shown that the peripheral administration of PYY3-36 leads to increased energy expenditure 
and fat oxidation, with circulating postprandial PYY concentrations being associated with 
postprandial energy expenditure and thermic effects of food (Doucet et al. 2008; Sloth et al. 
2007). Together these findings suggest that PYY plays a role in the long-term regulation of 
body weight by reducing energy intake and by increasing energy expenditure. 
2.3.2.6. Differences between lean and obese individuals 
Obese individuals exhibit lower fasting concentrations of PYY (Batterham et al. 2003; le 
Roux et al. 2006). Furthermore, fasting concentrations of PYY are found to correlate 
negatively with BMI; higher BMI’s are associated with lower concentrations of PYY 
(Batterham et al. 2003). 
Although normal weight and obese individuals express differing basal concentrations of PYY, 
similar decreases in energy intake and appetite following an infusion of PYY to generate 
supra-physiological concentrations (2 nmol·kg
-2
) have been observed (Batterham et al. 2003). 
This demonstrates that obese individuals are not resistant to the effects of PYY. However, 
despite consuming more calories than their lean counterparts, obese individuals expressed 
lower levels of PYY after an ad libitum meal (Batterham et al. 2003). This suggests that 
obese individuals are deficient in circulating concentrations of PYY and hence circulating 
PYY may be involved in the pathogenesis of obesity. 
2.3.2.7. PYY as a remedy for obesity? 
Finding that obese individuals are sensitive to the effects of PYY, implicated its role as a 
potential remedy for obesity and weight management. Peptide hormones cannot be 
administered orally due to degradation within the stomach. Consequently, a PYY nasal spray 
was developed and administered 20 min before breakfast, lunch and dinner. Over 12 weeks, 
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obese individuals used either a placebo, 200 µg PYY3-36 or 600 µg PYY3-36 nasal sprays 
whilst consuming a hypocaloric diet and exercise regime (Gantz et al. 2007). The spray was 
not efficacious with 59% of individuals in the 600 µg PYY3-36 nasal spray group dropping out 
of the study due to feelings of nausea and vomiting. It was suggested that these feelings were 
a result of sharp rises in plasma PYY levels caused by the nasal spray. For PYY to be used as 
an effective therapy, it will be necessary to deliver stable levels of the hormone that avoid 
sharp peaks (Troke et al. 2014). In particular, it has been suggested that manipulating the 
release of PYY through alterations in diet could be effective for treating obesity (Batterham 
et al. 2006).  
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2.3.3. GLP-1 
2.3.3.1. Discovery 
The discovery of GLP-1 was initiated after the development of glucagon immunoassays 
(Unger et al. 1961). This highlighted the presence of glucagon like substances in the 
gastrointestinal tract after an oral glucose load (Unger et al. 1968), later determined as GLP-1 
and GLP-2 (Bell et al. 1983). 
2.3.3.2. Structure, production, and regulation of secretion 
Glucagon-like peptide-1 is cleaved from preproglucagon within the L cells of the intestinal 
mucosa (Donnelly 2012). GLP-1 is secreted into the circulation in two forms; GLP-11-37 and 
GLP-11-36 (Lockie 2013; Kieffer & Habener 1999; Neary & Batterham 2009). GLP-11-36 is the 
major form found in the blood (Neary & Batterham 2009), and is the form considered to be 
active. When in the circulation GLP-1 is rapidly broken down by DPP-IV into the inactive 
forms GLP-19-36 and GLP-19-37 (Lockie 2013). Due to the rapid break down of active GLP-1, 
most of the GLP-1 that leaves the gut is inactive, with only ~10-15% of the newly secreted 
GLP-1 being active in the circulation (Holst 2007). The secretion of GLP-1 is dictated by 
food consumption. During fasting, plasma concentrations of GLP-1 are very low, and these 
are seen to increase rapidly within 10 min of consuming a meal. The amount of GLP-1 
released into the circulation is dependent on the size of the meal and the rate of gastric 
emptying (Kieffer & Habener 1999; Miholic et al. 1991; Vilsbøll et al. 2003). The release of 
GLP-1 is biphasic, with levels initially rising 10 min after food consumption, peaking after 30 
min and remaining elevated for several hours (Orskov et al. 1996). However, the release of 
GLP-1 from L cells is not solely under the control of nutrients, hormones and neural inputs 
also play a role. This causes the biphasic pattern in GLP-1 release seen after a meal. The 
initial rise of GLP-1 in the 10 min after food intake is mediated both hormonally and neurally. 
Whereas the later secretion of GLP-1, seen 30 min after food consumption, is caused by 
direct nutrient contact with the L cells in the ileum (Kieffer & Habener 1999). The release of 
GLP-1 into the circulation stimulates insulin secretion and inhibits glucagon secretion (Field 
et al. 2009; Holst 2007; Lockie 2013). This allows for increased glucose uptake and glucose 
clearance, which is important for the regulation of glucose (Lockie 2013). Specifically, GLP-
1 is classified as an incretin hormone (Holst 2007) a collection of molecules responsible for 
amplifying the secretion of insulin. 
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Fitting with GLP-1’s incretin hormone role, carbohydrate ingestion stimulates GLP-1 
secretion (Elliott et al. 1993; Herrmann-Rinke et al. 1995). However when glucose is 
systemically administered no rise in circulating GLP-1 is seen. This in tandem with the 
observation of increased GLP-1 after glucose infusion into the intestinal lumen suggests that 
the cells required to detect GLP-1 are distributed on the luminal side of the intestine (Kieffer 
& Habener 1999). As well as glucose, fat also appears to be partially responsible for the 
release of GLP-1 and other proglucagon derived peptides. Consuming either mixed fats or 
triglycerides (TAG) in humans, causes an increase in the secretion of GLP-1. The chain 
length and degree of saturation of the ingested fats influences GLP-1 secretion, with 
monounsaturated long chain fatty acids causing a greater secretion than short chain or 
medium chain polyunsaturated or saturated fatty acids (Kieffer & Habener 1999). When 
looking at the responses to amino acids and proteins, it has been found that GLP-1 secretion 
does not increase in humans. However, when mixed meals containing protein are consumed 
GLP-1 secretion increases (Kieffer & Habener 1999). 
2.3.3.3. Physiological functions and mechanisms of action 
Glucagon-like peptide-1 has multiple physiological functions in the peripheral tissues (Figure 
2.4), mediated through its own distinct receptor. These GLP-1 receptors are concentrated in 
areas closely related to appetite regulation, in particular on the beta cells of the pancreatic 
islets, the brain (in particular the hypothalamus), kidney, heart and GI tract (Holst 2007). 
As very little active GLP-1 that leaves the L cells reaches the circulation, it has been 
proposed that GLP-1 may interact with afferent sensory nerve fibres as it crosses the capillary 
wall to induce its effects (Holst 2007). Specifically, sending impulses to the nucleus of the 
solitary tract, and onwards to the hypothalamus (Holst 2007). 
Glucagon-like peptide-1 is suggested to be one of the most important incretin hormones 
(Vilsbøll & Holst, 2004). GLP-1 acts on pancreatic β cells to stimulate the release of insulin 
and inhibit the release of glucagon, in a glucose dependent manner (Field et al. 2009; Holst 
2007). GLP-1 may also override the inhibition of insulin secretion by leptin (Kieffer & 
Habener 1999). This will ensure that an adequate insulin response occurs after a meal. 
Consequently, the release of GLP-1 from the gut is dependent on the quantity of glucose 
consumed, and will ensure that plasma glucose concentrations remain constant whatever the 
size of the glucose load (Holst 2007). 
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Figure 2.4. Physiological actions of GLP-1. Adapted from Baggio & Drucker (2007). 
When those with type 2 diabetes are chronically infused with GLP-1, weight loss and 
improved glycaemic control are observed (Zander et al. 2002). This suggests that GLP-1 
could be used in the treatment of type 2 diabetes; however, more investigation is required to 
determine its long term effects. 
Glucagon-like peptide-1 inhibits gastric secretion and motility, gastric emptying and 
pancreatic secretions (Field et al. 2009; Holst 2007). This suggests that GLP-1, alongside 
PYY, is responsible for mediating the ‘ileal brake’ (Holst 2007). Specifically inhibiting upper 
gastrointestinal functions, due to the presence of unabsorbed nutrients in the ilium (Holst 
2007), this effect is thought to be induced via afferent sensory neurons that are responsible 
for relaying impulses to the brain, in particular the hypothalamus (Holst 2007). 
Glucagon-like peptide-1 has been shown to have satiating effects in humans, whereby energy 
intake at an ad libitum meal is reduced after acute intravenous infusion of GLP-1 (Flint et al. 
1998). GLP-1 is suggested to mediate this effect by slowing gastric emptying and acting 
directly on the CNS (Field et al. 2009). Non-digestive effects include the inhibition of heart 
contractibility in the basal state and enhancing myocardial performance (Holst 2007; Kieffer 
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& Habener 1999). Additionally, GLP-1 has anabolic effects on the liver, skeletal muscle and 
fat cells, causing glucose uptake (Kieffer & Habener 1999). 
2.3.3.4. Acute energy regulation 
After a meal, circulating concentrations of GLP-1 show a biphasic response. Levels rise 
within 10 min of the meal, and peak at about 30 min, remaining elevated for several hours 
(Orskov et al. 1996). The magnitude of this response is determined by the nutrients consumed 
(Holst 2013). This pattern of secretion mirrors that of satiety and for this reason the GLP-1 is 
thought to have an anoeretic effect. 
In rats, the acute administration of GLP-1 by injection results in decreased food intake 
(Turron et al. 1996). Similarly, a dose dependent reduction in food intake with GLP-1 
infusion has been shown in humans (Verdich et al. 2001). Together these further imply GLP-
1 has an acute role in energy regulation. 
The mechanism for satiety and food intake regulation is unclear. However, both central and 
peripheral mechanisms could play a role (McGrath et al. 2015). Firstly, GLP-1 may transmit 
nutritional signals via the vagus nerve in the gastrointestinal tract (McGrath et al. 2015). 
Secondly, the small amount of GLP-1 that is not broken down by DPP-IV could cross the 
blood brain barrier acting directly on GLP-1 receptors to induce satiation (Dailey & Moran 
2013). Finally, feelings of satiation could be generated by decreased gastrointestinal motility 
(Holst 2007). 
2.3.3.5. Chronic energy regulation 
After weight loss in humans, fasting concentrations of GLP-1 have been shown to decrease 
(Adam et al. 2005). It has been suggested that this could increase appetite and promote 
weight regain during and after dieting (Neary & Batterham 2009). However, after bariatric 
surgery, circulating concentrations and secretions of GLP-1 are elevated and this is believed 
to help reduce appetite and food intake and weight loss (Ashrafian & le Roux 2009). 
Together these imply GLP-1 plays a role in chronic energy balance and potentially 
contributes in the pathogenesis of obesity (Neary & Batterham 2009). 
Similarly, by inducing supra-physiological circulating concentrations of GLP-1 through five 
days of prandial subcutaneous injections in obese individuals, calorie intake was reduced by 
15% and 0.5 kg weight loss was seen (Näslund et al. 2004). This suggests that low 
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concentrations of GLP-1 could be responsible for obesity and restoration of these may 
increase satiety and cause weight loss. 
2.3.3.6. Differences between lean and obese individuals 
With regards to fasting concentrations of GLP-1 in obese and normal weight individuals, 
mixed findings have been reported. Some show no difference (Adam & Westerterp-Plantenga 
2004; Verdich et al. 2001), whereas others report lower concentrations in the obese 
(Chanoine et al. 2008; Ranganath et al. 1996). Discrepancies in these findings may have been 
caused by recruitment of obese individuals who are losing weight or have recently lost weight 
(Adam et al. 2005). 
In response to a meal, obese individuals have shown attenuated postprandial GLP-1 secretion 
in comparison to lean individuals (Adam & Westerterp-Plantenga 2005; Ranganath et al. 
1996; Verdich et al. 2001). However, again some studies have reported no difference (Fukase 
et al. 1993). 
Irrespective of these differing reports between obese and lean individuals, it has been shown 
that both lean and obese individuals show a dose response relationship between GLP-1 
infusion and energy intake with both populations showing equal sensitivity to GLP-1 
(Verdich et al. 2001). This suggests that GLP-1 or its agonists could be useful in the 
treatment of obesity. 
2.3.3.7. GLP-1 as a remedy for obesity 
The preservation of GLP-1’s anoeretic effects in the obese sparked an interest in the potential 
GLP-1 may have in the treatment of obesity. However, a major barrier in the development of 
GLP-1 as a therapeutic drug is the short life of GLP-1 within the circulation. Two methods 
have been adopted to overcome this; production of a more stable GLP-1 analogue and 
inhibiting DPP-IV, to prevent GLP-1 breakdown. 
Pharmaceutical companies have developed a number of long lasting GLP-1 agonists. Amylin 
pharmaceuticals developed ‘exenatide’, a product derived from exerdin-4, a potent GLP-1 
analogue discovered in venomous lizards. Initially developed as a diabetes drug, it was also 
found to induce weight loss (Buse et al. 2004). When trialled in non-diabetic obese 
individuals nausea was observed, and this seemed to be the cause for observed weight loss. 
However, dose titration still resulted in weight loss whilst nausea was attenuated. Exenatide 
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is administered by injection, twice daily. To improve patient compliance a once weekly 
administration was trialled, with similar reductions in weight loss observed (Drucker et al. 
2008). The final limitation to this drug is the high percentage of patients that develop 
antibodies to it, reducing its efficacy (Buse et al. 2004; Kendall et al. 2005). To help 
overcome the production of antibodies a GLP-1 analogue which has greater similarities to the 
human form is required. Novo Nordisk trialled ‘litaglutide’ for use in type 2 diabetic patients, 
which is 97% identical to GLP-11-37 (Knudsen et al. 2000). The drug also caused weight loss 
in this diabetic population (Marre et al. 2009). In a non-diabetic population, after 52 weeks of 
treatment more than 35% of participants achieved at least 10% weight loss (Novo Nordisk 
2008). Only 10% of participants withdrew from the study, and the most common reason was 
for feelings of nausea. However, it was also reported that these sensations subsided with 
continual use of the drug. 
Development of DPP-IV inhibiting drugs has been less successful. All initially licensed for 
type 2 diabetes treatment, and all administered orally, these have shown improvements in 
glycaemic control but not in weight loss (Green et al. 2006). Batterham & Neary (2005) 
suggest an alternative method would be to develop a drug whereby endogenous GLP-1 
secretion is increased. Alternatively, to help reduce sensations of nausea, a combination drug 
could be developed where lower doses of two or more drugs are taken together to induce 
weight loss (Chaudhri et al. 2006).  
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2.3.4. Leptin 
2.3.4.1. Discovery 
Leptin was identified in 1994 following genetic cloning of the obese (ob) gene in mice 
(Zhang et al. 1994). The word leptin is derived from the Greek word ‘leptos’, meaning thin, 
this was chosen as the administration of this hormone to obese mice resulted in significant 
weight loss. 
2.3.4.2. Structure, production and regulation of secretion 
Leptin is a 167-amino acid peptide with a 21 amino acid secretory signal sequence. The 
signal sequence is removed prior to release into the circulation, consequently leptin circulates 
in the blood as a 146 amino acid residue (Margetic et al. 2002; Zhang et al. 1994). Leptin is 
primarily produced by and secreted into the circulation from adipose tissue, the placenta, and 
the gastrointestinal tract (Margetic et al. 2002; Prolo et al. 1998). 
Human plasma leptin concentrations express a circadian rhythm, which is affected by sleep 
patterns (Scheer et al. 2009). Plasma concentrations are found to peak between midnight and 
early morning, whilst lowest concentrations are seen in the early to mid-afternoon (Friedman 
& Halaas 1998; Kanabrocki et al. 2001). Obese individuals show higher circulating 
concentrations of leptin than their lean counterparts (Saad et al. 1998); rate of leptin 
production and circulating concentrations are related to fat mass with higher leptin 
concentrations when adipocyte stores are larger (Hamilton et al. 1995). Sex also influences 
the secretion of leptin (Frederich et al. 1995). Females express higher concentrations of 
circulating leptin compared to males, which is thought to be caused by reproductive 
hormones (Mantzoros & Moschos 1998). Feeding behaviour also appears to influence 
circulating concentrations of leptin, with both short and long term overfeeding increasing 
leptin expression in adipocytes and concentrations within the circulation (Kolaczynski et al. 
1996; Levine et al. 1999). 
Leptin binds to leptin receptors (ObRs) found in the brain, specifically the hypothalamus and 
cerebellum, stomach and placenta (Burguera et al. 2000; Henson et al. 1998; Sierra-
Honigmann et al. 1998). Leptin acts on receptors in the brain to signal energy status. Leptin 
influences several other physiological functions, namely; wound healing, bone formation, 
angiogenesis, haematopoiesis, immune and inflammatory responses (Klok et al. 2007). 
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2.3.4.3. Energy regulation 
Leptin regulates energy homeostasis by acting on receptors in the hypothalamus. After 
secretion from adipose tissues, leptin crosses the blood brain barrier and binds to receptors, 
providing information on body energy stores (Sahu 2003). Leptin stimulates hypothalamic 
neurones resulting in anorexic effects on energy balance (Klok et al. 2007). In particular 
leptin induces weight loss by suppressing food intake and stimulating metabolic rate. 
Supporting this notion, a leptin deficient child born a normal weight, rapidly becomes obese 
due to overeating (Montague et al. 1997). Similarly, leptin treatment in leptin deficient 
patients sees decreased appetite, weight loss and increased physical activity (Licinio et al. 
2004). Evidence on the effect of leptin on metabolic rate and energy expenditure is not as 
clear. Researchers show mixed findings of leptin concentrations and RMR, with some 
showing no correlation (Kennedy et al. 1997; Levine et al. 1999; Roberts et al. 1997), whilst 
others have found positive correlations (Jorgensen et al. 1998). 
Leptin also appears to play a role in short term energy regulation, specifically in response to 
individual meals. Evidence to support this includes; leptin production in the stomach, 
insulin’s ability to influence secretion of leptin, high fat meals lowering leptin concentrations 
and the possibility of leptin working in tandem with satiety peptides to reduce food intake 
(Attele et al. 2002; Dallongeville et al. 1998; Sobhani et al. 2002). More research is required 
to confirm this.  
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2.4. Exercise, appetite and energy intake in lean and obese individuals 
2.4.1. Appetite assessment 
Appetite is a subjective measurement assessed using indirect methods, such as, eating pattern 
and food intake questionnaires or by biomarkers i.e. appetite related hormones (Mattes et al. 
2005). Initial appetite questionnaires, using visual analogue scales (VAS), showed a weak to 
moderate association between pre-meal hunger and energy intake at that meal (Hill & 
Blundell 1982). It was suggested that this was because only one aspect of ‘hunger’ was 
assessed, and that taking a multidimensional approach to hunger would be more appropriate. 
To fully understand a multidimensional model it is first important to clarify the different 
definitions of appetite. Appetite is a broad term covering food intake, selection, motivation 
and preference of food items (Blundell et al. 2010). Appetite can be broken down into a 
collection of feelings; hunger, satiation and satiety. Hunger is defined as the sensation that 
promotes the intake of food and is found to decrease after food intake (Mattes et al. 2005). 
Metabolic, sensory and cognitive signals all influence an individual’s feeling of hunger 
(Blundell et al. 2010; Mattes & Friedman 1993). Hunger is objectively measured by rating 
sensations for the desire to eat. These are felt in various parts of the body including the 
stomach, limbs and head and are described as feelings of light-headedness, weakness or 
emptiness in the stomach (Blundell et al. 2010). Satiation is the sensation that determines 
how long we eat for and how much we consume (Blundell & Macdiarmid 1997). This feeling 
becomes stronger during a meal and contributes to an individual finishing a meal and 
beginning a phase of fasting (Mattes et al. 2005). Satiation, also termed intra-meal satiety or 
post-ingestive satiety, determines how long we fast between meals (Blundell et al. 2010; 
Mattes et al. 2005). 
Measuring an individual’s food intake is a common method used to assess hunger, based on 
the assumption that appetite and food intake are correlated (Mattes et al. 2005). However, 
there are several factors that can interfere with this relationship. Factors that could inhibit an 
individual eating enough include; lack of food availability and social constraints. Whereas 
factors such as boredom, availability of palatable food and emotional stress can all cause an 
individual to overeat (Mattes et al. 2005). 
Visual analogue scales (VAS) and category scales are the most commonly used appetite 
questionnaires. VAS comprise of lines either 100 or 150 mm in length anchored with 
opposing phrases. The participant marks on the line how they feel, and this is measured using 
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a ruler by the investigator. Initially only one question (‘how hungry are you right now?’) was 
asked to determine hunger (Hill & Blundell 1982). However, to address the multidimensional 
nature of hunger it was suggested using a set of questions would be more appropriate. For 
example, ‘how strong a desire to eat do you have now?’, ‘how much could you eat now?’, 
‘how full are you now?’, ‘how strong a desire to eat something savoury/sweet do you have 
now’ and ‘how thirsty are you now?’ (Mattes & Friedman 1993; Mattes et al. 2005). To 
ensure the multidimensional nature of appetite is assessed, questionnaires should incorporate 
a combination or all of the questions stated above (Mattes et al. 2005). Flint et al. (2000) 
measured the reproducibility of VAS measures in a group of 55 healthy normal weight male 
individuals. Participants ate a breakfast, ad libitum lunch meal and completed VAS over a 
period of four h. The trials were separated by one to three weeks. The scales were shown to 
be reproducible after identical meals, suggesting suitability to assess appetite in studies with a 
single meal. Additionally, the validity of VAS was determined by testing the correlation 
between hunger and energy intake at the ad libitum meal. Post-meal scores were found to 
have a stronger correlation with food intake at the meal than the pre-meal values and pre-post 
differences of appetite. 
When deciding which VAS scales to use, it is necessary to consider their qualities; are the 
scales easily applied and can they be unambiguously interpreted by investigators and subjects? 
Do they demonstrate repeat-reliability? Do they show convergent validity with other similar 
scales? and are they suitable for relevant mathematical and statistical handling (Blundell et al. 
2010)? 
Category scales or line scales are a similar measure to VAS, but instead of being a continuous 
scale with anchors at each end, the line is divided into categories. Subjects tend to assume 
that each category is equally spaced; however, this is not always the case with scales not 
having ratio properties (Mattes et al. 2005). 
Eating patterns is another method used to assess appetite. This is based on the assumption 
that there is a direct relationship between inter-meal fasts and hunger (Mattes et al. 2005). For 
this to be true the meal following an overnight sleep would be the largest. However, few 
individuals show hunger ratings to peak early in the morning. Portion sizes and meal times 
are also influenced by social norms (de Castro 1988). These drawbacks make this method of 
appetite assessment less reliable and valid. 
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Biomarkers of appetite, such as gut peptide hormones, are related to appetite ratings and food 
intake and can also be used as measures of appetite. In order for biomarkers to be relevant 
they need to meet a number of criteria (Mattes et al. 2005). Firstly, the marker must be clearly 
related to appetite physiology, and be sensitive to the changes seen in appetite. Secondly, it is 
necessary for the measurement of this biomarker to be reproducible under similar conditions. 
Measures of biomarkers are perhaps more useful for detecting potential mechanisms of 
behavioural patterns, rather than being direct measures of appetite themselves; this is partly 
due to the invasive nature for measuring these. 
2.4.2. Food intake assessment 
Both indirect and direct methods can be used to measure food intake. Indirect methods 
include diet history questionnaires and food diaries, whilst direct measures include ad libitum 
homogenous meals and buffets. There are three major concepts of food intake that need to be 
considered when determining the suitability of an assessment type; habitual intake, validity 
and precision (Livingstone & Black 2003). Habitual intake is the mean energy intake of an 
individual over a prolonged period of time, ideally measured over weeks or months. However 
this is hard to do accurately, as it varies so much from day to day for each individual 
(Livingstone & Black 2003). In order for food intake assessment to be valid, it needs to 
measure the true intake of an individual, i.e. it is accurate and complete for the measured days, 
and not influenced by taking part in the study (Livingstone & Black 2003). Finally, for a 
method to be precise it should provide the same results on repeated tests. However, this is 
difficult to achieve during food intake assessment as habitual patterns vary so widely 
(Livingstone & Black 2003). Each of the food intake assessment methods has strengths and 
limitations, summarised below. 
Indirect methods of assessment include food diaries and diet recalls via questionnaire or 
interview. For a diet diary to be valid, it must be completed fully and accurately for all food 
and drink consumed on test days (Livingstone & Black 2003). Questionnaires allow 
assessments to be made whilst participants are ‘free living’, and theoretically the external 
validity of these measures is high (Blundell et al. 2010). However, in reality, the internal 
validity of these methods is limited by; a bias in habitual food intake, with a tendency for 
under-reporting of energy and misreporting of macronutrient content of the participant’s diet 
(Blundell et al. 2010; Livingstone & Black 2003). 
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Direct measures of food intake require ad libitum meals to be consumed within strict 
laboratory environments. Meal formats vary, with either a selection of buffet foods (hot or 
cold) or a homogenous meal presented to participants. The main function of an ad libitum 
meal is to measure satiation, i.e. the termination of an eating occasion (Blundell et al. 2010). 
Feelings of fullness and boredom of taste are two factors that contribute to the ending of a 
meal; a homogenous meal is most likely to be terminated due to boredom of taste whereas 
feelings of fullness are more likely to influence participant’s cessation at a buffet meal 
(Blundell et al. 2010). Meals consumed within laboratory environments should have high 
internal validity and sensitivity as interventions and their outcomes can be controlled 
(Blundell et al. 2010). However, it is impossible to control for the participant’s expectations 
and the novelty of the laboratory environment could influence behaviour (Blundell et al. 
2010). Meal palatability, texture and energy density should be considered alongside the 
motivational state of the participant, environmental cues and cognitive factors as potential 
aspects that may influence energy intake (Blundell et al. 2010). Ad libitum buffet meals allow 
for participants to express their own individual selection pattern and have been shown to be 
reproducible for both macronutrient preferences and energy intake in lean healthy males 
(Arvaniti et al. 2000; Gregersen et al. 2008; Nair et al. 2009). This reproducibility still stands 
when assessing energy intake after exercise in lean males (Laan et al. 2010). However, this 
was not the case in obese women (Brown et al. 2012). Further research is required to confirm 
these findings, but this would suggest that it is also necessary to consider the group being 
examined when selecting methods to measure food intake. 
To conclude, both direct and indirect methods of energy intake measurement have limitations. 
To control for these a combination of methods should be adopted (Blundell et al. 2010; 
Livingstone & Black 2003). 
2.4.3. Exercise and appetite in lean individuals 
In 1994, King and colleagues proposed and investigated the existence of ‘exercise induced 
anorexia’; a condition where appetite is transiently suppressed after exercise. King et al. 
(1994) found that in lean healthy males appetite was temporarily suppressed during and after 
high intensity cycling (~70% V̇O2max). The suppression of appetite was found to last for 15 
min after exercise, before returning to control values. In response to this finding, many more 
studies have further examined the effect of exercise on appetite. Most have supported the 
work of King et al. (1994) showing moderate to vigorous intensity exercise, using a range of 
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modes to suppress appetite (Bailey et al. 2015; Broom et al. 2007; Broom et al. 2009; 
Deighton et al. 2012; Deighton et al. 2013a; King & Blundell 1995; King et al. 2010a; King 
et al. 2010b; King et al. 2011a; Martins et al. 2007; Thompson et al. 1988; Tsofliou et al. 
2003; Wasse et al. 2013; Westerterp-Plantenga et al. 1997). However, increases and no 
change in appetite during and after exercise have also been reported (Hubert et al. 1998; 
Imbeault et al. 1997; King et al. 1996; King et al. 1997; Lluch et al. 1998; Maraki et al. 2005; 
Martins et al. 2015; Melanson et al. 1999; Ueda et al. 2009b; Wasse et al. 2013). 
Exercise induced anorexia is dependent on the intensity of the exercise bout performed. Low 
intensity exercise (30-35% V̇O2 max) has not been shown to induce a suppression of appetite, 
both during and after the bout of exercise (King et al. 1994; Thompson et al. 1988). Similarly, 
few studies have found suppression of appetite after moderate intensity exercise (50% 
V̇O2 max (Ueda et al. 2009b)). Instead, the majority of research shows that high intensity 
exercise is required to create exercise induced anorexia, implying a threshold of 
approximately 60% V̇O2max (Cheng et al. 2009; King & Blundell 1995; King et al. 1994; 
Kissileff et al. 1990; Martins et al. 2007; Thompson et al. 1988). 
Several studies have directly compared the influence of exercise on appetite during fed and 
fasted conditions. All are in agreement; appetite is suppressed to a greater extent and for 
greater duration postprandially after exercise in the fed state vs. fasted state (Borer et al. 2005; 
Cheng et al. 2009; Deighton et al. 2012). 
Little of the literature has directly compared appetite responses in males and females. 
However, after an acute bout of cycling at 70% V̇O2 max, lean healthy males and females 
showed no difference in appetite ratings (hunger, satisfaction, fullness (Hagobian et al. 
2013)). Similarly, after an acute bout of treadmill running (70% V̇O2 max) males and females 
exhibited similar appetite responses (Alajmi et al. 2016). In both of these studies males and 
females were not matched for body fat percentage, but instead matched by physical activity 
level or age. This may have impacted findings as differences in body fat percentages can be a 
true difference of sex. 
2.4.4. Exercise and appetite in obese individuals 
The effects of exercise on appetite in obese individuals are unclear. Moderate intensity 
exercise has not been found to alter appetite perceptions, despite increasing PYY and GLP-1 
(Ueda et al. 2009b; Unick et al. 2010). Ueda et al. (2009b) also observed a decrease in energy 
33 
intake and relative energy intake (REI) after exercise. This finding suggests that after a bout 
of exercise, it takes less food to satisfy this population. This could help to maintain the energy 
deficit created from exercise and hence aid weight loss. However, this study is limited by its 
short two hour observation period and low participant numbers. Moderate intensity exercise 
has also been shown to reduce appetite in this population (Tsofliou et al. 2003; Westerterp-
Plantenga et al. 1997). In a group of obese females, moderate physical activity (20 min 
treadmill walking) reduced appetite in the 30 min after exercise (Tsofliou et al. 2003). Satiety 
and fullness were also shown to be higher after exercise in comparison to control conditions. 
Preliminary research examining the effects of exercise intensity on appetite in overweight 
participants found no difference in appetite between trials (Sim et al. 2014). Healthy 
overweight young men completed a 30 min bout of; rest, continuous moderate exercise (60% 
V̇O2 peak), intermittent high intensity exercise (60 seconds at 100% V̇O2 peak: 240 seconds 
at 50% V̇O2 peak) and very high intermittent intensity exercise (15 seconds at 170% 
V̇O2peak: 60s at 32% V̇O2 peak). Unlike their lean counterparts who show that there is a clear 
intensity threshold for reducing appetite perceptions, no such observation has been seen in 
obese or overweight individuals. Further work within this population is necessary to help 
with the understanding of their appetite control systems. 
2.4.5. Energy intake in response to acute exercise in lean individuals 
Table 2.1 summarises studies looking at the effects of acute exercise on energy intake. The 
majority of studies have shown individuals do not compensate for the energy expended 
during exercise in the immediate hours after exercise through the alteration of energy intake. 
A recent meta-analysis quantified these findings, showing exercise to have a trivial effect on 
energy intake (~200 kJ, ES=0.14) and large effect on relative energy intake (~2017 kJ, 
ES=-1.35 (Schubert et al. 2013)). However, findings are not unanimous, with some studies 
showing an increase in energy intake after an acute bout of exercise (Erdmann et al. 2007; 
Laan et al. 2010; Larson-Meyer et al. 2012; Martins et al. 2007; Shorten et al. 2009). 
Schubert et al. (2013) suggested that despite discrepancies in energy intake reports, exercise 
remains effective at producing a short-term energy deficit. 
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Table 2.1. Acute exercise and energy intake in lean individuals. 
Dailey 
Participants 
Intervention Meal(s) 
Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
Balaguera-
Cortes 
et al. 2011 
10 
(M) 
23.7 
(2.0)
 
45 min treadmill run 
@ 70% V̇O2 max 
Ad libitum meal 
30 min post-exercise 
CON: 5283 
(1342) 
CON: 5027 
(1531) 
EX: 5516 
(1558) 
EX: 2698 
(1140) 
45 min resistance exercise 
3 sets of 12 reps or to failure, 
8 exercises, 1 min between sets 
CON: 5283 
(1342) 
CON: 5027 
(1531) 
EX: 5441 
(1503) 
EX: 4101 
(830) 
         
Deighton 
et al. 2012 
12 
(M) 
22.9 
(2.1)
 
60 min treadmill run 
@ 70% V̇O2 max 
Standard breakfast 
30 min post-exercise 
Ad libitum meals 
4.5 and 8.5 h post-exercise 
CON: 13452 
(2682) 
CON: 9774 
(2694) 
EX: 16652 
(2385) 
EX: 6481 
(2318)
*
 
     
Standard breakfast 
2.5 h pre-exercise 
Ad libitum meals 
4.5 and 8.5 h post-exercise 
CON: 13452 
(2682) 
CON: 9774 
(2694) 
EX: 12929 
(2933) 
EX: 6017 
(3050)
*
 
         
Deighton 
et al. 2013a 
12 
(M) 
24.2 
(2.9) 
60 min cycling 
@ 65% V̇O2 max 
Standardised breakfast 
1.75 or 2.25 h pre-exercise 
Ad libitum meals 
45 min and 4.25 h post-exercise 
Overnight food bags 
CON: 12941 
(3113) 
CON: 12941 
(3113) 
EX: 13548 
(3205) 
EX: 10908 
(3238)
*
 
30 min cycling including 
6 x 30 second sprints 
CON: 12941 
(3113) 
CON: 12941 
(3113) 
EX: 12920 
(2983) 
EX: 12326 
(2987) 
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Study 
Participants 
Intervention Meal(s) 
Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
Deighton 
et al. 2013b 
12 
(M) 
23.7 
(3.0) 
60 min cycling 
@ 60% V̇O2 max 
Standardised meals 
2 h pre-exercise and 
45 min post-exercise 
Ad libitum meal 
4 h post-exercise 
CON: 4759 
(1268) 
CON: 4759 
(1268) 
EX: 4813 
(1316) 
EX: 2362 
(1224)
*
 
10 x 4 min cycling bouts 
@ 85-80% V̇O2 max, 2 min rest 
CON: 4759 
(1268) 
CON: 4759 
(1268) 
EX: 4952 
(1351) 
EX: 2523 
(1402)
*
 
         
Deighton 
et al. 2014 
12 
(M) 
23.8 
(2.7) 
30 min cycling 
@ 65% V̇O2 max 
Standardised meals 
30 min and 3.5 h post-exercise 
Ad libitum meal 
6.5 h post-exercise 
CON: 4376 
(1634) 
CON: NM 
EX: 4217 
(1850) 
EX: NM 
         
Erdmann 
et al. 2007 
7 
(5F:2M) 
21.4 
(0.8) 
30 min cycling 
@ 50 W 
Ad libitum meal 
15 min post-exercise 
CON: 1721 
(217) 
CON: NM 
EX: 1825 
(375) 
EX: NM 
30 min cycling 
@ 100 W 
CON: 1721 
(217) 
CON: NM 
EX: 1758 
(262) 
EX: NM 
7 
(3F:4M) 
22.1 
(NM) 
30 min cycling 
@ 50 W 
CON: 2350 
(135) 
CON: NM 
EX: 1992 
(412) 
EX: NM 
60 min cycling 
@ 50 W 
CON: 2350 
(135) 
CON: NM 
EX: 2386 
(497) 
EX: NM 
120 min cycling 
@ 50 W 
CON: 2350 
(135) 
CON: NM 
EX: 3248 
(511)
*
 
EX: NM 
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Study 
Participants 
Intervention Meal(s) 
Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
George & 
Morganstein 
2003 
12 
(F) 
22.0 
(1.0) 
60 min treadmill walk 
@ 60% HR max 
Standard breakfast 
90-150 min pre-exercise 
Ad libitum meal 
30 min post-exercise 
CON: 1846 
(859) 
CON: NM 
EX: 1503 
(536) 
EX: NM 
         
Hubert 
et al. 1998 
11 
(F) 
21.5 
(1.1) 
40 min cycling 
@ 70% V̇O2 max 
Standardised breakfast 
immediately post-exercise (~270 kJ) 
Ad libitum lunch 
3 h post-exercise 
CON: 3182 
(783) 
CON: NM 
EX: 2843 
(1076) 
EX: NM 
     
Standardised breakfast 
immediately post-exercise (~2100 kJ) 
Ad libitum lunch 
3 h post-exercise 
CON: 2525 
(821) 
CON: NM 
EX: 2495 
(900) 
EX: NM 
         
Imbeault 
et al. 1997 
11 
(M) 
23.2 
(2.3) 
2050 kJ EE treadmill walk 
@ 35% V̇O2 max 
Standard breakfast 
3.5 h pre-exercise 
Ad libitum meal 
15 min post-exercise 
CON: 6593 
(NM) 
CON: 6593 
(NM) 
EX: 7387 
(NM) 
EX: 5719 
(NM) 
2050 kJ EE treadmill run 
@ 75% V̇O2 max 
CON: 6593 
(NM) 
CON: 6593 
(NM) 
EX: 6623 
(NM) 
EX: 4796 
(NM)
*
 
         
Jokisch 
et al. 2012 
10 
(inactive 
M) 
23.0 
(1.9) 
45 min cycling 
@ 65-75% HR max 
Ad libitum meal 
60 min post-exercise 
CON: 4497 
(1968) 
CON: NM 
EX:
 
3915 
(929)
*
 
EX: NM 
10 
(active M) 
23.9 
(1.5) 
CON: 4258 
(1662) 
CON: NM 
EX: 4643 
(1629) 
EX: NM 
 
 
37 
Study 
Participants 
Intervention Meal(s) 
Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
King 
et al. 1994 
12 
(M) 
24.2 
(NM) 
 
~60 min cycle 
@ 30% V̇O2 max 
Ad libitum meal 
from 15 min post-exercise 
(participants instructed to eat when start 
to feel hungry) 
CON: 6443 
(1305) 
CON: 6213 
(1305) 
EX: 6889 
(1414) 
EX: 5397 
(1439) 
~30 min cycle 
@ 70% V̇O2 max 
CON: 6443 
(1305) 
CON: 6213 
(1305) 
EX: 6439 
(1778) 
EX: 5017 
(1816) 
12 
(M) 
23.2 
(2.2) 
~30 min cycle 
@ 70% V̇O2 max 
CON: 5841 
(2251) 
CON: 5640 
(2251) 
EX: 6351 
(2280) 
EX: 5113 
(2289) 
~60 min cycle 
@ 70% V̇O2 max 
CON: 5841 
(2251) 
CON: 5640 
(2251) 
EX: 5975 
(2222) 
EX: 3720 
(2142) 
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Study 
Participants 
Intervention Meal(s) 
Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
King & 
Blundell 
1995 
12 
(M) 
22.7 
(NM) 
~50 min cycle 
@ 70% V̇O2 max 
Low-fat/high-carbohydrate ad libitum 
meal available post-exercise or rest 
(participants instructed to eat when start 
to feel hungry) 
CON: 4782 
(1397) 
CON: 4540 
(1393) 
EX: 5088 
(1075) 
EX: 2502 
(987) 
Low-carbohydrate/high-fat ad libitum 
meal available post-exercise or rest 
(participants instructed to eat when start 
to feel hungry) 
CON: 7439 
(1987) 
CON: 7201 
(1983) 
EX: 8142 
(2050) 
EX: 4753 
(1987)
*
 
12 
(M) 
22.8 
(NM) 
~50 min treadmill run 
@ 70% V̇O2 max 
Low-fat/high-carbohydrate ad libitum 
meal available post-exercise or rest 
(participants instructed to eat when start 
to feel hungry) 
CON: 4975 
(1173) 
CON: 4745 
(1167) 
EX: 5314 
(1305) 
EX: 2795 
(1326)
*
 
Low-carbohydrate/high-fat ad libitum 
meal available post-exercise or rest 
(participants instructed to eat when start 
to feel hungry) 
CON: 8460 
(2264) 
CON: 8460 
(2264) 
EX: 9042 
(1770) 
EX: 6477 
(1711)
*
 
         
King 
et al. 1996 
13 
(F) 
21.9 
(1.6) 
~50 min cycle 
@ 70% V̇O2 max 
Low-fat/high-carbohydrate ad libitum 
meal available post-exercise or rest 
(participants instructed to eat when start 
to feel hungry) 
CON: 2730 
(549) 
CON: 2529 
(646) 
EX: 2998 
(506) 
EX: 1537 
(397)
*
 
Low-carbohydrate/high-fat ad libitum 
meal available post-exercise or rest 
(participants instructed to eat when start 
to feel hungry) 
CON: 4484 
(782) 
CON: 4283 
(811) 
EX: 4886 
(996) 
EX: 3010 
(844)
*
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Study 
Participants 
Intervention Meal(s) 
Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
King 
et al. 1997 
8 
(M) 
22.4 
(1.8) 
50 min treadmill run 
@ 70% HR max 
Free living choice for the rest of the trial 
day 
CON: 12154 
(2453) 
CON: NM 
EX: 12481 
(2085) 
EX: NM 
         
King 
et al. 2010a 
9 
(M) 
23.6 
(1.2) 
90 min treadmill running 
@ 70% V̇O2 max 
Ad libitum meals 
1, 4 and 8.5 h post-exercise 
Diet log completed overnight 
CON: 17191 
(3432) 
CON: NM 
EX: 17606 
(4152) 
EX: NM 
         
King 
et al. 2010b 
14 
(M) 
23.4 
(2.2) 
60 min self-paced 
“brisk walk” 
(45±7.5% V̇O2 max) 
Ad libitum meals 
30 min and 4 h post-exercise 
CON: 9212 
(2200) 
CON: NM 
EX: 9384 
(2466) 
EX: NM 
         
King 
et al. 2011a 
12 
(M) 
22.8 
(1.4) 
90 min treadmill run 
@ 70% V̇O2 max 
Standardised meals 
30 min and 3.25 h post-exercise 
Ad libitum meal 
8 h post-exercise 
CON: 4004 
(1479) 
CON: NM 
EX: 4343 
(2262) 
EX: NM 
         
King 
et al. 2011b 
14 
(M) 
23.2 
(2.2) 
60 min intermittent 
swimming 
Standardised breakfast 
60 min pre-exercise 
Ad libitum meals 
2 and 6.5 h post-exercise 
CON: 9161 
(2690) 
CON: 9161 
(2690) 
EX: 9749 
(3027) 
EX: 7828 
(2896)
*
 
         
Laan 
et al. 2010 
19 
(10F:9M) 
22.5 
(1.8)
 
35 min cycle 
@ 70% HRR 
Ad libitum meal 
30 min post-exercise 
CON: 3282 
(373) 
CON: NM 
EX: 3756 
(402)
*
 
EX: NM 
35 min resistance training 
2 sets of 10 reps 
@ 70% 1-RM, 5 exercises 
CON: 3282 
(373) 
CON: NM 
EX: 3868 
(398)
*
 
EX: NM 
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Study 
Participants 
Intervention Meal(s) 
Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
Larson-Meyer 
et al. 2012 
9 
(F) 
19.8 
(1.0) 
60 min treadmill running 
@ 70% V̇O2 max 
Standardised breakfast 
90 min pre-exercise 
Ad libitum meal 
2 h post-exercise 
CON: 2011 
(529) 
CON: 1188 
(505) 
EX: 2034 
(768) 
EX: -812 
(862)
*
 
10 
(F) 
22.1 
(3.4) 
CON: 2305 
(680) 
CON: 1532 
(769) 
EX: 2612 
(582)
*
 
EX: 531 
(820)
*
 
         
Martins 
et al. 2007 
12 
(6F:6M) 
22.0 
(3.2) 
60 min cycling 
@ 65% HR max 
Standardised breakfast 
60 min pre-exercise 
Ad libitum lunch 
60 min post-exercise 
CON: 3190 
(1055) 
CON: 2366 
(946) 
EX: 3822 
(1520)
*
 
EX: 1763 
(1264)
*
 
         
Melby 
et al. 2002 
13 
(F) 
21.6 
(0.2) 
2160 kJ EE cycling 
@ 65% V̇O2 max 
(~75 min) 
Ad libitum meal 
90 min post-exercise 
CON: 3236 
(1268) 
CON: 2495 
(1177) 
EX: 3266 
(1223) 
EX: 331 
(1117) 
         
O'Donoghue 
et al. 2010 
9 
(M) 
22.4 
(1.6) 
45 min running 
@ 75% V̇O2 max 
Ad libitum meals 
15 min, 5 and 10.5 h post-exercise 
CON: 19975 
(5909) 
CON: NM 
EX: 21145 
(4507) 
EX: NM 
         
Pomerleau 
et al. 2004 
13 
(F) 
22.2 
(2.4) 
350 kcal treadmill walk 
@ 40% V̇O2 max 
Standard breakfast 
90 min pre-exercise 
Ad libitum meals 
1 and 6.5 h post-exercise 
Snack bags 
4.5 and 9 h post-exercise 
CON: 9567 
(2495) 
CON: NM 
EX: 10040 
(1809) 
EX: NM 
350 kcal treadmill walk 
@ 70% V̇O2 max 
CON: 9567 
(2495) 
CON: NM 
EX: 10802 
(2215) 
EX: NM 
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Study 
Participants 
Intervention 
Meal(s) Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
Shorten 
et al. 2009 
11 
(M) 
24.1 
(2.3) 
40 min treadmill run 
@ 70% V̇O2 max 
Ad libitum meal 
35 min post-exercise 
CON: 3744 
(1566) 
CON:
 
3744 
(1566) 
EX: 5193 
(1998)
*
 
EX: 2818 
(1718) 
         
Vatansever-
Ozen 
et al. 2011 
10 
(M) 
22.0 
(20.4) 
105 min treadmill run 
@ 59% V̇O2 max 
and 15 min 
@ 70% V̇O2 max 
Ad libitum meal 
60 min post-exercise 
CON: 8194 
(2169) 
CON: 7210 
(2177) 
EX: 8587 
(2889) 
EX: 3081 
(2935)
*
 
         
Wasse 
et al. 2012 
10 
(M) 
24.8 
(2.4) 
60 min treadmill run 
@ 70% V̇O2 max 
Standard meal 
1 h post-exercise 
Ad libitum meal 
4.5 h post-exercise 
CON: 7535 
(2112) 
CON: 7435 
(2324) 
EX: 7909 
(2599) 
EX: 4542 
(2448) 
CON, control trial; EX, exercise trial; F, female; HR max, heart rate maximum; HRR, heart rate reserve; M, male; NM, data not measured; RM, repetition 
maximum; V̇O2 max, maximal oxygen uptake. 
*
significantly different from control trial. 
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Relative energy intake takes into consideration the energy expended during exercise, and is 
calculated by subtracting exercise energy expenditure from energy intake in the exercise trial. 
REI in the exercise trial can be compared to the energy intake of the control condition to 
determine if a negative energy balance occurred as a result of the exercise bout. King et al. 
(1994) suggest that this could be a more meaningful analysis than simply comparing total 
energy intake between trials, and this is especially true when determining the efficiency of 
exercise to induce weight loss. 
Direct examination of exercise intensity has revealed no significant effect on energy intake 
(Imbeault et al. 1997; Pomerleau et al. 2004). Imbeault et al. (1997) assessed energy intake 
15 min after a bout of low intensity exercise (35% V̇O2 max), high intensity exercise (75% 
V̇O2 max), and rest. Energy expenditure for the differing intensities was matched and energy 
intake was assessed using an ad libitum buffet. Post-exercise energy intake did not 
significantly differ between the three conditions, but energy intake did tend to be lower after 
the high intensity exercise bout compared to the low intensity exercise bout. Schubert et al. 
(2013) also confirmed that exercise intensity had no effect on energy intake in their meta-
analysis. 
Exercise mode does not influence variation in energy intake (Schubert et al. 2013). 
Specifically, King & Blundell (1995) examined the effects of 50 min of cycling or running at 
70% V̇O2 max on energy intake at an ad libitum meal immediately after exercise, and from 
food intake during the remainder of the trial day. No significant differences in energy intake 
between the two modes of exercise were found. Resistance exercise has shown similar 
absolute energy intake responses to aerobic exercise. However, due to the lower energy cost 
of resistance exercise, differences in REI are less pronounced after resistance exercise than 
aerobic exercise (Schubert et al. 2013). Laan et al. (2010) showed no difference in energy 
intake after a bout of resistance and a bout of aerobic exercise. Healthy men and women 
completed three trials in a randomised order; control, aerobic exercise and resistance exercise. 
Aerobic exercise was a 35 min cycle at 70% heart rate reserve. Resistance exercise consisted 
of two sets of 10 repetitions and a third set to voluntary fatigue at 70% 1-RM for chest press, 
leg press, seated leg extension, seated leg curl and seated row. Participants were presented 
with an ad libitum pasta meal 30 min after the exercise. Energy intake was higher after both 
the exercise sessions in comparison to the control session, but with no significant difference 
between these. When taking into consideration the energy expenditure of the exercise bouts, 
REI was lower after the aerobic bout vs. resistance and control conditions. 
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The size of the energy deficit generated by exercise does not seem to affect energy intake. In 
particular, King et al. (2010a) imposed a ~5000 kJ energy deficit in healthy males during a 90 
min treadmill run. Energy intake in the 24 h after exercise did not differ significantly from 
control. 
The majority of studies examining acute exercise and energy intake are limited by short 
observation periods; typically responses are limited to one meal. It is also important to 
consider the possibility that energy compensations could be made later on in the day, or on 
consecutive days. A few studies have continued to monitor energy intake for longer periods 
of time after an acute exercise bout (Deighton et al. 2012; King et al. 1997; King et al. 2010a; 
King et al. 2010b; O'Donoghue et al. 2010; Pomerleau et al. 2004). Some assessed energy 
intake multiple times on the day of exercise, via ad libitum buffets (Deighton et al. 2012; 
O'Donoghue et al. 2010; Pomerleau et al. 2004) others relied on food diaries to assess energy 
intake (King et al. 1997), whilst the remainder relied on a combination of these methods 
(King et al. 2010a; King et al. 2010b). Together these studies found that even by increasing 
the observation period, there was no compensation for the energy lost during exercise. Again, 
these studies are limited as those relying on ad libitum meals to assess energy intake still only 
looked at the response to exercise within 10.5 h of the bout ending (Deighton et al. 2012; 
O'Donoghue et al. 2010; Pomerleau et al. 2004). Similarly, the reliance on food diaries to 
assess food intake is unreliable. Therefore, it is still necessary for a robust study to be 
designed in which energy intake is accurately assessed for a longer period of time after the 
cessation of exercise to determine if the energy deficit is compensated for. 
2.4.6. Energy intake in response to acute exercise in obese individuals 
Fewer studies have examined the effect of exercise on energy intake in overweight and obese 
individuals (Table 2.2). Findings have been mixed, with some reporting no difference in 
absolute energy intake compared to control conditions (Martins et al. 2015; Tsofliou et al. 
2003; Unick et al. 2010), with others report reductions in absolute energy intake after 
exercise (Sim et al. 2014; Ueda et al. 2009b). It is likely that these inconsistencies are due to 
differences in methodology. For example, a range of exercise intensities, modes and 
durations were utilised; 20 min brisk walk (Tsofliou et al. 2003), 40 min moderate walking 
(Unick et al. 2010), moderate intensity continuous 60 min cycling (Ueda et al. 2009b), and a 
range of moderate, high and very high intensity cycling sessions (Martins et al. 2015; Sim et 
al. 2014). In addition, studies differed in meal provision; with some providing homogenous 
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meals and others providing buffet style meals. These were provided at differing times after 
the exercise bouts, with many stopping observations immediately after the cessation of this 
meal. Consequently, the trial length of these studies was short, lasting no longer than 3.5 h. It 
is therefore unknown how this population respond to exercise later on in the day. 
Despite these discrepancies, early findings within this population are similar to those within 
lean individuals. This would suggest that exercise is as useful at generating a negative energy 
balance, and exercise could be prescribed as a weight loss tool if negative energy balances are 
sustained. Further research is required within this population to gain a greater understanding 
of how exercise affects appetite later on in the day. 
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Table 2.2. Acute exercise and energy intake in overweight/obese individuals. 
Study 
Participants 
Intervention Meal(s) 
Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
Martins et al. 
2015 
12 
(7F:5M) 
32.3 
(2.7) 
Cycling @ 85-90% HR max until 250 kcal 
expended: 
8 s all out sprinting separated by 12 s easy 
pedalling 
Standard breakfast 
1 h pre-exercise 
Ad libitum meal 
3 h post-breakfast 
CON: 2013 
(862) 
CON: 481 
(806) 
EX: 2213 
(820) 
EX: -364 
(728)* 
Cycling @ 70% HR max until 250 kcal 
expended: 
continuous cycle 
CON: 2013 
(862) 
CON: 481 
(806) 
EX: 1987 
(757) 
EX: -590 
(715)* 
Cycling @ 85-90% HR max until 125 kcal 
expended: 
8 s all out sprinting separated by 12 s easy 
pedalling 
 
CON: 2013 
(862) 
CON: 481 
(806) 
EX: 1941 
(636) 
EX: -113 
(594)* 
Sim et al. 
2014 
17 
(M) 
27.7 
(1.6)
 
30 min continuous cycling 
@ 60% V̇O2 peak 
Standardised meal 
5 min post-exercise 
Ad libitum meal 
70 min post-exercise 
CON: 3199 
(1642) 
CON: NM 
EX: 2974 
(1370) 
EX: NM 
30 min cycling: 
alternating between 60s @ 100% V̇O2peak and 
240s @ 50% V̇O2 peak 
CON: 3199 
(1642) 
CON: NM 
EX: 2602 
(1086)* 
EX: NM 
30 min cycling: 
alternating between 15s @ 170% V̇O2peak and 
60s @ 32% V̇O2 peak 
CON: 3199 
(1642) 
CON: NM 
EX: 2488 
(1202)* 
 
EX: NM 
Tsofliou et 
al. 2003 
10 
(F) 
37.2 
(6.5) 
20 min brisk walk Ad libitum meal 
1 h post-exercise 
CON: 3032 
(NM) 
CON: NM 
EX: 2860 
(NM) 
EX: NM 
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Study 
Participants 
Intervention Meal(s) 
Energy intake (kJ) 
N 
BMI 
(kg·m-2) 
Absolute 
energy intake 
Relative 
energy intake 
Ueda et al. 
2009b 
7 
(M) 
30.0 
(3.1) 
60 min cycle 
@ 50% V̇O2 max 
Standard breakfast 
1 h pre-exercise 
Ad libitum meal 
1 h post-exercise 
 
CON: 3951 
(737) 
CON: 2569 
(364) 
EX: 2769 
(640)* 
EX: -387 
(467)* 
Unick et al. 
2010 
19 
(F) 
32.5 
(4.3) 
Walk @ 70-75% age predicted HR max until 
3.0 kcal.kg
-1
 of body weight expended 
Ad libitum meal 
1 h post-exercise 
CON: 2296 
(1200) 
CON: 2110 
(1214) 
EX: 2307 
(1025) 
EX: 828 
(1073)* 
CON, control trial; EX, exercise trial; F, female; HR max, heart rate maximum; M, male; NM, data not measured; V̇O2 max, maximal oxygen 
uptake; V̇O2 peak, peak oxygen uptake. Values are mean (SD). 
*
significantly different from control trial.
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2.4.7. Energy intake in response to acute exercise, differences between males and 
females 
When comparing energy intake responses to exercise in males and females, no significant 
differences have been found for either total energy intake or REI (Hagobian et al. 2013; King 
et al. 1996; Laan et al. 2010); Schubert et al. (2013) reported no effect of sex on absolute 
energy intake. However the effect size was large and approached significance (ES=0.64, 
p=0.054). This suggests that the effects of exercise on energy intake are similar between 
males and females, showing exercise to be as effective at generating a negative energy 
balance on the day of exercise. 
2.4.8. Exercise and macronutrient intake in lean individuals 
An advantage for using ad libitum buffets for energy intake assessment is that these meals 
allow for participants to express their own selection pattern. Consequently the effect that 
exercise has on macronutrient intake can be measured. It is important to consider the 
composition of food selected as macronutrients differ in the amount of energy per gram of 
food. If participants were to favour high fat foods over proteins or carbohydrates, this could 
undo the energy deficit generated by exercise. 
Although some studies have reported differences in macronutrient intake after exercise 
(Pomerleau et al. 2004; Shorten et al. 2009; Wasse et al. 2012), the majority of studies report 
there to be no change in macronutrient preference after exercise (Balaguera-Cortes et al. 2011, 
Deighton et al. 2012; Deighton et al 2013a; George & Morganstein 2003; Hubert et al. 1998; 
Imbeault et al. 1997; Jokisch et al. 2012; King et al. 1994; King et al. 1997; King et al. 2010a; 
King et al. 2010b; King et al. 2011a; King et al. 2011b; Larson-Meyer et al. 2012; Martins et 
al. 2007; O’Donoghue et al. 2010; Vatansever-Ozen et al. 2011). 
It is likely that these differing results are caused by differences in protocol. Specifically, 
studies will have presented a different range of foods to participants, and this could have 
caused the favouring of certain foods. 
2.4.9. Exercise and macronutrient intake in obese individuals 
Of the few studies that have examined the effects of exercise on energy intake in obese 
individuals, only three examined macronutrient selection (George & Morganstein 2003; 
Martins et al. 2015; Tsofliou et al. 2013). These studies were in agreement, all showing no 
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effect of exercise on macronutrient choice at a buffet meal after exercise. Further research 
within this population is required to determine the true effects of exercise on macronutrient 
intake.  
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2.5. Effects of exercise on appetite regulating hormones in lean and obese individuals 
2.5.1. Acute exercise and ghrelin 
When looking at the effects of exercise on ghrelin concentrations results are divided. This is 
likely a result of differing study protocols; for example, exercise mode, intensity and form of 
ghrelin measured all vary. Table 2.3 summarises studies looking at the effects of aerobic 
exercise on ghrelin. A recent meta-analysis quantified the effects of acute exercise on 
acylated ghrelin (Schubert et al. 2014). It was found that exercise had a small suppressing 
effect on circulating concentrations of acylated ghrelin (ES = -0.20). 
The concurrent suppression of appetite and acylated ghrelin concentrations during strenuous 
exercise sparked a plethora of research in this area. Of particular interest to researchers was 
the role of ghrelin in exercise induced anorexia and if ghrelin could play a role in the 
compensation of energy intake after exercise, to restore the energy deficit caused by exercise. 
These findings would have particular relevance in determining the efficacy of exercise for 
weight loss and management. 
Ghrelin responses to exercise in obese and normal weight individuals have been found to 
differ (Heden et al. 2013). The morning after a bout of treadmill walking, obese individuals 
showed no change in fasting or postprandial acylated ghrelin concentrations vs. control. 
Normal weight individuals expressed reduced concentrations both pre- and post-prandially. 
Despite showing no changes in acylated ghrelin, obese individuals reported a standardised 
meal to be less filling. It was hypothesised that this could result in greater energy intake later 
in the day. However as energy intake was not measured in this study, this is only a 
speculation. Research into exercise and ghrelin in obese individuals is limited, and more is 
required to determine its effects, especially in relation to post exercise energy intake. 
Mode of exercise appears to have little effect on ghrelin responses. When comparing running 
and cycling at the same relative intensity plasma acylated ghrelin concentrations were 
similarly suppressed vs. resting control (Wasse et al. 2013). However, energy expenditure 
was not matched between the two exercise trials, potentially confounding these findings. 
Further to this, Kawano et al. (2013) compared responses between rope skipping and cycling. 
Here the exercise bouts were matched for energy expenditure, showing acylated ghrelin to be 
similarly suppressed during and immediately after both exercise bouts. 
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Exercise intensity appears to be important when considering the response of ghrelin. When 
exercise intensity is low (i.e. treadmill walking), ghrelin concentrations remain unchanged to 
control conditions (King et al. 2010b; Ueda et al. 2009a; Unick et al. 2010). Whilst intense 
exercise (~70% V̇O2 max) is shown to decrease ghrelin concentrations (Broom et al. 2007; 
Broom et al. 2009; King et al. 2010a; King et al. 2011a; Wasse et al 2012). 
Several studies have compared ghrelin responses to exercise in males and females (Alajmi et 
al. 2016; Burns et al. 2007; Hagobian et al. 2009; Hagobian et al. 2013). In lean individuals, 
no significant difference in total ghrelin response was seen between males and females after 
1 h of treadmill running at 75% V̇O2 max (Burns et al. 2007). However, phase of menstrual 
cycle was not controlled for. Similarly, no sex differences in acylated ghrelin responses to 
moderate intensity exercise have been reported (Alajmi et al. 2016; Hagobian et al. 2013). 
Further research is required to confirm these findings. 
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Table 2.3. Effects of acute aerobic exercise on ghrelin. 
Study 
Participants 
Intervention 
Ghrelin form 
measured 
Ghrelin response compared to 
control 
N 
BMI 
(kg·m-2) 
During exercise After exercise 
Broom et al. 2007 9 
(M) 
22.2 
(0.7) 
60 min treadmill running 
@ 72% V̇O2 max 
 
Acylated ↓ ↔ 
Broom et al. 2009 11 
(M) 
23.1 
(0.4) 
60 min treadmill running 
@ 70% V̇O2 max 
 
Acylated ↓ ↔ 
90 min resistance exercise; 
3 sets of 12 reps @ 80% 12 RM max, 10 exercises 
 
↓ ↔ 
Burns et al. 2007 18 
(9F:9M) 
22.9 
(0.6) 
60 min treadmill running 
@ 73.5% V̇O2 max 
 
Total ↔ ↔ 
Christ et al. 2006 11 
(M) 
22.6 
(0.5) 
180 min cycle 
@ 50% W max 
 
Total ↑ NM 
Dall et al. 2002 12 
(M) 
23.6 
(0.5) 
45 min cycle 
@ LT 
 
Total ↔ ↔ 
Deighton et al. 2013a 12 
(M) 
24.2 
(2.9) 
60 min cycling 
@ 65% V̇O2 max 
 
Acylated ↔ ↓ 
30 min cycling 
including 6 x 30 s sprints 
 
↓ ↓ 
Deighton et al. 2014 12 
(M) 
23.8 
(2.7) 
30 min cycling 
@ 65% V̇O2 max 
 
Acylated ↔ ↔ 
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Study 
Participants 
Intervention 
Ghrelin form 
measured 
Ghrelin response compared to 
control 
N 
BMI 
(kg·m-2) 
During exercise 
After 
exercise 
Erdmann et al. 2007 7 
(5F:2M) 
21.4 
(0.8) 
30 min cycle 
@ 50 W 
 
Total ↑ ↑ 
30 min cycle 
@ 100 W 
 
Total ↔ ↔ 
7 
(3F:4M) 
22.1 
(NM) 
30 min cycle 
@ 50 W 
 
Total ↔ ↔ 
60 min cycle 
@ 50 W 
 
Total ↔ ↔ 
120 min cycle 
@ 50 W 
 
Total ↔ ↔ 
Gholipour et al. 2011 9 
(M) 
32.7 
(0.8) 
36 min treadmill run: 
10 min, 10 min, 5 min, 2 min @ 65% V̇O2 max, 
separated by 3 min @ 3 km·h-1 
 
Acylated ↓ ↓ 
Hagobian et al. 2013 11 
(M) 
26.0 
(2.0) 
Cycle @ 70% V̇O2 peak 
until 30% of total daily expenditure expended 
Acylated ↔ ↔ 
10 
(F) 
 
24.0 
(2.0) 
↔ ↔ 
Jurimae et al. 2007a 9 
(M) 
24.8 
(NM) 
Constant load sculling 
5 bpm below anaerobic threshold 
 
Total ↔ ↔ 
Constant load sculling 
5 bpm above anaerobic threshold 
 
Total ↔ ↔ 
Jurimae et al. 2007b 8 
(M) 
97.4 
(7.4) 
6000m maximal rowing 
ergometer test 
 
Total ↑ ↔ 
 
53 
Study 
Participants 
Intervention 
Ghrelin form 
measured 
Ghrelin response compared 
to control 
N 
BMI 
(kg·m-2) 
During exercise 
After 
exercise 
Kallio 2001 9 
(2M:7F) 
 
22.8 
(0.9) 
5 min warm up at ≥ 20 W 
Workload increased by 20% V̇O2 max at 2 min intervals until 
80% V̇O2 max was reached 
Maintained for 12 min and followed by 10 min cooling period 
at 20% V̇O2 max 
 
Total ↔ ↔ 
Kelly et al. 2012 10 
(M) 
23.9 
(2.1) 
45 min treadmill run 
@ 70% V̇O2 max 
 
Total ↔ ↔ 
King et al. 2010a 9 
(M) 
23.6 
(0.4) 
90 min treadmill run 
@ 70% V̇O2 max 
 
Acylated ↓ ↔ 
King et al. 2010b 14 
(M) 
23.4 
(2.2) 
60 min self-paced “brisk walk” 
(45% V̇O2 max) 
 
Acylated ↔ ↔ 
King et al. 2011a 12 
(M) 
22.8 
(1.4) 
90 min treadmill run 
@ 70% V̇O2 max 
 
Acylated ↓ ↔ 
King et al. 2011b 14 
(M) 
23.2 
(2.2) 
60 min 
intermittent swimming 
 
Acylated ↓ ↔ 
Kraemer et al. 2004 6 
(M) 
NM Intermittent treadmill exercise session: 
10 min @ 60% V̇O2 max, 
10 min @ 75% V̇O2 max, 
5 min @ 90% V̇O2 max and 
2 min @ 100% V̇O2 max. 
Each stage was separated by 3.5 to 4 min of rest 
 
Total ↔ ↔ 
Martins et al. 2007 12 
(6F:6M) 
22.0 
(3.2) 
60 min cycle 
@ 65% HR max 
Total ↔ ↔ 
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Study 
Participants 
Intervention 
Ghrelin form 
measured 
Ghrelin response compared to 
control 
N 
BMI 
(kg·m-2) 
During exercise 
After 
exercise 
Martins et al. 2015 12 
(5F:7M) 
32.3 
(2.7) 
 
Cycling @ 85-90% HR max until 250 kcal expended: 
8 s all out sprinting separated by 12 s easy pedalling 
 
Acylated ↔ ↓ 
Cycling @ 70% HR max until 250 kcal expended: 
continuous cycle 
 
Acylated ↔ ↓ 
Cycling @ 85-90% HR max until 125 kcal expended: 
8 s all out sprinting separated by 12 s easy pedalling 
 
Acylated ↔ ↔ 
Marzullo et al. 2008 8 
(M) 
22.1 
(1.2) 
Cycle at 60 rpm @ 20 W, 
increased by 20 W every 4 min until physical exhaustion 
On recovery subjects cycled for two more min effortlessly 
 
 
Acylated ↓ NM 
Total ↔ NM 
8 
(M) 
33.7 
(1.5) 
Acylated ↓ NM 
Total ↔ NM 
Schmidt et al. 2004 8 
(M) 
22.2 
(0.5) 
Treadmill exercise 
@ 50%, 70% and 90% of V̇O2 max 
 
Total ↔ ↔ 
Shorten et al. 2009 11 
(M) 
24.1 
(2.3) 
40 min treadmill run 
@ 70% V̇O2 max 
 
Acylated ↔ ↔ 
Sim et al. 2014 17 
(M) 
27.7 
(1.6) 
30 min continuous cycling 
@ 60% V̇O2 peak 
 
Acylated NM ↓ 
30 min cycling: 
alternating between 60s @ 100% V̇O2 peak and 240s @ 50% 
V̇O2 peak 
 
 NM ↔ 
30 min cycling: 
alternating between 15s @ 170% V̇O2 peak and 60s @ 32% 
V̇O2 peak 
 NM ↔ 
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Study 
Participants 
Intervention 
Ghrelin form 
measured 
Ghrelin response compared to 
control 
N 
BMI 
(kg·m2) 
During exercise After exercise 
Tiryaki-Sonmez et al. 
2013 
9 
(F) 
28.3 
(1.8) 
60 min running 
@ 53% V̇O2 max 
 
Acylated ↓ ↓ 
Ueda et al. 2009b 7 
(M) 
22.4 
(2.4) 
60 min cycle 
@ 50% V̇O2 max 
Total ↔ ↔ 
7 
(M) 
30.0 
(3.1) 
60 min cycle 
@ 50% V̇O2 max 
 
 ↔ ↔ 
Unick et al. 2010 19 
(F) 
32.5 
(4.3) 
40 min walk 
@ 70-75% HR max 
 
Acylated ↔ ↔ 
Vatansever-Ozen et al. 
2011 
10 
(M) 
22.0 
(20.4) 
105 min treadmill run 
@ 59% V̇O2 max and 15 min @ 70% V̇O2 max 
 
Acylated ↓ ↓ 
Vestergaard et al. 2007 29 
(8F:21M) 
F 23.5 
(0.2) 
M 22.4 
(0.4) 
 
Maximal exercise test according to their sport 
(either long distance cycling, sprint cycling or weight lifting) 
Total NM ↓ 
Wasse et al. 2012 10 
(M) 
24.8 
(2.4) 
60 min treadmill run 
@ 70% V̇O2 max 
 
Acylated ↔ ↓ 
Wasse et al. 2013 11 
(M) 
23.4 
(2.4) 
60 min treadmill run 
@ 70% V̇O2 max 
Acylated ↓ ↓ 
60 min cycle 
@ 70% V̇O2 max 
 ↓ ↓ 
BPM, beats per min; F, females; LT, lactate threshold; M, males; NM, not measured; HRmax, heart rate maximum; V̇O2 max, maximal oxygen uptake; V̇O2 peak; W, watts; W max, 
watt max; ↓, decreased; ↑, increased; ↔, no change. 
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2.5.2. Acute exercise and PYY 
After an acute bout of exercise, circulating concentrations of PYY have been found to be 
transiently increased (Broom et al. 2009; Deighton et al. 2013a; Deighton et al. 2013b; 
Deighton et al. 2014; King et al. 2011a; Martins et al. 2007; Shorten et al. 2009; Ueda et al. 
2009a; Ueda et al. 2009b; Wasse et al. 2012). This suggests a role for PYY in exercise 
induced anorexia, as the reductions in PYY are synchronised with decreases in hunger. 
However concentrations have also been shown to be unaltered by acute exercise (Balaguera-
Cortes et al. 2011; Holmstrup et al. 2013; Martins et al. 2015; Shorten et al. 2009; Sim et al. 
2014). These discrepancies are also seen within overweight and obese individuals (Martins et 
al. 2015; Sim et al. 2014; Ueda et al 2009b). It is likely that the discrepancies in findings are a 
result of differences in study protocol; study population, form of PYY measured, exercise 
intensity and mode, and observation period all vary. Despite these discrepancies a recent 
meta-analysis (Schubert et al. 2014) quantified exercise to increase concentrations of PYY 
(ES = 0.24). In particular, circulating levels of PYY are seen to rise during a bout of exercise 
compared to control conditions (Broom et al. 2009; Deighton et al. 2013a; Deighton et al. 
2013b; King et al. 2011a; Martins et al. 2007; Ueda et al. 2009a; Ueda et al. 2009b; Wasse et 
al. 2012) and remain elevated for several hours after (Broom et al. 2009; Deighton et al. 
2013b; King et al. 2011a; Ueda et al. 2009a; Wasse et al. 2012). Further to this, PYY 
responses to a meal are heightened more so after an acute exercise bout vs. control, 
suggesting exercise enhances satiation (Broom et al. 2009; Cheng et al. 2009; King et al. 
2011). 
When examining the effects of exercise intensity on concentrations of PYY, the responses 
seem to be less clear cut than to those of ghrelin. Moderate intensity exercise (~50% V̇O2 
max) both increases (Ueda et al. 2009a; Ueda et al. 2009b) and has no effect on 
concentrations of PYY (Cheng et al. 2009). Discrepancies are still seen at higher intensities 
(≥60% V̇O2 max (Balaguera-Cortes et al. 2011; Broom et al. 2009; Deighton et al. 2013a; 
Deighton et al. 2013b; King et al. 2011a; Martins et al. 2007; Shorten et al. 2009; Wasse et al. 
2012)). It has instead been suggested that duration of exercise could impact concentrations of 
PYY, with changes only seen after 60 min of continuous exercise. A 45 min bout of treadmill 
running at 70% V̇O2 max caused no changes in PYY concentrations (Balaguera-Cortes et al. 
2011), whereas a 60 min treadmill run at 70% V̇O2 max increased PYY concentrations 
(Wasse et al. 2012). However, this is unlikely to be a determinant, as Ueda and colleagues 
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(2009a) showed 30 min of cycling was enough to alter concentrations of PYY. Conflicting 
results could be a result of authors measuring different forms of PYY, with some measuring 
the active form (PYY3-36) whilst others have measured the total form. Although it has been 
suggested that PYY3-36 has more potent anorectic effects than total PYY (Chelikani et al. 
2005), the responses of PYY3-36 and total PYY are similar in response to high protein, high 
carbohydrate and high fat meals (Batterham et al. 2006). This suggests that measuring either 
form of PYY should form comparable findings. 
To the authors knowledge no study has directly compared the effects of running and cycling 
on circulating concentrations of PYY. However, studies have compared the effects of 
resistance training to endurance training (Balaguera-Cortes et al. 2011; Broom et al. 2009). 
Again these studies found conflicting results. Broom and colleagues (2009) compared a bout 
of 60 min treadmill running at 70% V̇O2 max with a 90 min resistance training session. PYY 
concentrations increased during and after the run, but were unaffected by the resistance 
session. Perhaps strengthening the relationship between PYY and appetite, sensations of 
hunger were only found to decrease during the bout of endurance exercise. However, PYY 
concentrations were also observed to remain elevated for the rest of the trial day whereas 
sensations of hunger returned to control values. Balaguera-Cortes and colleagues (2011), 
compared a 45 min treadmill run at 70% V̇O2 max with a 90 min resistance training session 
and found no effect of either exercise session on concentrations of PYY. Further research is 
required to determine the true effects of different modes of exercise on circulating 
concentrations on PYY and how any changes impact sensations of appetite and energy intake. 
2.5.3. Acute exercise and GLP-1 
Few studies have examined the effects of acute exercise on GLP-1, with mixed findings. The 
majority of studies have reported increases of GLP-1 during exercise (Martins et al. 2007; 
Martins et al. 2015; Ueda et al. 2009a; Ueda et al 2009b), with concentrations remaining 
elevated compared to control conditions for the rest of the observation period (Martins et al. 
2007; Martins et al. 2015; Ueda et al. 2009a; Ueda et al 2009b). However Unick et al. (2010) 
reported no change in GLP-1 concentrations during exercise, and that concentrations were 
reduced after exercise. Despite these discrepancies, a recent meta-analysis found GLP-1 to be 
increased by acute exercise (ES = 0.28 (Schubert et al. 2014)). 
Increases in GLP-1 concentrations during exercise coincided with decreases in hunger 
(Martins et al. 2007; Ueda et al 2009a), implying that GLP-1 may also play a role in exercise 
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induced anorexia. However, Martins et al. (2015) reported no difference in hunger during 
exercise despite seeing increases in GLP-1 concentrations. The association between GLP-1 
and hunger is further weakened as GLP-1 concentrations have been shown to remain elevated 
later in the trial day, whilst hunger levels return to control values (Martins et al. 2007), 
remain suppressed after exercise (Ueda et al. 2009a) or are found to be similar to control 
values (Martins et al. 2015). 
Due to the small number of studies looking at exercise and GLP-1, it is hard to make 
judgements on the effect that exercise intensity and mode, BMI and sex have on GLP-1 
concentrations. In general it would appear that there is no effect of mode, with both cycling 
and running increasing GLP-1 concentrations (Martins et al. 2007; Martins et al. 2015; Ueda 
et al. 2009a; Ueda et al 2009b). Similarly, exercise intensity does not seem to influence GLP-
1 responses, with both moderate and vigorous intensities causing increases in GLP-1 (Martins 
et al. 2007; Martins et al. 2015; Ueda et al. 2009a; Ueda et al 2009b). Further research is 
required to determine the effects of resistance exercise on GLP-1 responses. In addition, 
comparisons between sex, BMI and exercise intensity will help with the understanding of 
GLP-1effect on appetite and energy intake.  
2.5.4. Acute exercise and leptin 
The effects of exercise on leptin concentrations have received a lot of interest. As leptin 
levels have been shown to be up- and down- regulated through alterations in energy intake, 
focus has been placed on determining if manipulations in energy expenditure via exercise can 
influence leptin concentrations. After acute bouts of exercise, leptin concentrations have been 
shown to be reduced (Elias et al. 2000; Fisher et al. 1985; Kraemer et al. 1999) or remain 
unchanged (Racette et al. 1997; Torjman et al. 1999; Weltman et al. 2000) in the immediate 
hours after exercise. When leptin concentrations were controlled for haemoconcentration and 
circadian rhythm, exercise values no longer differed from control conditions. However, when 
observation time is expanded, leptin concentrations are reduced 48 h after exercise (Essig et 
al. 2000; Olive & Miller 2001; Yang et al. 2014). It should also be noted that these studies 
induced a large energy deficit; reductions in leptin could be reflections of alterations in 
energy balance rather than being caused by the exercise bout per-se (Borer et al. 2009; Hilton 
& Loucks 2000). 
More recently, the effects of an acute bout of treadmill running (90 min at 70% V̇O2 max) on 
leptin concentrations in the subsequent 24 h was examined (King et al. 2015). In agreement 
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with previous findings, leptin concentrations expressed a delayed reduction. Specifically, a 
large energy expenditure of ~5020 kJ, caused a 33% reduction in fasting concentrations of 
leptin 20 h after exercise. This reduction was sustained throughout this second observation 
day (20-27 h post-exercise). Participants were required to follow strict dietary and physical 
activity control in the 27 h post-exercise; authors could therefore postulate that the reduced 
leptin concentrations were in response to the disturbance in energy balance. 
The effects of resistance training on leptin concentrations have also been explored. Kanaley 
et al. (2001) found that in healthy individuals, lower and upper body resistance exercises (3-
RM test on nine muscle groups) had no influence on 24 h leptin concentrations. However, 
when a large energy deficit (~850 kcal) was generated through resistance exercise (50 sets of 
four exercises), leptin concentrations were reduced 9, 12 and 13 h after exercise (Nindl et al. 
2002). This finding supports previous work, showing that leptin concentrations are only 
reduced after greater energy expenditures, and subsequent disturbances in energy balance. 
Further research is required to compare the effects of exercise and sex on leptin 
concentrations, and to compare responses of resistance and aerobic exercise. To help with the 
understanding of leptin’s time course, longer observation periods and more frequent blood 
sampling are required, with stringent physical activity and diet controls. Together these will 
better explain the responses of leptin to exercise, help with designing the most effective 
exercise strategy for positive leptin concentration adaptations and aid weight management 
strategies.  
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2.6. Summary 
The current literature suggests that in healthy lean individuals, acute bouts of exercise cause 
transient reductions in appetite during exercise, and that these rapidly return to control values 
after exercise. This is concordant with transient decreases in acylated ghrelin and increases in 
PYY and GLP-1. Energy intake after exercise generally remains unaltered, implying there is 
no compensatory response to acute exercise and that a negative energy balance is induced 
over the trial period. However, research is limited by short observation periods, lack of direct 
comparison between males and females, and overweight, obese and lean individuals. 
Furthermore, study protocols lack resemblance to ‘real-life’ scenarios, and consequently limit 
the extent to which findings can be applied to the general population. The role of appetite 
regulatory hormones in appetite and energy intake responses still remains unclear. This thesis 
therefore aims to examine the responses of appetite regulatory hormones, subjective appetite 
sensations and energy intake over longer periods and after repeated bouts of exercise. In 
addition comparisons will be made between lean and ow/ob individuals and between males 
and females. 
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CHAPTER III 
A comparison of two methods of blood sample collection for determining plasma 
acylated ghrelin concentration in humans 
3.1. Introduction 
Acylated ghrelin is a unique orexigenic hormone found to stimulate appetite in humans when 
circulating concentrations are high (Cummings et al. 2001; Druce et al. 2006; Wren 2001a). 
Originally discovered in rats, ghrelin is a purified ligand made of 28 amino acids. Ghrelin is 
synthesised within the stomach and enters the circulation, with feeding being considered the 
most important factor for its release. Concentrations are seen to increase in short term fasting 
and decrease after feeding. Ghrelin is found in two forms in the circulation; acylated and 
desacylated. In the acylated form the serine 3 molecule is covalently linked to octanic acid 
via an ester bond (Sato 2012). An enzyme called GOAT is responsible for the conversion of 
desacylated ghrelin to acylated ghrelin (Yang 2008). With regards to appetite regulation, 
ghrelin is considered to be in its active form when it is acylated allowing ghrelin to cross the 
blood brain barrier and act on receptors in the brain (Kojima et al. 1999). However, the 
majority of ghrelin found within the circulation is desacylated, a form considered to be 
inactive, with respect to appetite regulation. Therefore when measuring total ghrelin 
concentrations, the effects of acylated ghrelin could be masked. 
The ester bond formed by GOAT is both chemically and enzymatically unstable and the 
breakdown of this molecule can occur easily during storage and handling of these samples. In 
particular, the ester bond is easily cleaved and digested by a number of cellular proteases 
(Sato 2012). Consequently effective sample collection and processing protocols have been 
developed to allow for accurate determination of acylated ghrelin from plasma samples 
(Blatnik & Soderstrom 2011; Hosada et al. 2006; Hosada et al. 2012). Blatnik & Soderstrom 
(2011) pre-treated plasma with aprotinin, 4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF) and a protease inhibitor cocktail. AEBSF and protease inhibitors 
yielded approximately three- and two-fold higher acylated ghrelin concentrations than 
aprotinin in fasting and fed samples, respectively. Furthermore, work by Hosoda and 
Colleagues (2006, 2012) identified that collecting blood samples with ethylenediaminetetra-
acetic acid (EDTA) and aprotinin was most effective at stabilising acylated ghrelin 
concentrations in the plasma, compared with EDTA, heparin sodium and no pre-treatment. 
62 
Subsequent acidification of plasma samples to pH 4 using 1 M hydrochloric acid further 
preserved acylated ghrelin concentrations in these samples. 
Within our laboratory, we currently use manufacture guidelines to preserve acylated ghrelin 
in plasma samples. Blood samples are collected with EDTA, p-hydroxymercuribenzoic acid 
(PHMB), potassium phosphate buffer (PBS), and sodium hydroxide (NaOH). Plasma is 
subsequently acidified and stored at -20°C until frozen and then transferred to -80°C for later 
analysis. This method requires plasma samples to be spun twice using a centrifuge, making 
this procedure time consuming. In addition, PHMB preparation requires a fume cupboard, as 
this chemical is toxic when inhaled. The additional resources required to follow this method 
could prevent or deter other research groups from measuring acylated ghrelin within human 
plasma. Furthermore, the cost associated with AEBSF, justifies identifying if the quicker, 
cheaper and safer method outlined by Hosoda and Colleagues (2006, 2012) is as effective at 
preserving acylated ghrelin concentrations and would facilitate research in this area. 
Therefore, the purpose of this study was to compare the use of aprotinin vs. PHMB for the 
determination of circulating acylated ghrelin in human plasma.  
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3.2. Methods 
3.2.1. Participants 
Loughborough University’s Ethics Advisory Committee approved the following study and all 
participants provided written informed consent before taking part in this research experiment. 
Participants were recruited from Loughborough University by word of mouth and email 
advertisement. 
Participants were provided with a participant information sheet, describing the purpose, 
protocol, demands and potential risks/harms of the study. After a verbal explanation of the 
study and discussion of any questions, participants completed an informed consent form 
(Appendix A) and a health screen questionnaire (Appendix B) before any experimental 
procedures began. 
Inclusion criteria for participation were as follows: not taking any medication had no history 
of infectious disease within the previous month of the study or a history of cardiovascular or 
metabolic disease. 
Nine healthy participants, five males and four females, volunteered to take part in this study. 
The physical characteristics of the participants were as follows: age 26 (3) y, BMI 22 (2) 
kg·m
-2
, body mass 68 (10) kg. 
3.2.2. Preliminary visit 
Prior to the main trial, participants visited the laboratory to provide anthropometric measures 
and to be familiarised with the laboratory environment. Specifically, height was measured to 
the nearest 0.1 cm using a stadiometer (Seca Ltd, Germany) and body mass was measured to 
the nearest 0.1 kg using a digital scale (Seca Ltd, Germany). For measurements of height and 
weight, participants wore light clothing and removed their shoes. BMI was subsequently 
calculated as weight in kilograms divided by squared height in metres. 
3.2.3. Experimental protocol 
The main trial lasted 1 h and began at 08:45 after an overnight fast of at least 10 h. The main 
trial commenced with the collection of a fasting venous blood sample. Participants were 
provided with a standardised breakfast meal at 09:00. This was consumed within 15 min. The 
trial ended approximately 30 min after the end of the test meal with the collection of a 
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postprandial venous blood sample. Participants rested between blood samples (sitting reading, 
working at a desk or watching television). 
3.2.4. Standardised breakfast 
The breakfast meal consisted of jam sandwiches (brown bread, margarine and strawberry 
jam), banana and orange juice. The macronutrient content of this meal was 72% carbohydrate, 
10% protein and 18% fat. The breakfast meal provided 30% of the estimated daily energy 
needs for a healthy weight inactive individual (643 kcal for males, 578 kcal for females). 
The energy needs for an inactive individual were calculated using the Mifflin equation and a 
physical activity factor of 1.4 (Mifflin et al. 1990). This equation was selected as it considers 
the participants age, height, body mass and sex allowing for a more accurate estimation. A 
1.4 activity factor was selected to represent the sedentary nature of the experimental visit. 
The Mifflin equations for males and female are below: 
Male resting energy expenditure = (10 x body mass) + (6.25 x height) – (5 x age) + 5; 
Female resting energy expenditure = (10 x body mass) + (6.25 x height) – (5 x age) – 161. 
Water was available ad libitum throughout the trial. 
3.2.5. Blood sampling 
Venous blood samples were taken by venepuncture of an antecubital vein. At each sampling 
point blood samples were collected into two pre-chilled 4.9 mL pre-chilled EDTA 
monovettes (Sarstedt, Leicester, UK) for the measurement of acylated ghrelin. One 4.9 mL 
EDTA monovette was treated with a 50 µL solution containing PHMB/PBS/NaOH (PHMB 
method). Immediately after the collection of a blood sample, this monovette was spun in a 
refrigerated centrifuge (Heraeus Labofuge 400R, Thermo Electron, Osterode, Germany) at 
1165 x g for 10 min at 4°C. The plasma supernatant was immediately dispensed into a 
Polypropylene tube and 100 µL of 1 M hydrochloric acid was added per mL of plasma. 
Samples were then spun at 1165 x g for 5 min at 4°C prior to storage in 2 mL Eppendorf 
tubes at -20°C for later analysis. The second 4.9 mL EDTA monovette was treated with 
aprotinin (Nordic Pharma, Reading, UK) at a final concentration of 500 KIU per mL of blood 
(aprotinin method). This monovette was spun in a refrigerated centrifuge at 1165 x g for 10 
min at 4°C. The plasma supernatant was immediately dispensed into an Eppendorf tube and 
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100 µL of 1 M hydrochloric acid was added per mL of plasma. The plasma was stored in the 
Eppendorf tube at -20°C for later analysis. 
3.2.6. Biochemical analysis 
Plasma acylated ghrelin concentrations were determined using a commercially available 
enzyme linked immunosorbent assay kit (SPI BIO, Montigny le Bretonneux, France) with the 
aid of a plate reader to measure absorbance (Expert plus, ASYS Atlantis, Eugendorf, Austria). 
Precision of analysis was ensured by the quantification of an internal quality control on each 
assay plate. To eliminate inter-assay variation, samples from each participant were analysed 
on the same run. The within-batch coefficients of variation for the assays were 10.9%. 
3.2.7. Statistics 
Data were analysed using IBM SPSS statistics, version 21.0 for Windows. Data for the two 
preservation methods were compared using Student’s paired t-tests. The Pearson product 
moment correlation coefficient was used to examine the relationship between the two 
preservation methods. A Bland-Altman analysis was used to assess the limits of agreement 
(LOA) between the two preservation methods, comparing the aprotinin method to the PHMB 
method. The 95% LOA were determined as the mean difference ± 1.96 standard deviations (s) 
of the mean difference. It is expected that the 95% LOA include 95% of the differences 
between the two measures. Statistical significance was accepted at 5%. Results are shown as 
mean (SD) in text and tables.  
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3.3. Results 
The Pearson product moment correlation coefficient indicated that the two methods were 
moderately correlated at both the pre- and post-meal time points (see Table 3.1). However 
blood samples treated with aprotinin yielded significantly lower plasma acylated ghrelin 
concentrations that those treated with PHMB. The mean difference was 14% for the pre-meal 
values and 18% for the post-meal values. 
Table 3.1. Acylated ghrelin (pg·mL
-1
) values at the pre- and post-meal time points assessed 
via the two methods, mean difference between the methods, t-test, correlation and LOA 
values for acylated ghrelin. 
 
PHMB Aprotinin 
Mean 
difference 
T-test Correlation -1.96s +1.96s 
Pre-meal 184 
(80) 
159 
(66)
 
-25 
(27) 
P=0.024 r=0.73, 
P=0.026 
-77 28 
Post-meal 97 
(55) 
80 
(55)
 
-17 
(9) 
P<0.001 r=0.75, 
P=0.021 
-35 1 
Values are mean (SD). N=9. Mean difference, aprotinin minus PHMB; -1.96 and +1.96 show 
the lower and upper 95% LOA when using aprotinin. 
Bland-Altman analysis suggests that for both pre- and post-meal concentrations of acylated 
ghrelin there was no relationship between the difference and mean of the two methods. 
Limits of agreement highlight a large variance when using the aprotinin method (See Figure 
3.1 and 3.2).
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3.4. Discussion 
These findings suggest that the aprotinin method is less effective for preserving plasma 
acylated ghrelin than the PHMB method. The LOA values suggest that with a PHMB 
determined value of 184 pg·mL
-1 
the aprotinin determined value could lie anywhere between 
107 and 212 pg·mL
-1
. Similarly, for a PHMB determined value of 97 pg·mL
-1 
the aprotinin 
determined value could lie anywhere between 62 and 98 pg·mL
-1
. 
Despite aprotinin being less effective at preserving acylated ghrelin, this method was still 
able to detect a typical acylated ghrelin response post-feeding, and mirrored the pattern of 
change shown by the PHMB method. If time is limited or a fume cupboard is unavailable, 
these results suggest that it is still viable to use the aprotinin method to identify patterns of 
acylated ghrelin within human plasma. 
However, for the studies within this thesis, blood collection tubes were pre-treated using the 
PHMB method for the determination of acylated ghrelin. 
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CHAPTER IV 
Appetite, appetite hormone and energy intake responses to two consecutive days of 
running in healthy young men 
4.1. Introduction 
The interaction between exercise, appetite control and energy balance has direct relevance for 
the implementation of exercise as a therapeutic strategy for weight control. Over the last 
decade, many studies have investigated the impact of acute exercise, and exercise training, on 
appetite perceptions, food intake and energy balance (Hopkins et al. 2010). Currently, a 
disparity exists whereby on the one hand evidence suggests that exercise training (4-12 
months) does not induce substantial weight loss due to compensatory responses i.e. increases 
in appetite and food intake (King et al. 2007; Hopkins et al. 2014; Wing 1999); while on the 
other hand acute laboratory-based studies consistently document that acute exercise has no 
influence ad libitum food intake in the hours after exercise (King et al. 2013; Wasse et al. 
2012). Indeed, a recent meta-analysis concluded that acute exercise has a trivial effect on 
subsequent energy intake (Schubert et al. 2013). Studies have consistently shown a transient 
suppression of appetite after moderate to vigorous intensity acute exercise, lasting up to 15 
minutes (Alajmi et al. 2016; Broom et al. 2007; Deighton et al. 2013a; King et al. 1994; King 
et al. 2011a). However, this is not seen to extend later into the trial day. It is possible that this 
inconsistency between outcomes is related to the rather loose coupling which exists between 
perturbations to energy balance induced by exercise and subsequent energy intake (Blundell 
& King 1998). Compensatory alterations in appetite and food intake in response to single 
bouts of exercise could possibly occur over a longer duration than that previously examined 
in acute laboratory studies i.e. over more than 24 h. To date, only two studies have looked at 
this proposition in detail under strict laboratory conditions. In one study, appetite responses 
before and after a test meal were examined on the day after a single bout of moderate-
intensity exercise (Heden et al. 2013). The researchers reported that exercise on the previous 
evening reduced perceptions of fullness in obese volunteers, but had no influence in lean 
individuals. More recently, Beaulieu et al. (2015) examined appetite and ad libitum energy 
intake responses over 34 h with an acute bout of sprint interval exercise being performed at 
the beginning of the trial. The researchers observed a transient suppression of appetite, 
characteristic of exercise-induced anorexia (King et al. 1994), but then observed a latent 
increase in hunger and motivation to eat several hours after exercise leading to increased 34 h 
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area under the curve (AUC) values compared to control conditions. There was no effect of 
exercise on energy intake. However, it should be noted that in this study appetite perceptions 
and ad libitum energy intake may have been compromised by reports of nausea and vomiting 
during and after exercise (Seimon et al. 2010). Additional work is needed to extend these 
preliminary findings in order to identify the initial stage of compensation and to better 
understand the regulatory mechanisms. 
Advancements in knowledge about the neuro-humoral regulation of appetite and energy 
homeostasis have catalysed research investigating the influence of exercise on hormones 
implicated in appetite control and energy balance (King et al. 2013; Schubert et al. 2014; 
Stensel 2010). Findings from this body of work were recently pooled in a meta-analysis 
which concluded that acute exercise has a small to moderate effect on appetite hormones, 
suppressing acylated ghrelin, and stimulating PYY, GLP-1 and pancreatic polypeptide (PP) 
(Schubert et al. 2014). These alterations are transient, and often coincide with appetite loss 
during and after moderate to high intensity exercise (however, there is often little effect on 
subsequent changes in food intake). Unfortunately, at present, there is a dearth of information 
regarding the more protracted effects of exercise on these important mediators of appetite 
control. As an exception, Heden et al. (2013) observed attenuated fasting and post-meal 
suppression of acylated ghrelin after a standardised breakfast meal in lean individuals on the 
morning after exercise the prior evening. This response is suggestive of a compensatory 
mechanism serving to defend energy balance i.e. less effective suppression of an appetite 
stimulating signal. No changes in acylated ghrelin were seen in obese individuals. 
Unfortunately in this study energy intake was not examined on the day after exercise; thus 
future research is required to identify if the highlighted changes in acylated ghrelin influence 
subsequent energy intake. It has been hypothesised that compensatory responses in appetite 
regulatory hormones and energy intake may be delayed, and future research is needed to 
investigate this by examining longer term responses to energy imbalance. 
The present investigation sought to advance previous research by characterising the impact of 
exercise, performed on two consecutive mornings, on appetite, ad libitum food intake and key 
hormones implicated as important regulators of appetite and eating (acylated ghrelin, PYY, 
leptin and insulin). Specifically, by eliciting a marked perturbation to energy homeostasis by 
performing two prolonged bouts of moderate-high intensity treadmill running, we imposed a 
notable and unfamiliar stimulus (for the participants) through which to assess the impact of 
exercise in controlled conditions over a more prolonged period than typically implemented. 
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Based on previous findings, in response to this stimulus, it was hypothesised that appetite and 
energy intake would be unaltered on the first day of exercise, but that on the second day, 
compensatory increases in appetite, energy intake and acylated ghrelin would be seen. 
Conversely, compensatory decreases in circulating PYY and leptin may be apparent.  
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4.2. Methods 
4.2.1. Participants 
Loughborough University’s Ethics Advisory Committee approved the following study and all 
participants provided written informed consent before taking part in this research experiment. 
Participants were recruited from Loughborough University by word of mouth, email and 
poster advertisement. 
The inclusion criteria for participation were as follows; 
 male 
 aged 18-40 y 
 non-smoker 
 not taking medication 
 weight stable for at least 3 months before the study (St Jeor et al. 1997) 
 not dieting or exhibiting extreme eating habits 
 no history of cardiovascular or metabolic disease 
 tolerance for food items provided during the experiment 
 sufficient ability to complete the exercise protocol 
Fifteen healthy males (18-24 y) matching the inclusion criteria volunteered to participate in 
this study. Most participants recruited were students studying at Loughborough University, 
who were recreational games players, not accustomed to performing repeated, prolonged 
bouts of moderately-high intensity running. Table 4.1 describes the participant characteristics. 
Table 4.1. Characteristics of the study participants. 
Characteristic Mean (SD) 
Age (y) 21.1 (1.7) 
BMI (kg·m
-2
) 23.0 (1.9) 
Body mass (kg) 74.8 (6.8) 
Waist circumference (cm) 78.5 (5.2) 
Treadmill peak oxygen uptake (mL·kg
-1
·min
-1
) 57.9 (4.2) 
Values are mean (SD). N=15.  
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4.2.2. Preliminary trial 
Prior to the main trials, participants visited the laboratory to undergo screening and 
preliminary anthropometric measures. Participants were also familiarised with the laboratory 
environment, test equipment and procedures before completing two preliminary exercise tests. 
Participants were provided with a participant information sheet, describing the purpose, 
protocol and demands of the study (including any potential risks or harms). After a verbal 
explanation of the study and discussion of any questions participants completed an informed 
consent form (Appendix A) and a health screen questionnaire (Appendix B) before any 
experimental procedures began. Participants also completed questionnaires assessing physical 
activity levels (Appendix C) and a questionnaire assessing eating habits (Three-Factor Eating 
Questionnaire (TFEQ), Appendix D, Stunkard & Messick 1985) to screen participants who 
exhibited extreme dietary tendencies (including disinhibited and restrained eating). 
Participants scoring 11 or more for any factor on the TFEQ were determined to exhibit 
restrained or disinhibited eating tendencies, and consequently excluded from taking part. This 
score was selected, as it represents the mean suggested ‘high’ cut off for all three behaviours 
measured in this questionnaire (Stunkard & Messick 1985). Those who score either high or in 
the clinical range for these variables could confound appetite and energy intake data, 
justifying their exclusion from the study. A food preference questionnaire (Appendix E) was 
also completed to ensure participants enjoyed >80% of food items available. 
Height and body mass were measured as described in Chapter 3. Waist circumference was 
determined as the narrowest part of the torso between the xiphoid process and the iliac crest 
(Ross et al. 2008). Measurements were taken in duplicate to the nearest 0.1 cm. If the 
measurements were within 1 cm of each other, the mean was calculated. If these measures 
differed by more than 1 cm, a third measurement was repeated, and so on (WHO, 2011). 
Participants completed two preliminary exercise tests on a level motorised treadmill 
(Technogym Excite Med, Cesena, Italy). After familiarisation with the protocol and treadmill, 
participants completed a 16 min progressive submaximal test to determine the relationship 
between treadmill speed and oxygen consumption. The test was designed to exercise 
participants through a range of intensities from moderate to vigorous but was not exhaustive. 
The test was continuous in nature, subdivided into four, 4 min segments. The initial treadmill 
speed was set between 8 and 11 km·h
-1
 depending on the fitness level of each participant and 
was increased between 1 and 1.5 km·h
-1
 after the completion of each 4 min stage. Oxygen 
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consumption and carbon dioxide production were determined in the last min of each stage 
from expired air samples collected into Douglas bags (Plysu Protection Systems, Milton 
Keynes, UK) and analysed using a dry gas meter (Harvard Apparatus, Edenbridge, Kent, UK) 
and paramagnetic oxygen/infra-red carbon dioxide analyser (Series 1400, Servomex, 
Crowborough, East Sussex, UK). Prior to sample analysis, the analysers were calibrated with 
certified reference gases. Expired air temperature was determined using a thermistor during 
evacuation (Edale, type 2984, Model C, Cambridge, UK). Expired air samples were corrected 
to standard temperature and pressure (dry). The Borg scale was used to obtain the participants 
rating of perceived exhaustion (RPE) at these time points (Borg 1973). This scale ranged 
from six (no exertion) to 20 (maximal exertion). Heart rate was measured throughout using 
short-range radio telemetry (Polar T31; Electro, Kempele, Finland). 
After a 20 min rest participants completed a V̇O2 peak test. An incremental uphill treadmill 
protocol was used to test participants until volitional exhaustion. Run speed was constant and 
set at a speed corresponding to a heart rate of ~150 beats·min
-1
. Treadmill gradient began at 
3.5% and increased by 2.5% at 3 min intervals until exhaustion, which was reached within 9-
12 min. Samples of expired air were collected for 1 min, 1.75 min into each stage i.e. 1:45-
2:45, 4:45-5:45 etc. A final expired air sample was collected when participants indicated that 
they could continue for only one more minute. Heart rate and RPE were also collected at 
these time points. 
To ensure attainment of V̇O2 peak participants were required to meet ≥2 of the following 
criteria: 
 plateau in oxygen consumption 
 heart rate within 10 beats.min-1 of age predicted maximum 
 non-protein respiratory exchange ratio (RER)≥1.1 
 RPE≥19 (Cooke 2001) 
The achieved V̇O2 peak of each participant was used in combination with individual running 
speed-oxygen uptake regression equations to determine a running speed corresponding to 
70% V̇O2 peak. Participants started at this speed during main trials, with subtle adjustments 
made if necessary i.e. for cardiovascular drift.  
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4.2.3. Experimental protocol 
Participants completed two, two-day experimental trials (exercise and control) in a 
randomised crossover design with each trial being separated by at least one-week (Figure 4.1). 
Each trial lasted 31 h and required participants to attend the laboratory for 7 h on day one and 
day two. 
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Figure 4.1. Schematic representation of the main trial protocol. 
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B 
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Each trial commenced at 09:00 after an overnight fast of at least 10 h. Before the first trial 
participants recorded their dietary intake for 48 h using a weighed food record. Participants 
were instructed to consume identical amounts of food and drink items in the 48 h before the 
second trial to ensure dietary standardisation. After 23:00 on the evening prior to each main 
trial participants refrained from eating, however water was available ad libitum. Alcohol, 
caffeine and structured physical activity were not permitted during this time. Participants 
were asked to confirm that they had adhered to the dietary and exercise standardisations 
before starting each experimental trial day. 
Day one of the exercise trial commenced with a 60 min continuous treadmill run (Technogym 
Excite Med, Cesena, Italy) at a speed predicted to elicit 70% of V̇O2 peak. Expired air 
samples were collected at 15, 30, 45 and 60 min during exercise to estimate energy 
expenditure and to monitor the intensity with subtle adjustments being made to the treadmill 
speed if necessary. Heart rate and RPE were also assessed at these times. Energy expenditure 
during the exercise session was calculated from oxygen uptake and carbon dioxide 
production (Frayn 1983). These measurements were also used to calculate RER (carbon 
dioxide production divided by oxygen consumption). 
After the run, participants rested in the laboratory for 6 h (sitting, reading, working at a desk 
or watching films). At the end of this time participants left the laboratory and were instructed 
to remain physically inactive in the time spent away from the laboratory in-between days one 
and two (<5000 steps; Tudor-Locke & Bassett 2004) and this was confirmed by a pedometer 
(Yamax DIGI-WALKER SW200, San Antonio, USA) which each participant wore. 
Participants returned the next morning at 09:00 (minimum 10 h overnight fast) to commence 
day two of the trial. Day two of main trials was identical to day one. 
The procedures in the control trial were identical to the exercise trial except that no exercise 
was performed. The sole exception to this was that resting expired air samples were collected 
during the first hour of each control trial day to assess resting metabolic rate. These data 
subsequently permitted the calculation of net exercise energy expenditure i.e. gross exercise 
energy expenditure minus resting energy expenditure.  
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4.2.4. Appetite measures 
During the laboratory phase of the main trials, appetite perceptions (hunger, fullness, 
satisfaction and prospective food consumption (PFC)) were assessed at baseline and at every 
30 min thereafter using validated visual analogue scales (Appendix F, Flint et al. 2000). Each 
visual analogue scale was 100 mm in length, with opposing descriptors positioned at either 
end (e.g. ‘I am not hungry at all’ and ‘I have never been more hungry’). Participants rated 
their appetite by making each scale with a vertical mark. Participants could not refer back to 
previous ratings when completing the scales. The scales were analysed by measuring the 
horizontal distance from the left hand side anchor of the scale to the point marked by the 
participant. 
4.2.5. Ad libitum meals and overnight food bags 
Energy and macronutrient intake were assessed at two ad libitum meals provided on both 
days of the exercise and control trials. Specifically, at 2 h a cold buffet meal was provided 
from which participants were free to consume food ad libitum for 30 min. Acceptability of 
the buffet items was ensured during the preliminary trial via the completion of a food 
preference questionnaire (Appendix E). The questionnaire required participants to rate 
preselected food items on a Likert scale ranging from one (dislike extremely) to ten (like 
extremely). Participants were excluded from the study if they rated >20% of the items at 4 or 
less. The items available are listed in Appendix G. The buffet foods were presented 
identically on each occasion and were in excess of expected consumption. Participants were 
instructed to eat until ‘comfortably full’ and informed that additional food was available if 
desired. 
At 6 h ad libitum energy intake was assessed using a hot homogenous pasta meal. This 
method attempted to blind the participants from the amount of food they had eaten. The ad 
libitum meal was composed of white fusilli (Tesco Fusilli Pasta Twists), tomato sauce (Tesco 
Bolognese sauce), Cheddar cheese (Tesco British Mature White Cheddar) and olive oil 
(Tesco Extra Virgin Olive Oil). For each trial, 500 g of pasta was cooked in 2 L of unsalted 
water at 900 W for 11 min. The pasta was drained with the weight recorded 4 min after 
cessation of cooking. The cooked pasta was then thoroughly mixed with 156 g of cheese, and 
375 g of pasta sauce, until homogenous in nature. The pasta was then covered and allowed to 
cool completely. Approximately 30 min before the ad libitum meal was due to be served; 
50 g of olive oil was added and mixed into the pasta meal. The pasta was then reweighed and 
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divided equally between 5 smaller serving bowls. Immediately prior to serving the meal, a 
small bowl was reheated at 900 W for 1 min in the microwave. The bowl of pasta was 
allowed to cool for 90 s before weighing and presented to the participant. The next bowl was 
subsequently heated, cooled and replaced the partially consumed bowl. Each returned bowl 
was weighed. This process was continued until the participant felt ‘comfortably full’, with no 
time limit set. The macronutrient composition of the meal was balanced (52% carbohydrate, 
14% protein and 34% fat), and designed to meet current UK dietary guidelines (Food 
Standards Agency, 2007). 
Participants consumed meals in isolation so that social influence did not affect food selection 
or quantity eaten (except for the replacement of fresh, and retrieval of used pasta bowls). 
Leftovers were weighed and food consumption was determined as the weighed difference of 
items before and after each meal. The energy and macronutrient content of the items 
consumed were determined from manufacturers’ values. Previously, authors have shown a 
high level of reproducibility when measuring energy intake by ad libitum buffets (Arvaniti et 
al. 2008; CV 8.2%) and hot homogenous meals (Gregersen et al. 2008; CV 14.5%). This 
suggests that these methods are reliable for assessing ad libitum energy intake in a laboratory 
environment. 
For the time spent away from the laboratory in-between the visits on day one and day two 
participants were free to select, and consume, a selection of items presented at the cold buffet 
meal. Participants were permitted to consume these items after leaving the laboratory on day 
one and until 23:00. The food items available for selection are listed in Appendix H. 
Leftovers were returned the next day to determine actual consumption. Water was available 
ad libitum throughout trials. 
4.2.6. Blood sampling 
Venous blood samples were collected at 0 and 7 h on day one of each trial, and at 0, 2, 3, 6 
and 7 h during day two. Both samples on day one, and the baseline sample on day two, were 
collected by venepuncture of an antecubital vein. The remaining blood samples on day two (2, 
3, 6 and 7 h) were collected using a cannula (Venflon, Becton Dickinson, Helsinborg, 
Sweden) inserted into an antecubital vein. Patency of the cannula was maintained by flushing 
with 10 mL of non-heparinised saline (0.9 % (w/v) sodium chloride, Baxter Healthcare Ltd., 
Norfolk, UK) after each blood sample collection. To avoid dilution of the subsequent sample 
residual saline was drawn off immediately before each collection using a 2 mL syringe. 
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Venous blood samples were taken into two pre-chilled EDTA monovettes (4.9 mL and 9 mL) 
(Sarstedt, Leicester, UK) for the measurement of plasma total PYY, acylated ghrelin, leptin, 
glucose and insulin. To prevent the degradation of acylated ghrelin, blood samples collected 
into the 4.9 mL monovette were pre-treated and processed following manufacturer 
instructions (see Chapter 3). The remaining analytes were measured from the resulting 
plasma collected into the 9 mL monovette. After blood collection, the 9 mL monovette was 
immediately spun at 1165 x g for 10 min at 4°C in a refrigerated centrifuge (Heraeus 
Labofuge 400R, Thermo Electron, Osterode, Germany). The plasma supernatant was 
aliquoted into 2 mL Eppendorfs and stored at -20°C for future analysis. 
At each sampling point duplicate 20 µL blood samples were collected into micropipettes for 
the determination of haemoglobin, and triplicate 20 µL blood samples were collected into 
heparinised micro haematocrit tubes for the determination of blood haematocrit concentration. 
These data were used to estimate plasma volume changes over time (Dill & Costill 1974). 
Haematocrit was determined using a microliter-haematocrit centrifuge (MIKRO, 20, Andreas 
Hettich GmbH and Co.KG, Tuttlingen, Germany). Haemoglobin was determined using 
cyanmethaemoglobin method with the aid of a spectrophotometer (CECIL CE1011, Cecil 
Instruments Ltd., Cambridge, UK). 
4.2.7. Biochemical analysis 
Commercially available enzyme immunoassays were used to determine concentrations of 
plasma acylated ghrelin (SPI BIO, Montigny le Bretonneux, France), total PYY (Millipore, 
Billerica, USA), leptin (R&D Systems, Minneapolis, USA) and insulin (Mercodia, Uppsala, 
Sweden) with the aid of a plate reader to measure absorbance (Expert Plus, ASYS Atlantis, 
Eugendorf, Austria and Varioskan Flash Multiple Mode Reader, Vantaa, Finland). Plasma 
glucose concentrations were determined by enzymatic, colorimetric methods using a bench 
top analyser (Pentra 400; HORIBA ABX Diagnostics, Montpellier, France). Precision of 
analysis was ensured by quantification of an internal quality control exhibiting high and low 
values. To eliminate inter-assay variation, samples from each participant were analysed on 
the same run. The within-batch coefficients of variation for the assays were as follows: 
acylated ghrelin 10.9%, total PYY 7.7%, leptin 5.9% insulin 7.9% and glucose 0.6%.  
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4.2.8. Statistical analysis 
Data were analysed using IBM SPSS statistics, version 21.0 for Windows. Appetite 
perceptions and appetite hormone total AUC calculations were performed using the 
trapezoidal method. Comparison between trials for exercise responses, energy and 
macronutrient intake, and day two total AUC appetite hormone data were compared using 
Student’s paired t-tests. Two-way repeated measures ANOVA was used to examine 
differences between trials over time for appetite perceptions, energy and macronutrient intake 
and appetite hormones. Where significant trial and interaction effects were found, post-hoc 
analysis was performed using Holm-Bonferroni correction for multiple comparisons 
(Atkinson 2002). The Pearson product moment correlation coefficient was used to examine 
relationships between variables. Corrections of plasma analyte values for changes in plasma 
volume did not alter the statistical significance of the results, therefore, for simplicity, the 
unadjusted values are presented. Statistical significance was accepted at 5%. Results are 
shown as mean (SD) in text and tables, and mean (SEM) in figures (for clarity).  
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4.3. Results 
4.3.1. Exercise responses 
The exercise responses for day one and day two are summarised in Table 4.2. There was no 
significant difference in oxygen consumption, exercise intensity, running speed, RPE, net 
energy expenditure, RER, carbohydrate or fat utilisation between the two days of exercise. 
Heart rate data was not available for two subjects, therefore analysis was completed on 13 
subjects. Heart rate was found to be significantly higher on the first day of exercise (P=0.029). 
There was no difference between trials in pedometer-assessed physical activity (Control 4337 
(1683); Exercise 4524 (2112) counts P=0.991, r=0.84) demonstrating that participants 
remained equally inactive outside of formal exercise periods during main trials (<5000 steps; 
Tudor-Locke & Bassett 2004). 
Table 4.2. Exercise responses during the 60 min treadmill run on day one and day two. 
Response Day one Day two P 
VO2 (mL.kg
-1
.min
-1
) 40.6 (3.1) 40.5 (3.5) 0.87 
VO2 (L.min
-1
) 3.0 (0.2) 3.0 (0.2) 0.77 
Exercise intensity (% of V̇O2peak) 70.1 (2.5) 70.0 (3.2) 0.85 
Running speed (km·h
-1
) 11.9 (1.0) 11.9 (1.0) - 
RPE (6 – 20) 15 (2) 15 (2) 0.62 
Heart rate (beats.min
-1
 ) 175 (11) 171 (13) 0.03 
Net energy expenditure (kJ [kcal]) 3779 (327) 
[903 (78)] 
3787 (327) 
[905 (78)] 
0.85 
RER 0.95 (0.04) 0.93 (0.03) 0.17 
Carbohydrate utilisation (%) 83.5 (11.5) 82.1 (10.0) 0.56 
Fat utilisation (%) 16.5 (11.5) 17.9 (10.0) 0.56 
Values are mean (SD). N=15, except for heart rate where N=13. 
4.3.2. Resting expired air samples 
Expired air samples were not available for one subject, therefore analysis was completed on 
14 subjects. The resting expired air values for day one and day two are summarised in Table 
4.3. There was no significant difference in oxygen consumption or energy expenditure 
between the two resting days. RER and carbohydrate utilisation were found to be 
84 
significantly higher on the second day of rest (P≤0.003). Fat utilisation was found to be 
significantly higher on the first day of rest (P=0.003). 
Table 4.3. Resting expired air values on day one and day two. 
Response Day one Day two P 
VO2 (mL.kg
-1
.min
-1
) 2.6 (0.5) 2.8 (0.6) 0.64 
VO2 (L.min
-1
) 0.20 (0.04) 0.21 (0.04) 0.34 
Energy expenditure (kJ [kcal]) 252.1 (50.5) 
[60.3 (12.1)] 
272.8 (55.8) 
[65.2 (13.3)] 
0.13 
RER 0.85 (0.06) 0.91 (0.04) <0.01 
Carbohydrate utilisation (%) 53.21 (18.97) 74.36 (13.05) <0.01 
Fat utilisation (%) 46.79 (18.97) 25.64 (13.05) <0.01 
Values are mean (SD). N=14. 
4.3.3. Appetite 
Fasting appetite perceptions (hunger, satisfaction, fullness and PFC) did not differ between 
trials at baseline on either day of each trial (all P>0.061). Two-way ANOVA revealed 
significant main effects of time (all P<0.001) and interaction effects (all P<0.001) for each 
appetite perception (Figure 4.2). Significant trial effects were also reported for hunger 
(P=0.046) and PFC (P=0.045), indicating suppressed levels in the exercise trial across days 
one and two. Compared with control, post-hoc analysis revealed suppressed hunger ratings at 
1.5 h on day one (P=0.029) and at 0.5 (P=0.029) and 1 h (P<0.001) on day two of the 
exercise trial. Fullness ratings were significantly elevated at 1 h on day one of the exercise 
trial (P=0.030), whilst PFC was lower at 0.5 (P=0.029) and 1 h (P<0.001) on day two of the 
exercise trial.  
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Analysis of the appetite total AUC (calculated separately for day one and two) using two-way 
ANOVA (day vs. trial) confirmed significant trial effects for hunger (P=0.042), fullness 
(P=0.050), and PFC (P=0.036) but did not show any differences in appetite between trial days 
one and two (Table 4.4). 
Table 4.4. Total area under the curve values for appetite perceptions in the control and 
exercise trials. 
 
Values are mean (SD). N=15. *significant difference between trials.  
 
Day One 
(7 h) 
Day Two 
(7 h) 
Total Trial 
(14 h) 
Hunger    
Control 309 (96) 301 (83) 610 (173) 
Exercise 272 (79) 259 (80) 531 (148)* 
Satisfaction    
Control 345 (80) 361 (73) 705 (143) 
Exercise 381 (75) 382 (80) 763 (141) 
Fullness    
Control 333 (85) 353 (74) 685 (152) 
Exercise 384 (64) 389 (61) 772 (102)* 
PFC    
Control 355 (86) 332 (83) 687 (161) 
Exercise 308 (80) 299 (74) 606 (140)* 
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4.3.4. Energy and macronutrient intake 
Table 4.5 and 4.6 show the energy and macronutrient intake data from the exercise and 
control trials. No significant main effects were apparent for energy intake (all P>0.137). 
There was no effect of trial order on total energy intake (P=0.77). For macronutrient intake, 
no significant main effects were found for carbohydrate or fat intake (all P>0.261), however a 
main effect of time was observed for protein intake (P<0.001) which was reduced during the 
evening period between days 1 and 2 on both the control and exercise trials. 
Table 4.5. Ad libitum energy intake during the control and exercise trials. 
Day Meal 
Exercise 
(kJ) 
Control 
(kJ) 
P 
1 Cold Buffet (2 h) 5950 (1855) 6053 (2363) 0.84 
1 Hot Meal (6 h) 5777 (1407) 6052 (902) 0.43 
1 Overnight 5085 (1087) 5163 (1214) 0.80 
2 Cold Buffet (2 h) 5432 (1231) 5839 (1587) 0.39 
2 Hot Meal (6 h) 6288 (1738) 6109 (821) 0.60 
 Total Trial 28532 (3899) 29217 (4006) 0.45 
Values are mean (SD). N=15. Food consumption outside of the lab on day 1 (overnight) was 
between 16:30 and 22:30.  
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Table 4.6. Macronutrient intake in the control and exercise trials. 
Day  Fat (g) 
 
Carbohydrate (g) Protein (g) 
  [%] [%] [%] 
 Control Trial    
1 Cold Buffet (2 h) 51 (35) 203 (62) 45 (17) 
  [29 (10)] [58 (11)] [13 (4)] 
1 Hot Meal (6 h) 54 (8) 187 (28) 51 (8) 
  [34 (0)] [52 (0)] [14 (0)] 
1 Overnight Food bag 
ag 
47 (14) 188 (46) 14 (3) 
  [34 (5)] [61 (6)] [5 (0)] 
2 Cold Buffet (2 h) 47 (24) 201 (55) 43 (16) 
  [29 (11)] [59 (12)] [13 (5)] 
2 Hot Meal (6 h) 54 (7) 189 (24) 52 (7) 
  [34 (0)] [52 (0)] [14 (0)] 
 Total Trial 252 (59) 968 (133) 205 (29) 
  [32 (4)] [56 (4)] [12 (2)] 
 Exercise Trial    
1 Cold Buffet (2 h) 51 (28) 195 (48) 46 (19) 
  [30 (11)] [57 (11)] [13 (4)] 
1 Hot Meal (6 h) 54 (13) 188 (44) 52 (12) 
  [34 (0)] [52 (0)] [14 (0)] 
1 Overnight Food bag 
 
47 (12) 184 (43) 14 (3) 
  [35 (5)] [60 (5)] [5 (0)] 
2 Cold Buffet (2 h) 48 (24) 175 (24) 43 (16) 
  [31 (11)] [56 (12)] [13 (3)] 
2 Hot Meal (6 h) 58 (13) 201 (45) 54 (13) 
  [34 (0)] [52 (0)] [14 (0)] 
 Total Trial 258 (45) 942 (111) 208 (41) 
  [33 (4)] [55 (4)] [12 (1)] 
Values are mean (SD). N=15. Food consumption outside of the lab on day 1 (overnight) was 
between 16:30 and 22:30.  
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4.3.5. Relative energy intake 
Relative energy intake was calculated for days one and two as energy intake minus the net 
energy expenditure elicited by exercise (exercise day one: 13302 (2450) kJ; exercise day two: 
8090 (1342) kJ; control day one: 17268 (2775) kJ; control day two: 11948 (1692) kJ). 
Significant trial (P<0.001) and time (P<0.001) effects were found, indicating lower REI 
across days one and two on the exercise trial and also reflecting the fewer number of meals 
consumed on day two compared with day one (three vs. two) on both trials. 
4.3.6. Plasma total PYY, leptin, acylated ghrelin, triglyceride, glucose and insulin 
concentrations 
Due to problems with blood sampling data for plasma acylated ghrelin, total PYY and leptin 
are presented for 14 (rather than 15) participants while data for plasma insulin are presented 
for 13 (rather than 15) participants. Figure 4.3 shows the circulating appetite hormone 
responses on days one and two of the control and exercise trials. 
Fasting acylated ghrelin concentrations did not differ between the exercise and control trials 
at baseline on day one or day two (control day one: 128 (113); exercise day one: 144 (169); 
control day two: 127 (121); exercise day two: 117 (143) pg·mL
-1
 (P for trial, time and 
interaction all >0.05)) (Figure 4.3A). Across the whole trial, two-way repeated measures 
ANOVA did not show any significant main effects for plasma acylated ghrelin (all P>0.05). 
Fasting plasma total PYY concentrations did not differ between trials at baseline on day one 
or day two of main trials (control day one: 84 (40); exercise day one: 95 (63); control day two: 
87(37); exercise day two: 104 (50) pg·mL
-1
 (P for trial, time and interaction all >0.05)) 
(Figure 4.3B). Across the whole trial, two-way repeated measured ANOVA revealed a 
significant main effect of trial (P=0.029) indicating higher total PYY concentrations on the 
exercise trial. There was also a significant main effect of time (P<0.001) for total PYY. 
Fasting plasma leptin concentrations did not differ between trials at baseline on day one or 
day two of the exercise and control trials (control day one: 1543 (1042); exercise day one: 
1738 (1716); control day two: 1860 (2044); exercise day two: 1710 (1733) pg·mL
-1
, P>0.333) 
(Figure 4.3C). Across trial days, two-way repeated measures ANOVA revealed a significant 
main effect of time (P<0.001) but no trial or interaction effects (P>0.05). Fasting plasma 
insulin concentrations were found to differ across time (P=0.0015), however there were no 
trial or interaction effects (both P>0.05) (control day one: 21 (5); exercise day one: 25 (10); 
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control day two: 30 (10); exercise day two: 29 (13) pg·mL
-1
) (Figure 4.3D). Across trial days, 
two-way repeated measures ANOVA revealed a significant trial (P=0.025), time (P<0.001) 
and interaction effect (P=0.019) for plasma insulin concentrations. Post-hoc analysis showed 
insulin levels to be significantly lower for the exercise condition in comparison to the control 
condition at 2 h on day two (P<0.001). 
Total area under the curve calculations for day two of each trial revealed no significant 
differences for acylated ghrelin (control: 833 (1090); exercise: 909 (1337) pg·mL·h
-1
) and 
leptin (control: 10376 (10652); exercise: 9783 (9244) pg·mL·h
-1
) (both P>0.050). For insulin, 
values were significantly lower during the exercise trial (control: 1446 (785); exercise: 852 
(316) pg·mL·h
-1
, P=0.050), whilst total PYY values were significantly higher (control: 720 
(253); exercise: 883 (374) pg·mL·h
-1
, P=0.010). 
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4.3.7. Correlations 
Correlation analyses were performed for all major outcomes (total AUC hormone data and 
appetite ratings, energy intake and subject characteristics); however no statistically 
significant outcomes were found (data not shown).  
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4.4. Discussion 
The consensus from the research literature suggests that exercise does not stimulate appetite 
on the day it is performed, even when responses have been examined for several hours post-
exercise. Conversely, daily exercise undertaken over four to five consecutive days has been 
shown to increase hunger, motivation to eat or reduce satiation (Mackelvie et al. 2007; 
Hagobian et al. 2009). The present study sought to explore whether initial alterations in 
appetite could be detected after two bouts of exercise performed on consecutive days across a 
period of 30 h after the first bout of exercise. Besides witnessing a transient exercise-induced 
suppression of appetite on each day, we observed no subsequent changes in any of the 
subjective appetite measurements assessed. Thus, repeated bouts of exercise on two days did 
not impact hunger, satiation or satiety. These findings indicate that over this duration, 
exercise and its associated energy expenditure, are not compensated for. 
Previously, King et al. (1997) examined appetite responses across two days with two bouts of 
exercise being performed on the first day of the exercise trial (combined energy expenditure 
4983 (1004) kJ). Similar to the current investigation, these researchers observed no 
alterations in appetite. It should however be noted that in this particular study appetite 
assessments were made in participants’ free living environment; meaning that various 
extraneous factors may have confounded the results. More recently, Heden et al. (2013) also 
observed no changes in fasting or postprandial ratings of hunger and fullness in response to a 
test meal consumed on the morning after moderate-intensity exercise completed on the 
previous evening. In contrast to these findings, Beaulieu et al. (2015) recently published data 
showing a greater motivation to eat on the day after a single bout of sprint interval training 
(supra-maximal exercise) in a small group of trained men (N=8). Taken collectively, the 
available data suggests that acute exercise, even when repeated on two days, does not 
automatically stimulate appetite. Very high intensity exercise may be an exception; however 
additional studies with a larger group of more diverse participants are needed to state this 
with any certainty. 
An additional aim of the present investigation was to characterise the extended impact of 
exercise on energy and macronutrient intake. Consistent with the lack of alteration in appetite, 
we also observed no significant changes in energy or macronutrient intake assessed from 
several ad libitum meals consumed across days one and two. Previous studies have shown 
that over an extended period (one to two weeks) individuals may begin to partially increase 
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the amount of food consumed in an attempt to counter the heightened energy expended 
during exercise (Stubbs et al. 2002a; Stubbs et al. 2002b; Whybrow et al. 2008). The precise 
point at which this response is initiated is not known, however it is clear that such 
compensation does not occur immediately on the actual day that exercise is performed 
(Schubert et al. 2013). When considering responses on the day after exercise, King et al. 
(1997) previously reported a lack of change in energy intake. Unfortunately, in this study the 
implementation of diaries to assess energy intake, and the aforementioned lack of study 
control, limits the strength of these findings. The present study sought to provide a more 
rigorous analysis by utilising laboratory based assessments of energy and macronutrient 
intake. The present results are consistent with recent findings reported by Beaulieu et al. 
(2015) who observed no changes in energy intake within the 36 h after sprint interval training. 
Together, these data indicate that the initial stages of energy intake compensation are not seen 
on the day after exercise, even when a successive bout is performed on the second day. It is 
likely that compensatory responses will begin to appear after additional days of exercise with 
a higher level of energy expenditure and/or negative energy balance. 
Appetite and food intake are subject to regulation by a complex network of neural-hormonal 
mediators which act acutely (meal to meal) and chronically (over days/weeks) to facilitate 
energy homeostasis (Neary & Batterham 2009; Perry & Wang 2012). Notable within the 
short-term regulation of appetite and energy intake are acylated ghrelin and PYY which work 
antagonistically to coordinate meal initiation and termination (De Vriese et al. 2010; 
Manning & Batterham 2014). Specifically, acylated ghrelin remains unique as the only 
known hormonal stimulant of appetite, with circulating levels increasing prior to meal 
initiation and subsequently decreasing postprandially (Cummings et al. 2004). Conversely, 
PYY is a key mediator of satiation and satiety, with circulating levels increasing in response 
to nutrient intake and remaining elevated between meals (Le Roux et al. 2005). Acylated 
ghrelin and PYY are also implicated in the chronic regulation of energy homeostasis with 
each being sensitive to deviations in energy balance/stores. Specifically, negative energy 
balance and weight loss increase circulating levels of acylated ghrelin (King et al. 2011; 
Leidy et al. 2007) and reduced those of PYY (Hill et al. 2011; King et al. 2011). These 
responses serve to promote the restoration of energy balance and limit perturbations in body 
weight. The present study sought to characterise the latent impact of exercise on acylated 
ghrelin and PYY. Specifically, we wanted to determine how exercise, and the associated high 
level of energy expenditure, would impact circulating levels of these hormones over an 
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extended duration. It was anticipated that fasting and/or postprandial levels of acylated 
ghrelin on day two would be elevated, whilst those of PYY would be reduced as mechanisms 
to preserve energy homeostasis. In contrast, we saw no changes in acylated ghrelin whilst 
PYY was transiently elevated on day two after exercise. The present findings therefore 
contrast recent data reported by Heden et al. (2013) who observed attenuated fasting and 
postprandial suppression of acylated ghrelin at a test meal consumed on the morning after 
exercise completed on the previous evening. The discrepancy in findings is likely related to 
key differences between protocols such as the time between exercise and blood sampling and 
the additional bout of exercise performed in the present study. This inconsistency in outcome 
identifies a need to further scrutinise the protracted impact of exercise on acylated ghrelin. 
In the present investigation, we saw no change in fasting levels of PYY on day two; however, 
a transient increase in circulating PYY levels was apparent after the second bout of exercise 
i.e. on day two. This investigation is the first to assess the impact of exercise on the fasting 
level of PYY on the day after exercise and therefore the lack of change despite a high level of 
energy expenditure is a novel observation. The short-term increase in PYY after exercise on 
day two is consistent with previous research, which has described a transient increase in PYY 
in response to moderate-high intensity exercise (Broom et al. 2009; Martins et al. 2007; Ueda 
et al. 2009). It is beyond the scope of the present thesis to speculate on the mechanisms 
mediating this response; it is clear however that this acute effect is maintained with repeated 
bouts of exercise on consecutive days. Nonetheless, there was no observation of any 
compensatory down-regulation of PYY in response to exercise-related energy expenditure 
across the time-frame examined. Furthermore, as shown in previous studies, this exercise-
induced change in PYY does not appear to have any influence on appetite or energy intake. 
PYY has many physiological functions in the body e.g. gastrointestinal transit, substrate 
metabolism, thermogenesis; and it is possible that the change witnessed with exercise is 
unrelated to appetite control and food intake. Conversely, it is also possible that the response 
is relevant but is insufficient to overcome ingrained habits and behaviour relating to food 
intake so that visible effects on these outcomes may only be seen over a greater period of 
time or with a larger stimulus. 
Episodic signals regulating appetite and energy intake function synergistically with additional 
chronic hormonal mediators which are primarily sensitive to perturbations in energy balance 
and bodily energy stores. Within this system, leptin and insulin are well defined; being 
positively associated with energy availability and responding dynamically to perturbations in 
96 
energy balance (Gautron & Elmquist 2011; Woods et al. 2006). Previous research has shown 
that leptin is sensitive to negative energy balance induced by exercise (≥3340 kJ) with 
compensatory decreases in circulating levels being detectable after a latency period of 12-
24 h (Essig et al. 2000; Olive & Miller 2001). In the present investigation, despite a net 
energy expenditure of ~3765 kJ on day one, we did not detect any change in fasting leptin on 
the following morning; nor did we see any changes after the second bout of exercise on day 
two. It is possible that the second bout of exercise on day two may have masked any latent 
changes which may have otherwise occurred. Furthermore, despite exercise on day one 
inducing a relative energy deficit of 4234 kJ, the somewhat high amount of energy intake 
across each trial on day one (control 17268 (2775); exercise 16812 (2899) kJ) may have been 
sufficient to block any exercise-related decrease in leptin. 
In addition to its central role in regulating glycaemia, insulin is also a tonic signal regulating 
energy balance either by acting directly within the hypothalamus, or by modulating the 
brain’s sensitivity to episodic appetite signals (McMin et al. 2000; Woods et al. 2006). 
Chronically, circulating levels of insulin are positively related to adiposity and insulin 
resistance within key metabolic tissues. An increase in insulin sensitivity is a well-
characterised effect of acute exercise that endures for up to 72 h after each individual bout 
(Hawley & Lessard 2008). In the present study, our participants were young and healthy, 
with low basal insulin levels. It is therefore perhaps unsurprising that fasting concentrations 
on day two were not lowered further by prior exercise. On day two we did however observe 
reduced levels of insulin in response to the morning meal; a response which is consistent with 
an enhancement of insulin sensitivity induced by exercise. Although important for glycaemic 
control, this transient response is unlikely to have any influence on energy balance. 
This study has some notable limitations. By estimating participants’ energy requirements 
(Mifflin et al. 1990) it appears that participants overate during main trials. This was likely 
due to the wide selection of foods available at ad libitum meals and an associated ‘banquet 
effect’. Consequently, the sensitivity to detect changes in energy intake after consecutive 
days of exercise may have been reduced. Furthermore, such overconsumption may have also 
dampened the ability to detect changes in appetite hormones in response to exercise. Another 
limitation of this study is that performance of a second bout of exercise may have masked any 
changes in study outcomes on day 2; however, this is unlikely given other recent findings of 
ours (King et al. 2015). Finally, this study focused solely on homeostatic factors contributing 
to the regulation of appetite and food intake. Recent investigations have highlighted the 
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importance of hedonic factors contributing to these outcomes (Crabtree et al. 2014; Evero et 
al. 2012). 
In summary, this investigation sought to characterise the impact of two bouts of moderate to 
high intensity exercise, performed on consecutive mornings, on appetite perceptions, food 
intake and circulating levels of key appetite regulatory hormones. This study found that 
besides inducing a transient inhibition of appetite, exercise did not exert any other influence 
on subjective appetite perceptions and did not alter ad libitum energy or macronutrient intake 
on day one or two. Furthermore, exercise had no impact upon circulating levels of leptin or 
acylated ghrelin, but did augment levels of total PYY and reduce those of insulin, on day two. 
These findings support previous data in lean individuals, indicating that acute exercise does 
not induce compensatory appetite or food intake responses within the short-term (King et al. 
1994; King et al. 2013; Wasse et al. 2012). This study has demonstrated that this lack of 
response persists on the day after exercise. 
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CHAPTER V 
Acute exercise and appetite-regulating hormones in overweight and obese individuals: 
A meta-analysis 
5.1. Introduction 
‘Exercise induced anorexia’ was a term coined in 1994 by King and colleagues, to describe 
the condition where appetite is suppressed after acute exercise. King et al. (1994) showed that 
appetite was temporarily suppressed during and after high intensity exercise in lean healthy 
males. Subsequent researchers confirmed these earlier findings (Broom et al. 2007; Broom et 
al. 2009; King et al. 2010a; King et al. 2010b; King et al. 2011). At rest, feelings of hunger 
are mediated by gut hormones such as acylated ghrelin, PYY and GLP-1 (Cummings et al. 
2001; Harrold et al. 2012; Karra et al. 2009). It has been hypothesised that ‘exercise induced 
anorexia’ is mediated by altered concentrations of these hormones. For example, acylated 
ghrelin (an appetite stimulating hormone) has been found to be suppressed after vigorous 
exercise (Broom et al. 2009; King et al. 2011; Ueda et al. 2009b). In contrast, circulating 
concentrations of PYY and GLP-1 (satiety hormones), have been shown to increase after 
exercise in healthy lean adults (Broom et al. 2009; King et al. 2011; Ueda et al. 2009b). 
Researchers have also examined the effects that exercise has on energy intake after exercise. 
The majority of studies indicate that individuals do not compensate for the energy expended 
during exercise in the immediate hours after exercise (Schubert et al. 2013). Therefore, these 
individuals are in an energy deficit, and if maintained over time this could result in weight 
loss. 
Most studies on exercise and appetite regulation involve crossover designs and relatively 
small sample sizes. Meta-analyses can be useful to quantify the effects of an intervention 
with greater precision from a pooled estimate. A standardised mean difference (SMD) is 
often reported. This is a summary statistic, and is used when studies measure the same 
outcome but report it in a variety of ways (i.e. different units of concentration or time). The 
SMD standardises the results of the studies so that they can be combined. In particular, the 
SMD is calculated as follows: 
SMD=
(Difference in mean outcome between groups)
(Standard deviation of outcome among participants)
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Therefore, regardless of how outcomes are reported in each study, the SMD expresses the 
size of the invention effect relative to the variability observed in that study. Findings can then 
be pooled and analysed using meta-analysis software. 
Recently, the effects of acute exercise on appetite regulatory hormones were examined in 
lean, ow/ob individuals (Schubert et al. 2014). It was concluded that an acute bout of exercise 
suppresses acylated ghrelin (SMD: 0.20) and increases PYY (SMD: 0.24), GLP-1 (SMD: 
0.28) and PP (SMD: 0.50). Of the 25 studies included in this review, only two involved 
ow/ob individuals. Clearly, there are fewer studies on ow/ob individuals and no previous 
systematic review and meta-analysis have been undertaken on this population. Such a review 
would capture new studies involving ow/ob individuals, and clarify if they respond in a 
similar way to their lean counterparts. This in turn could enhance understanding of the role 
exercise plays in weight maintenance and control. Therefore, we aimed to synthesise this 
evidence from studies investigating acute exercise bouts and circulating concentrations of 
acylated ghrelin, total PYY and total GLP-1, measured in ow/ob participants.  
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5.2. Methods 
5.2.1. Data source 
A systematic review of peer-reviewed studies was undertaken comparing concentrations of 
appetite regulatory hormones, quantified as time averaged area under the curve. The review 
was registered with the PROSPERO database (CRD42014006265). 
The literature search was conducted by an information specialist using commonly-used 
research databases (Applied Social Sciences Index and Abstracts (ASSIA), Campbell 
Collaboration, Centre for Review and Dissemination, Database of Promoting Health 
Effectiveness Reviews (DoPHER), Cochrane Central Register of Controlled Trials 
(CENTRAL), Cochrane Database of Systematic Reviews, Cochrane Methodology Register, 
Database of Abstracts of Reviews or Effects (DARE), EMBASE, NHS Economic Evaluation 
Database (NHS EED), PROSPERO, PubMed, PsycINFO MEDLINE (Ovid), Sports Discus, 
SCOPUS, Web of Knowledge and CINAHL). These databases were searched in January 
2014 with an update search in June 2014 and October 2016. Keyword searches were 
performed for ‘exercise’, ‘physical activity’, ‘energy expenditure’, ‘energy intake’, ‘appetite’, 
‘hunger’, ‘food intake’, ‘ghrelin’, ‘acylated ghrelin’, ‘total ghrelin’, ‘acyl ghrelin’, ‘peptide 
YY’, ‘PYY’, ‘peptide YY3-36’, ‘PYY3-36’, ‘total PYY’, ‘glucagon like peptide-1’, ‘GLP-1’, 
‘active GLP-1’, ‘GLP-1(7-36)’, ‘GLP-1(9-36)’, ‘obese’, ‘overweight’, ‘meta-analysis’ and 
‘appetite hormones’. Details of the search strategy are provided in Appendix I. 
5.2.2. Inclusion criteria 
For inclusion, studies were required to meet the following criteria: 
 study participants were; 
o overweight or obese 
o had no history of diabetes, gastrointestinal, inflammatory, metabolic, 
cardiovascular or psychological disease 
o non-smokers 
o had no abnormal eating tendencies 
 studies were; 
o not limited by the duration or observation period post-exercise 
o not limited by exercise intensity, duration or modality 
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o required to have a control condition (completed by the same participants who 
completed the exercise condition) 
o required to use identical exercise and control conditions (minus the exercise 
bout) 
o measure acylated ghrelin, total PYY or total GLP-1 plasma concentrations 
 investigators were not blinded (due to the nature of the study) 
 published in; 
o peer-reviewed journals  
o conference proceedings  
o theses 
o dissertations 
A broad range of sources for study inclusion where chosen to minimize the risk of small 
study effects, which can occur if only published studies are included. 
5.2.3. Exclusion criteria 
Studies were excluded if: 
 did not measure acylated ghrelin, total PYY or total GLP-1 responses to an exercise 
bout  
 did not measure responses in ow/ob individuals 
 did not include a control trial 
5.2.4. Study selection 
Potential studies were identified by examining the abstracts and full-text copies were 
obtained if they met the initial criteria of evaluating appetite hormone changes in response to 
an acute exercise bout. This process was checked independently by an expert in the field. 
Notes of the two researchers were compared, and a mutual consensus reached. In the original 
literature search conducted in January 2014, five studies met the inclusion criteria. Two 
updated searches conducted in June 2014 and October 2016, identified one further study. 
Together six studies met the inclusion criteria for the current meta-analysis (Figure 5.1).  
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Figure 5.1. Flowchart of study selection.  
57 full text articles 
excluded due to 
incomplete data and 
exclusion criteria 
718 articles 
identified through 
first database  
search 
22 articles 
identified through 
second database 
search 
621 articles after 
duplicates removed 
63 full-text articles 
assessed for eligibility 
559 articles excluded 
on basis of title and 
abstract 
6 studies included in the 
systematic review 
125 articles 
identified through 
third database 
search 
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5.2.5. Data synthesis 
Included studies were assessed for quality and validity, and independently checked by 
another expert in the field, using established criteria (Physiotherapy Evidence Database 
[PEDro], http://www.pedro.org.au/english/downloads/pedro%20scale/). Data on the study 
methods, sample size, participant characteristics, blood analytical methods, exercise 
intervention information, and hormone (pmol·L
-1
 h
-1
, pg·mL
-1 
h
-1
, µU·mL
-1
 h
-1
) and appetite 
AUC data were extracted for both control and exercise conditions into a computerised 
spreadsheet. Data entry was checked by one other expert in the field and discrepancies 
discussed and checked again. If standard error of the mean (SEM) was reported, these were 
converted to standard deviations (Deeks et al. 2011). 
5.2.6. Meta-analysis procedures 
Comprehensive Meta-Analysis software (Version 2.2.064; Biostat, Englewood, NJ, USA), 
was used to conduct a random effects (DerSimonian-Laird inverse variance approach) meta-
analysis of the mean difference in acylated ghrelin, total PYY and total GLP-1 during control 
and exercise trials (Deeks et al. 2011). The inputted data included sample sizes, AUCs for the 
control and exercise conditions (with their respective standard deviations) and an imputed 
correlation coefficient to take into account the fact that all studies were crossover in nature. 
These correlation coefficients were estimated from prior reliability studies in our laboratory 
and were as follows; acylated ghrelin; r=0.93, total PYY: r=0.71 and GLP-1: r=0.94. The 
software calculated the pooled standardised difference in means to determine the effect size 
(Higgins et al. 2011). All data are presented as means (95% confidence interval). 
We interpreted SMD values of <0.2 as trivial, 0.2-0.3 as small, 0.4-0.8 as moderate and >0.8 
as large. A negative effect size indicates that exercise was associated with decreased hormone 
concentrations, while a positive effect size indicates that hormone concentrations increased 
with exercise (Hopkins et al. 2009). Heterogeneity was explored using a Q-test, I-square 
statistic and the tau-squared statistic. A Q statistic was deemed significant when P<0.05, and 
an I-square statistic >50% was deemed to be indicative of substantial heterogeneity.  
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5.2.6.1. Meta-regression analyses for BMI of acylated ghrelin time-averaged AUC 
between exercise and control conditions 
BMI was used as a moderator in a meta-regression analysis (methods-of-moments model), to 
determine if BMI could explain the variation in effect size values seen between studies for 
acylated ghrelin concentrations (Higgins et al. 2011). Mean BMIs were pooled from studies 
collected in the current review together with those reported for lean individuals in a recent 
review by Schubert et al. (2014). Mean BMI was included as a moderating variable, based on 
the hypothesis that a negative association exists between study mean BMI and acylated 
ghrelin for a pooled sample of studies across a full range of BMIs. This analysis was only 
performed for acylated ghrelin as there were not enough studies (N<3) reporting data for total 
PYY or total GLP-1 to obtain sufficiently-precise and meaningful estimations of meta-
regression slope 
5.2.6.2. Exploration of small study effects 
Small study effects were explored with a funnel plot of standard difference in means vs 
associated standard errors (Sterne et al. 2011) and by quantifying Egger’s linear regression 
intercept. A large and statistically significant Egger’s statistic indicates the presence of a 
small study effect. This analysis was only performed for acylated ghrelin as there were not 
enough studies reporting data for a precise exploration of total PYY and total GLP-1.  
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5.3. Results 
5.3.1. Overview 
Six studies involving a total of 73 participants met the inclusion criteria for the meta-analysis. 
All of these had been published (or accepted for publication) in peer-reviewed scientific 
journals. The experimental trials in each study lasted between 2 and 3 h, with exercise 
conducted in a fasted condition or following a standardised breakfast. Three studies included 
standardised meals before the exercise bout (Martins et al. 2014; Ueda et al. 2009; Unick et al. 
2010) and four studies included ad libitum meals after the exercise bout (Martins et al. 2014; 
Sim et al. 2014; Ueda et al. 2009b; Unick et al. 2010). Blood samples were collected at 
regular intervals throughout all trials. 
The included studies are summarised in Table 5.1. The majority of studies recruited 
participants of the same sex. One study recruited both males and females (Martins et al. 
2015). Two of the studies involved more than one exercise intensity trial (Martins et al. 2015; 
Sim et al. 2014), and are reported in the analysis as “multiple trials”. Accounting for these, 
the total number of trials is 10, each including one control and one exercise condition. Six 
studies (10 trials) reported acylated ghrelin AUC data, two studies (four trials) reported total 
PYY AUC data and two studies (four trials) reported total GLP-1 AUC data. Of the 10 trials, 
one used treadmill walking as the mode of exercise, two used treadmill running and seven 
used a cycle ergometer. The mean PEDro score for the six studies was 6±0, rating all studies 
to have “good” methodological quality. 
5.3.2. Participant demographics and exercise intervention characteristics 
Of the 73 participants included in the meta-analysis, 57 were male (78%) and 16 were female 
(22%). Mean BMI values of the 73 participants ranged from 27.7 to 32.7 kg·m
-2 
(mean 30.6 
kg·m
-2
). Four studies used exercise which was aerobic in nature (Sim et al. 2014; Tiryaki-
Sonmez et al. 2013; Ueda et al. 2009b; Unick et al. 2010), and two compared aerobic exercise 
with two variations of high intensity exercise (Martins et al. 2015; Sim et al. 2014). The 
exercise interventions lasted between nine and 60 min (mean 34 min), and exercise intensity 
was set between 50 and 65% VO2 peak (mean 58% V̇O2 peak, N=6) or 72.5 and 87.5% 
HRmax (mean 79.4% HRmax, N=4). Between 7 and 19 participants took part in each study 
(mean 12 participants) (see Table 5.1 for summaries of study protocols). 
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Table 5.1. Hormone time averaged area under the curve (AUC) data for the six studies included in the meta-analysis. 
Study 
Participants 
Intervention 
Hormone 
AUC time 
(h) 
Hormone AUC (pg·mL-1) 
N 
BMI 
(kg·m-2) 
Acylated 
Ghrelin 
Total 
PYY 
Total 
GLP-1 
Gholipour 
et al. 2011 
9 
(M) 
32.7 
(0.8) 
36 min treadmill run: 
10 min, 10 min, 5 min, 
2 min at 65% V̇O2 max, separated by 
3 min at 3 km·h-1 
2.85 CON: 3512 
(654)
 
CON: NM CON: NM 
EX: 1935 
(302)
*
 
EX: NM EX: NM 
           
Martins 
et al. 2015 
12 
(7F:5M) 
 
32.3 
(2.7) 
Cycling @ 85-90% HRmax until 250 kcal 
expended: 
8 s all out sprinting separated by 
12 s easy pedalling 
(mean duration, 18 ± 3 min) 
3.00 CON: 3921 
(1318) 
CON: NM CON: 4181 
(1262)
 
EX: 3315 
(1219)
*
 
EX: NM EX: 4272  
(969) 
Cycling @ 70% HRmax until 250 kcal 
expended: 
continuous cycle 
(mean duration, 27 ± 6 min) 
CON: 3921 
(1318) 
CON: NM CON: 4181 
(1262) 
EX: 3296 
(1058)
*
 
EX: NM EX: 4638 
(1305) 
Cycling @ 85-90% HRmax until 125 kcal 
expended: 
8 s all out sprinting separated by 
12 s easy pedalling 
(mean duration, 9 ± 2 min) 
CON: 3921 
(1318) 
CON: NM CON: 4181 
(1262) 
EX: 3532 
(1393) 
EX: NM EX: 4072 
(1156) 
           
Sim 
et al. 2014 
17 
(M) 
27.7 
(1.6) 
30 min continuous cycling @ 60% V̇O2peak 1.58 CON: 70 
(37) 
CON: 85  
(43) 
CON: NM 
EX: 69 
(30) 
EX: 87  
(37) 
EX: NM 
30 min cycling: alternating between 60s @ 
100% V̇O2peak and 
240s @ 50% V̇O2peak 
 
CON: 70 
(37) 
CON: 85  
(43) 
CON: NM 
EX: 62 
(28) 
EX: 83  
(40) 
EX: NM 
30 min cycling: alternating between 15s @ 
170% V̇O2peak and 
60s @ 32% V̇O2peak 
CON: 70 
(37) 
CON: 85  
(43) 
CON: NM 
EX: 56 
(26) 
EX: 88  
(34) 
EX: NM 
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Study 
Participants 
Intervention 
Hormone 
AUC time 
(h) 
Hormone AUC (pg·mL-1) 
N 
BMI 
(kg·m-2) 
Acylated 
Ghrelin 
Total 
PYY 
Total 
GLP-1 
Tiryaki-
Sonmez 
et al. 2013 
9 
(F) 
28.3 
(1.8) 
60 min running 
@ 53% V̇O2max 
2.00 CON: 51 
(8) 
CON: NM CON: NM 
EX: 47 
(5) 
EX: NM EX: NM 
           
Ueda 
et al. 2009b 
7 
(M) 
30.0 
(3.1) 
60 min cycle @ 50% V̇O2max 2.00 CON: 15779 
(10046) 
CON: 393 
(50)
*
 
CON: NM 
EX: 16641 
(10725) 
EX: 425 
(46)
*
 
EX: NM 
           
Unick 
et al. 2010 
19 
(F) 
32.5 
(4.3) 
Walk @ 70-75% age predicted HRmax until 
3.0 kcal/kg of body weight expended 
(mean energy expenditure, 354 ± 72 kcal; 
mean duration 42 ± 8 min) 
2.00 CON: 6527 
(2646) 
CON: NM CON: 211400 
(51600) 
EX: 6361 
(3339) 
EX: NM EX: 201200 
(49400)* 
CON, control trial; EX, exercise trial; F, female; HRmax, maximum heart rate; M, male; NA, AUC data not available; NM, not measured.
*
Significantly different from 
control (P<0.05). Values are mean (SD).
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5.3.3. Meta-analysis 
Individual study statistics and results for both trials including ow/ob subjects and lean 
subjects are summarised in the appendix (See Appendix J, K, L). 
5.3.4. Effect size and moderator variable for acylated ghrelin time-averaged AUC 
analysis 
In ow/ob individuals there was a statistically significant moderate suppression in mean 
acylated ghrelin time-averaged AUC concentrations in exercise trials compared with resting 
trials (pooled effect size -0.34, 95% confidence interval -0.533 to -0.146; N=10; P=0.001; 
Figure 5.2). Heterogeneity was found to be high between these studies (I
2
=87.7%; Q=73.4, 
T
2
=0.084, df=9). For this reason a random effects model was chosen to conduct the meta-
analyses (Ades et al. 2005). 
 
Figure 5.2. Forest plot of effect sizes (means±95% confidence intervals [CIs]) for studies 
evaluating acylated ghrelin time-averaged AUC values in response to exercise in ow/ob 
individuals. 
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Sensitivity analysis showed that the study by Gholipour et al. (2011) increased the effect size 
of exercise on mean acylated ghrelin time-averaged AUC concentrations. The removal of this 
study decreased the pooled effect size to -0.23 (95% confidence interval -0.35 to -0.11, 
P<0.001). 
When data from lean individuals were included into the meta-analysis, with that of the 
previously-reported ow/ob individuals the pooled standardised effect size of exercise on 
acylated ghrelin time-averaged AUC data was reduced (pooled effect size -0.215, 95% 
confidence interval -0.324 to -0.105; N=33; P<0.001). 
Using BMI as a moderator in a meta-regression model, a higher mean BMI was associated 
with a greater exercise induced suppression of acylated ghrelin time-averaged AUC 
concentration. The slope of regression for BMI was shallow, but significantly negative (95% 
confidence interval -0.073 to -0.010; P=0.044; Figure 5.3). The standardised reduction in 
acylated ghrelin for exercise vs. control conditions was found to be 0.037 units more marked 
for every 1 kg·m
-2
 increase seen in BMI. Including baseline acylated ghrelin concentrations 
and BMI into a multiple meta-regression model had little effect on the results; the slope of 
regression became slightly more negative so that the standardised reduction in acylated 
ghrelin for exercise vs. control was 0.040 units more marked for every 1 kg·m
-2 
increase in 
BMI (95% confidence interval -0.080 to -0.010; P=0.020). Sensitivity analysis showed that 
the study by Gholipour et al. (2011) strengthened the relationship between BMI exercise 
induced suppression of acylated ghrelin time-averaged AUC concentration. The removal of 
this study decreased the slope of regression, making it non-significant (95% confidence 
interval -0.052 to 0.014; P=0.25). However, no methodological reason was identified for the 
relatively high effect size in this particular study. 
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Figure 5.3. Univariable meta-regression for study mean BMI vs. the SMD for acylated 
ghrelin. A negative correlation was observed which persisted even when baseline (control) 
mean ghrelin concentration was added as a covariate. The area of each circle is proportional 
to that study’s weight in the analysis.  
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Inspection of the funnel plot (Figure 5.4) and Egger’s regression intercept revealed that there 
was little evidence of small study effects (intercept=-3.647, 95% confidence interval -9.080 
to 1.785, P=0.264). 
Figure 5.4. Funnel plot of standard error by standard difference in means for studies 
evaluating the influence of acute exercise on acylated ghrelin time-averaged AUC values in 
ow/ob individuals.  
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5.3.5. Effect size for total PYY time-averaged AUC analysis 
In ow/ob individuals there was a trivial mean effect of exercise on total PYY (pooled effect 
size 0.099, 95% confidence interval -0.133 to 0.311; N=4; Figure 5.5), and this was not 
significantly different from zero (P=0.404). Heterogeneity was found to be low between these 
studies (I
2
=24.17%; Q=3.96, T
2
=0.014, df=3). 
 
Figure 5.5. Forest plot of effect sizes (means±95% confidence intervals [CIs]) for studies 
evaluating the influence of acute exercise on total PYY time-averaged AUC values in ow/ob 
individuals.  
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5.3.6. Effect size and moderator variable for total GLP-1 time-averaged AUC analysis 
In ow/ob individuals there was a trivial mean effect of exercise on GLP-1 (Pooled effect size 
-0.026, 95% confidence interval -0.184 to 0.133; N=4; Figure 5.6), and this was not 
significantly different from zero (P=0.749). Heterogeneity was found to be high between 
these studies (I
2
=65.7%; Q=8.74, T
2
=0.017, df=3). 
 
Figure 5.6. Forest plot of effect sizes (means±95 % confidence intervals [CIs]) for studies 
evaluating the influence of acute exercise on total GLP-1 time-averaged AUC values in 
ow/ob individuals.  
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5.4. Discussion 
Understanding the responses of appetite regulatory hormones to exercise and consequently 
the effect they may have on energy intake and appetite could enhance understanding of the 
role of exercise in weight control. The purpose of this review was to examine the 
concentration changes of acylated ghrelin, total PYY and total GLP-1 after acute exercise in 
ow/ob individuals. We found acylated ghrelin to be moderately suppressed by acute exercise, 
whilst there were trivial effects of exercise on total PYY and total GLP-1. Ghrelin is an 
appetite stimulating hormone and our results suggest that exercise in ow/ob individuals alter 
acylated ghrelin in a direction that would be associated with decreased hunger and energy 
intake. We can only speculate the effects ghrelin has on appetite and food intake as not all 
studies included these measures in their protocol. Future research should examine energy 
intake in addition to appetite and appetite regulatory hormone responses to clarify this 
assumption. 
The results of the current review appear to mirror those of lean individuals. In a recent review, 
lean individuals showed a small reduction in acylated ghrelin after exercise, whilst total PYY 
and total GLP-1 showed small increases (Schubert et al. 2014). Our findings suggest that 
ow/ob individuals show broadly similar appetite hormone responses to exercise in lean 
individuals, in such a direction that could alter energy intake and achieve weight loss if 
sustained over prolonged periods of time. Again, this can only be speculated as the studies 
included in both the review by Schubert et al. (2014) and the current review were acute in 
nature. 
The present meta-regression demonstrated greater exercise-induced suppression of acylated 
ghrelin as BMI increased. Although ow/ob individuals have shown a moderate suppression of 
acylated ghrelin after exercise, this suppression becomes more prominent as BMI increases 
from 27.7 to 32.7 kg·m
-2
. This finding differed from that of Schubert et al. (2014), where 
BMI was shown to have no influence on appetite regulatory hormones. Schubert et al. (2014) 
included 23 studies examining responses of lean individuals and two studies with ow/ob 
individuals. The inclusion of six, rather than two, studies with overweight/obese individuals 
in the present meta-regression may explain the differences found between the two reviews. 
The current review found ow/ob individuals to express a moderate reduction in acylated 
ghrelin during exercising conditions. Large variations in fasting and postprandial ghrelin 
concentrations between individuals make it difficult to establish the clinical relevance that 
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exercise has on this hormone. In lean individuals circulating concentrations of acylated 
ghrelin in the range of 40-67 pg·mL
-1
 may be expected in fasting conditions (Sato et al. 2012), 
with obese individuals expressing lower concentrations (Tschöp 2001; Shiiya et al. 2002). 
We attempted to control for differences in baseline levels of acylated ghrelin between studies 
by accounting for fasting values observed in resting trials. This had negligible influence on 
the relationship between increased BMI and acylated ghrelin. 
The current review found three studies that examined the acute effects of exercise on appetite 
regulatory hormones in males, two studies in females and one including both males and 
females. Due to the limited number of studies in this review, no conclusions can be drawn 
upon the effect of exercise and sex on appetite regulatory hormones. It has been hypothesised 
that exercise could influence acylated ghrelin differently in obese males and females. In one 
study, after four days of consecutive exercise females experienced an increase in acylated 
ghrelin, whereas males showed no change (Hagobian et al. 2009). This suggests that females 
may be prone to increasing energy intake after exercise training. However, after acute 
exercise lean individuals have shown no sex difference in responses of PYY3-36 or acylated 
ghrelin (Hagobian et al. 2013). Similar relative energy intakes were observed in males and 
females, suggesting that acute exercise is equally effective for both sexes. Future research is 
required to understand and compare the responses of males and females. 
The current review has several limitations. First, only six studies were identified as relevant 
following our literature searches. We recognise that meta-analyses are not immune from 
statistical power-related issues, and that the pooling of data from such a small number of 
studies may still provide relatively low statistical precision (wide confidence interval for 
pooled effect). For example, despite finding substantial heterogeneity amongst studies in 
which ghrelin and GLP-1 were measured, precise analyses such as one for the presence of 
outliers could not be performed due to the small number of studies. We restricted our search 
to acute exercise trials, further reviews should examine the effects of repeated bouts of 
exercise and exercise training on appetite regulatory hormones in ow/ob individuals although 
at present the literature on this aspect is very limited. The longest trial length in the current 
review was 3 h, future research should examine what happens to this population later on in 
the exercising day. Despite trials only lasting 2-3 h, protocols differed widely between studies, 
potentially confounding appetite hormone time-averaged AUC estimations. Specifically, the 
timing of exercise and meal provision within the study protocol. Time-averaged AUC 
calculations were made over the duration of each trial, irrespective of when exercise occurred. 
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The inclusion of rest periods prior to exercise into time-averaged AUC calculations could 
potentially underestimate the effect of exercise on hormone responses. Additionally, studies 
differed by exercising participants in both fasted and fed states. Further still, studies varied in 
meal provision (standardised, ad libitum or no meal) after exercise. Together these could 
further cofound the study of hormonal responses to exercise. We meta-regressed the SMD in 
acylated ghrelin vs. study mean BMI. Such study-level explorations of potential moderators 
of effect size should be interpreted with caution as within-study relationships can sometimes 
disagree with between-study relationships (Petkova et al. 2013). The mean BMI of the 
participants in this review was 30.6 kg·m
-2
 (i.e. borderline obese), therefore we cannot 
generalise the findings of this review to those who fall higher into the obese or severely obese 
category. Despite our best efforts, we cannot guarantee that we captured all the relevant 
studies for this review. Finally, we cannot directly link the effects of exercise on appetite 
regulatory hormones to weight loss and management due to the acute nature of the studies, 
and the lack of consistency in studies including energy intake and appetite ratings.  
An evidence synthesis of the six studies on ow/ob individuals indicated that a moderate 
reduction in acylated ghrelin occurs after acute exercise. Only trivial effects of exercise were 
quantified for total PYY and GLP-1. 
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CHAPTER VI 
The acute effects of exercise on appetite regulatory hormones, appetite perceptions and 
ad libitum energy intake in lean vs. obese men and women (INTAKE) 
6.1. Introduction 
The findings reported in Chapter 4 of this thesis suggest that that there is no compensation in 
subjective appetite ratings, appetite regulatory hormones or ad libitum energy intake after two 
consecutive days of exercise. Like many other studies to date, this study was completed in 
lean healthy individuals (Schubert et al. 2013; Schubert et al. 2014). This limitation of the 
current literature is highlighted in Chapter 5, which found only six studies to examine the 
effects of exercise on appetite regulatory hormones in ow/ob individuals, at the time of 
review. In addition, few have compared the responses of lean and ow/ob individuals 
(Holmstrup et al. 2013; Martins et al. 2015; Sim et al. 2014; Ueda et al. 2009b) or males and 
females (Alajmi et al. 2016; Hagobian et al. 2009). It is therefore unknown as to whether the 
effects of exercise on appetite regulation seen in lean healthy males translate into females, or 
to those who are overweight or obese. Thus, a direct comparison of subjective appetite, 
appetite regulatory hormones and ad libitum energy intake responses in lean and ow/ob, 
males and females would be needed to confirm this. 
Energy balance is the difference between energy consumed and energy expended. A 
sustained positive energy balance (whereby energy consumed outweighs that expended) 
results in weight gain and can cause overweight and obesity. The occurrence of a positive 
energy balance can be partially explained by dysfunctional appetite control. A number of gut 
hormones are responsible for appetite control, including acylated ghrelin, an appetite 
stimulating hormone, and appetite supressing hormones such as PYY and GLP-1. Typically, 
acylated ghrelin is suppressed after a meal, and PYY and GLP-1 increased, signalling meal 
cessation. The suppression of acylated ghrelin after a meal is attenuated in obese individuals 
(Morpurgo et al. 2003; Tentolouris et al. 2004) whilst PYY and GLP-1 responses are blunted 
after a meal (Adam & Westerterp-Plantenga 2005; Batterham et al. 2006; le Roux et al. 2005; 
le Roux et al. 2006; Ranganath et al. 1996; Verdich et al. 2001). Together these reduced 
feelings of fullness and satisfaction, promote food consumption and positive energy balance. 
After acute vigorous intensity exercise, lean individuals show transiently suppressed appetite. 
This is associated with suppressed circulating concentrations of ghrelin and increased levels 
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of PYY and GLP-1 (Broom et al. 2009; King et al. 1994; King et al. 2010a; King et al. 2011a; 
Martins et al. 2007). In addition to the negative energy balance generated from exercise, the 
associated hormone changes suggest appetite control could be altered in a fashion that could 
sustain this deficit. 
There are few studies examining the effects of acute exercise on subjective appetite 
perceptions, appetite regulatory hormones and ad libitum energy intake in ow/ob individuals. 
After exercise, acylated ghrelin has been shown to be decreased (Martins et al. 2015; Sim et 
al. 2014; Tiryaki-Sonmez et al. 2013) and unaltered (Ueda et al. 2009a; Unick et al. 2010), 
compared to control conditions. Similar discrepancies have also been found for other major 
appetite regulatory hormones, including PYY and GLP-1 (Martins et al. 2015; Sim et al. 
2014; Tiryaki-Sonmez et al. 2013; Ueda et al. 2009a; Unick et al. 2010). Despite studies in 
this population finding contradictory responses for appetite regulatory hormones, all seem to 
agree that appetite perceptions do not differ during exercise and control conditions and show 
REI to be reduced. To date, research in ow/ob mirrors that in lean individuals with the 
mechanism responsible for transient appetite suppression yet to be confirmed. Presently, it is 
difficult to draw any conclusions from these studies. Specifically, data is limited by the small 
number of participants in each study, the short observation periods after exercise and 
differing study protocols, including exercise duration and intensity. Further research is 
required to determine if the effects of exercise on appetite control seen in lean participants 
translate into the overweight and obese. 
Research on subjective appetite perceptions, appetite regulatory hormone and ad libitum 
energy intake responses to acute exercise has predominantly been conducted in males. Many 
have neglected responses in females, or failed to directly assess sex-based differences. A 
study by Hagobian and colleagues (2009) showed that after four consecutive days of acute 
exercise, designed to induce an energy deficit, a compensatory increase in circulating 
concentrations of acylated ghrelin was observed in females but not males, whilst hunger 
ratings remained unaltered in males and females. More recently, both males and females 
showed equal suppressions in appetite and circulating acylated ghrelin concentrations with no 
change in ad libitum energy intake after acute exercise (Alajmi et al. 2016). It is likely that 
these conflicting findings result from differing protocols, specifically, trial length and 
exercise intensity. Data on other key appetite regulatory hormones, such as, GLP-1 and total 
PYY within females is lacking. Further research is required to determine if males and females 
respond similarly to a bout of acute exercise. 
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The present investigation sought to advance on previous literature by comparing the effects 
of a single bout of aerobic exercise on subjective appetite perceptions, ad libitum energy 
intake and circulating concentrations of appetite regulating hormones (acylated ghrelin, 
desacylated ghrelin, total PYY, total GLP-1) as well as insulin, glucose, NEFA and TAG in 
lean and ow/ob males and females. Specifically, subjective appetite perceptions were 
examined during one hour of moderate intensity continuous exercise (60% V̇O2 peak) and 
for seven hours after. Plasma concentrations of appetite regulatory hormones were measured 
in responses to exercise, two standardised meals and an ad libitum buffet meal. The effects of 
exercise on energy intake were established at an ad libitum meal provided six hours after the 
cessation of exercise. Based on previous findings, in response to exercise, it was hypothesised 
that subjective appetite and ad libitum energy intake would be unaltered in lean individuals 
despite seeing transient increases in circulating concentrations of PYY and suppressed 
circulating concentrations of acylated ghrelin. Furthermore, it was hypothesised that females 
and ow/ob individuals would express similar appetite perceptions, energy intake and appetite 
regulatory responses to males and individuals who are lean, respectively.  
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6.2. Methods 
6.2.1. Ethics procedures 
Study design took several months, with input from experts in the field. Due to the nature of 
the project, it was necessary to seek NHS ethical approval. The ethics approval process was 
comprised of several stages (Figure 6.1). 
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‘Provisional opinion’ granted  29/08/2013
  
Further information submitted  26/09/2013
  
‘Favourable opinion’ granted  07/10/2013
  
Application submitted to R&D  29/10/2013
  
R&D permission granted  31/10/2013
  
SSI form submitted  04/03/2014
  
SSI permission received  26/03/2014
 
Figure 6.1. Schematic representation of the NHS ethics procedure. IRAS, integrated research 
application system; REC, research ethics committee; R&D, research and development; SSI, 
site-specific information.  
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The Integrated Research Application System (IRAS) was used to collate information required 
to apply for NHS/health and social care (HSC) Research & Development (R&D) and 
NHS/HSC Research Ethics Committee (REC) approval and to complete the Site Specific 
Information (SSI) form. Completion of the IRAS form also required submission of 
supporting study documentation, including; 
• Study protocol document (Appendix M) 
• Participant information sheet (Appendix N) 
• Consent form (Appendix O) 
• Study invitation letters (Appendix P) 
• Trial reminder letters (Appendix Q) 
• Recruitment posters (Appendix R) 
• Screening questionnaires (Appendix S) 
Upon completion, the IRAS application form and supporting documentation were submitted 
to REC for review. Part of the review process required research team members to attend a 
panel review meeting. Here the study protocol and supporting documentation were 
scrutinised by committee members. Subsequent email communication confirmed the 
outcomes of the meeting, requesting information for those areas needing further clarification 
and outlining any required document changes. After the submission of additional information, 
REC granted a ‘favourable opinion’. Both R&D and SSI applications were then submitted. 
After acceptance of these, the study had full approval to begin. 
During the study, it was necessary to make amendments to the original ethics documentation 
(Figure 6.2). Substantial amendments refer to those that made alterations to the study 
protocol, influenced safety of the participants or conduct of the study. Both REC and R&D 
were required to review these changes, and grant their approval. Non-substantial amendments 
refer to those where additional members of staff were added to the research team, minor 
changes were made to the study documentation (i.e. contact information), and study deadlines 
extended. Only R&D were required to grant approval for these changes. 
We adhered to Good Clinical Practice guidelines issued by the International Conference on 
Harmonisation, and to the Declaration of Helsinki. Independent local ethics committees 
approved the protocol, amendments, and informed consent documents. Participants provided 
written consent before study procedures began. 
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NSA # 1 
(Change to contact details and staff) 
Submitted: 14/04/2014 
Approved: 17/04/2014 
3 days 
   
NSA # 2 
(Change staff) 
Submitted: 05/06/2014 
Approved: 12/06/2014 
7 days 
   
NSA # 3 
(Change staff) 
Submitted: 30/06/2014 
Approved: 01/07/2014 
1 day 
   
NSA # 4 
(Change staff) 
Submitted: 26/01/2015 
Approved: 10/02/2015 
15 days 
   
NSA # 5 
(Change staff) 
Submitted: 09/02/2015 
Approved: 10/02/2015 
1 day 
   
NSA # 6 
(Change staff) 
Submitted: 14/04/2015 
Approved: 17/04/2015 
3 days 
   
NSA # 7 
(Study extension) 
Submitted: 13/01/2016 
Approved: 18/01/2016 
5 days 
   
SA # 1 
(Change to screening procedure and 
inclusion of extra blood samples) 
Submitted: 24/04/2014 
REC Approved: 06/05/2014 
R&D Approved: 07/05/2014 
Sponsor Approved: 13/05/2014 
19 days 
   
SA # 2 
(Measurement of HbA1c at 
screening, change in investigators) 
Submitted: 03/07/2014 
REC Approved: 25/07/2014 
R&D Approved: 11/08/2014 
Sponsor Approved: 14/08/2014 
42 days 
   
SA # 3 
(Change to inclusion criteria, study 
posters (Appendix T) and 
recruitment methods) 
Submitted: 02/10/2014 
REC Approved: 14/10/2014 
R&D Approved: 24/10/2014 
Sponsor Approved: 30/10/2014 
28 days 
 
Figure 6.2. Schematic representation of NHS amendments made. NSA, non-substantial 
amendment; SA, substantial amendment; REC, research ethics committee; R&D, research 
and development; HbA1c, haemoglobin A1c.  
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6.2.2. Recruitment  
A complex and thorough approach was adopted to recruit the necessary participants for this 
study (Figure 6.3). The original protocol document submitted for ethical approval allowed for 
recruitment within the local community. Specifically the protocol document permitted 
distribution of study posters and leaflets in public places and local companies. Posters and 
leaflets were required to contain a brief overview of the study, key inclusion and exclusion 
criteria and further contact information. Individuals who felt eligible to participate contacted 
the research team via email or telephone, at which time they provided contact details 
(telephone number or email address) so that a participant information sheet, and if 
appropriate, a study invitation letter could be provided. In particular, posters were distributed 
around Loughborough University campus and Loughborough town centre (shops, restaurants, 
local businesses, supermarkets, town hall, community centres, religious centres and leisure 
centres). E-mails were sent to Loughborough University departments, local clubs and 
societies. The internet and social media was another useful outlet for study advertisement; 
local clubs and societies mentioned the study in newsletters, Loughborough University 
included the study in ‘Twitter’ posts, news articles were posted on the Loughborough 
University and NIHR homepages. In addition to these ‘passive’ methods, a recruitment stand 
was also present at two NIHR participant and patient involvement (PPI) days, a series of 
public lecture events, local businesses and supermarkets (targeting both staff and customers), 
and local wellbeing fairs. A live interview on a local BBC radio channel was also broadcast. 
Original ethics documentation also allowed for contact with individuals who had previously 
consented to take part in future studies investigating diabetes from NHS study databases. 
Study invitation letters, reply slips and participant information sheets were sent to postal 
addresses. There was only one NHS study database within the department, where study 
inclusion criteria matched those of the current study. Eighty individuals were contacted from 
the ‘STAND’ (REC ref: 10/H0403/13) study, among the reply slips only two individuals 
were interested in taking part in the study. Only one matched the inclusion criteria, who later 
withdrew from the study after screening. 
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Figure 6.3. Schematic representation of the recruitment strategy. PPI, patient and public involvement.
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6.2.3. Participants 
Initial inclusion criteria for participation were as follows: 
 18-50 y 
 non-smoker 
 BMI of 18.5-24.9 or 30.0-39.9 kg·m-2 
 inactive or moderately active (category 1 or category 2 on International Physical 
Activity Questionnaire, IPAQ)  
 non-diabetic (fasting whole blood capillary glucose <7.0 mmol.L-1) and no history of 
diabetes (HbA1c <6.5%) 
 blood pressure <160/100 mmHg 
 weight stable for at least 3 months before the study 
 not dieting or exhibiting extreme eating habits 
 not currently suffering from gastrointestinal, inflammatory, metabolic, cardiovascular 
or psychological diseases and no history of these conditions 
 breakfast eaters 
 not night shift workers 
 no recent history of infectious disease 
 not taking medication 
 tolerance of food items provided during the experiment 
 if female: 
o premenopausal 
o not pregnant 
Later, due to slow recruitment, a substantial amendment was made to the inclusion criteria 
(Figure 6.2). Specifically, the criteria were widened, raising the age range to 18-65 y, the 
obese group was broadened to include those who were overweight (i.e. anyone with a BMI of 
25.0 to 39.9), and postmenopausal females and non-breakfast eaters could be included.  
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Sixty participants matching the inclusion criteria provided formal written consent to take part 
in the study. Thirteen withdrew from the study; therefore, reported data is for 47 participants. 
Reasons for withdrawal included; 
 cannulation issues (N=3) 
 injury or illness (N=2) 
 lost contact (N=3) 
 moved away from the area (N=1) 
 did not pass the screening visit (N=4). 
Table 6.1 describes the participant characteristics. Of the 22 females, 12 were pre-
menopausal (lean, 6; overweight, 6) and 10 post-menopausal (lean, 5; overweight, 5). Three 
females reported to be using contraceptives (lean, 2; overweight, 3).  
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Table 6.1. Characteristics of the study participants (N=47). 
 
Lean 
Females 
(N=11)
a
 
Ow/ob 
Females 
(N=11)
b
 
Lean 
Males 
(N=11)
c
 
Ow/ob 
Males 
(N=14)
d
 
Effect Size 
Sex BMI 
Age (years) 38.6 45.5 36.4 44.6 0.08 0.05 
(15.9) (13.2) (15.1) (12.1) 
Height (cm) 162.1 164.9 174.4 176.8 2.13 0.40 
(4.0) (7.2) (5.2) (6.0) 
Weight (kg)
*† 
57.5 78.5 69.8 92.9 0.99 1.96 
(4.9) (13.6) (5.0) (12.1) 
BMI (kg·m
-2
)
* 
 21.9 28.7 23.0 29.6 0.35 2.93 
(1.6) (2.8) (1.4) (3.0) 
Waist circumference (cm)
*
 69.7 85.4 81.6 96.9 1.25 1.88 
(4.1) (7.3) (5.3) (7.9) 
Body fat (%)
*†
 24.9 38.1 16.9 26.6 1.25 1.66 
(4.2) (3.5) (3.6) (4.2) 
Treadmill peak V̇O2 (mL·kg
-1
·min
-1
)
 *†
 39.2 29.7 48.1 38.6 0.79 0.84 
(9.9) (6.0) (13.0) (9.0) 
Treadmill peak V̇O2 (L·min
-1
)
†
 2.2 2.3 3.5 3.5 2.01 0.18 
(0.6) (0.5) (0.7) (0.7) 
Fasting plasma glucose (mmol·L
-1
) 5.0 4.7 4.5 4.7 0.29 0.03 
(0.7) (1.1) (0.9) (0.8) 
Fasting plasma total cholesterol 
(mmol·L
-1
)
*
 
3.9 4.4 3.9 5.1 0.33 0.71 
(1.1) (1.6) (1.1) (1.2) 
Fasting plasma HDL-cholesterol  
(mmol·L
-1
)
*†
 
2.5 1.8 1.5 1.2 1.49 0.94 
(0.2) (0.6) (0.5) (0.4) 
Fasting plasma LDL-cholesterol  
(mmol·L
-1
)
*†
 
1.2 2.3 2.1 3.5 0.85 1.05 
(1.0) (1.5) (1.1) (1.1) 
Fasting plasma triglyceride  
(mmol·L
-1
) 
1.3 1.6 1.0 1.7 0.08 0.56 
(1.0) (1.0) (0.7) (1.1) 
HbA1c (%) 5.3 5.5 5.5 5.3 0.11 0.07 
(0.2) (0.3) (0.2) (0.3) 
Fasting leptin (pg·mL
-1
)
*†
 13752 23328 2795 9063 1.47 0.74 
(10380) (9755) (930) (3796) 
HOMA-IR 1.0 1.4 1.1 1.5 0.12 0.51 
(0.6) (1.1) (0.4) (1.0) 
Physical activity (METS·min
-1
·week
-1
) 1777 1367 1668 1537 0.04 0.13 
(1016) (1000) (965) (1776) 
*Significantly different between lean and ow/ob (P≤0.03). †Significantly different between males and 
females (P<0.01).
a
HbA1c values only available for N=9. 
b
Body fat and HbA1c values are only 
available for N=10. 
c
Body fat values are only available for N=10 and HbA1c for N=5. 
d
Body fat 
values are only available for N=13 and HbA1c for N=10. Physical activity values were determined 
using the International Physical Activity Questionnaire. Values are mean (SD).  
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6.2.4. Preliminary testing 
Prior to main trials participants visited the laboratory for two preliminary trials; (i) participant 
screening and (ii) exercise familiarisation. 
6.2.4.1. Participant screening 
Before the start of any study procedures participants provided formal written consent. 
Participants underwent screening and preliminary anthropometric measures. After 
familiarisation with the laboratory environment, test equipment and test procedures, 
participants also completed two preliminary exercise tests. 
Participants were provided with a participant information sheet (Appendix M), describing the 
purpose, protocol, demands of the study and any potential risks or harms of taking part. 
Participants were allowed at least 48 h to read over the participant information sheet. After 
further verbal explanation of the study and discussion of any questions, participants 
completed an informed consent form (Appendix N). Written informed consent was obtained 
by means of participant dated signature and dated signature of the designated researcher who 
presented and obtained informed consent. The informed consent process was undertaken in 
privacy. The researcher taking consent was adequately trained, following completion of a 
Good Clinical Practise and Consent for Research training course. 
Experimental procedures began with the completion of a set of questionnaires to help 
determine participant’s suitability to take part in the study. Specifically, participants 
completed questionnaires (Appendix S) to assess; 
 health status (health screen questionnaire) 
 physical activity readiness (PAR-Q) 
 food preference and breakfast pattern questionnaire 
 dietary habits (TEFQ) 
The health status questionnaire screened for regular medication use and recent history of 
infectious disease. The PAR-Q is a validated questionnaire, used to determine if physical 
activity could pose a problem or hazard to participants. Tolerance to food items available at 
the standardised and buffet meals was assessed using the food preference questionnaire, those 
expressing a dislike for >20% of the food items available were excluded from the study. 
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The TFEQ screened participants who exhibited extreme dietary tendencies (including 
disinhibited and restrained eating). Participants scoring 11 or more for any factor on the 
TFEQ were considered to exhibit restrained or disinhibited eating tendencies, and 
consequently questionnaires were further scrutinised before determining suitability to take 
part in the study. 
Height was measured to the nearest 0.1 cm using a stadiometer (Seca Ltd, Germany) and 
body mass was measured to the nearest 0.1 kg using a segmental body composition analyser 
(Tanita, Illinois, US). Body fat percentage was measured using bioelectrical impedance 
(Tanita, Illinois, US). For measurements of height, body mass and body fat percentage 
participants wore light clothing and removed their shoes and socks. BMI was subsequently 
calculated as body mass in kilograms divided by squared height in metres. Waist 
circumference was determined as the narrowest part of the torso between the xiphoid process 
and the iliac crest (Ross et al. 2008). A manual sphygmomanometer and stethoscope was 
used to measure resting blood pressure. An appropriately sized blood pressure cuff was 
selected and positioned over the brachial artery. Measurements were taken in triplicate after 
sitting for at least five min and the mean of these were used. 
A fasting blood sample was collected to confirm that participants were non-diabetic (fasting 
glucose concentrations <7 mmol.L
-1
, HbA1c <6.5%), and for the measurement of fasting total 
cholesterol, high density lipid-cholesterol, low density lipid-cholesterol and triglyceride 
concentrations. To measure glucose, cholesterol and triglyceride a blood sample was 
collected from the participant’s finger using a lancet (Accu-Check Lancets, Roche, Basel, 
Switzerland). Samples were immediately dispensed onto test strips and analysed using hand 
held monitors (Accutrend Plus, Roche, Basel, Switzerland and CardioChek, PTS diagnostics, 
Indianapolis, USA). For the measurement of HbA1c, a venous blood sample was collected by 
venepuncture of an antecubital vein. 
All participants underwent a 12 lead resting echocardiogram (ECG), performed by a suitably 
qualified member of the research team. The results from the resting ECG determined whether 
the participant was suitable to continue in the study, or if further ECG examination was 
required under exercising conditions in a clinical setting by trained staff. 
Finally, a suitably trained member of staff performed a physical examination of the 
participant to assess the nervous, pulmonary and circulatory systems for abnormalities. A 
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verbal detailed medical history was also obtained, and this subsequently determined the 
suitability of the participant to continue in the study. 
Provided it was determined safe for participants to exercise, participants completed two 
preliminary exercise tests on a level motorised treadmill (Technogym Excite Med, Cesena, 
Italy). After familiarisation with the protocol and treadmill, participants completed a 16 min 
progressive submaximal test, as described in Chapter 4. The initial treadmill speed was set 
between 4.0 and 8.0 km·h
-1
 depending on the fitness level of each participant and was 
increased between 0.5 and 1.0 km·h
-1
 after the completion of each 4 min stage. Oxygen 
consumption and carbon dioxide production were determined from continuous breath-by-
breath analysis (MetaMax 3B, Cortex, Biophysik, Leipzig, Germany). Prior to sample 
analysis, the analyser was calibrated with certified reference gases. The Borg scale was used 
to obtain the participants RPE at the end of each 4 min stage (Borg 1973). This scale ranged 
from six (no exertion) to 20 (maximal exertion). Heart rate was measured throughout using 
short-range radio telemetry (Polar T31; Electro, Kempele, Finland). 
After a period of rest, dictated by the participant, participants completed a V̇O2 peak test. An 
incremental uphill treadmill protocol was used to test participants’ until volitional exhaustion. 
Run speed was constant and set at a speed corresponding to a heart rate of ~150 beats·min
-1
. 
Treadmill gradient began at 1% and increased by 1% at 1 min intervals until exhaustion, 
which was reached within 5 to 18 min. Samples of expired air and heart rate were collected 
throughout. Measures of RPE were collected at the end of each 1 min stage. 
To ensure attainment of V̇O2 peak participants were required to meet ≥2 of the following 
criteria: 
 plateau in oxygen consumption 
 heart rate within 10 beats·min-1 of age predicted maximum 
 RER≥1.1 
 RPE≥19 (Cooke 2001) 
The achieved V̇O2 peak of each participant was used in combination with individual 
walking/running speed-oxygen uptake regression equations to determine a walking/running 
speed corresponding to 60% V̇O2 peak. Participants started at this speed during 
familiarisation trials, with subtle adjustments made if necessary i.e. for cardiovascular drift. 
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6.2.4.2. Exercise familiarisation 
Participants visited the laboratory on a second occasion for an exercise familiarisation trial, at 
least 7 days after the screening visit. Participants performed 60 min of continuous treadmill 
exercise on a level motorised treadmill (Technogym Excite Med, Cesena, Italy) at a speed 
predicted to elicit 60% V̇O2 peak. Work rate was measured throughout (MetaMax 3B, Cortex, 
Biophysik, Leipzig, Germany) to monitor the intensity of the treadmill exercise, with 
adjustments made to the treadmill speed if necessary. Heart rate was also measured 
throughout (Polar T31; Electro, Kempele, Finland). Ratings of perceived exhaustion were 
collected at 15, 30, 45 and 60 min. 
To ensure that participants adhered to the strict dietary and physical activity standardisation 
before each main trial, participants were given verbal and written instructions at the 
familiarisation visit. Specifically, participants were reminded to refrain from alcohol, caffeine, 
and taking part in any structured form of physical activity in the 48 h before each main trial. 
An explanation was provided for how to record and subsequently replicate dietary intake 
before each main trial using a weighed food diary. Before the first trial participants recorded 
their dietary intake for 48 h and were instructed to consume identical amounts of food and 
drink items, at identical times, in the 48 h before the second trial. Participants were provided 
with a food record diary and set of food weighing scales, if required, to assist with this. 
Participants were provided with food to consume the eve before each main trial, along with 
verbal and written instructions on how to prepare this meal. This meal was the final meal 
consumed before each trial and was consumed before 21:00, water was available ad libitum 
after this time. Participants were instructed to note the time this meal was consumed on the 
eve of the first trial, and this was to be strictly matched on the eve of the second trial. 
Participants were asked to confirm that they had adhered to the dietary and exercise 
standardisations before starting each experimental trial day. 
6.2.5. Experimental protocol 
Participants completed two main trials (control and exercise) in a crossover design with each 
trial being separated by at least 7 days in males, and by 28 days in females to control for the 
effects of the menstrual cycle (Figure 6.4).Each trial lasted 8 h and commenced at 09:00 after 
an overnight fast of at least 12 h. 
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The exercise trial commenced with 60 min continuous treadmill exercise (Technogym Excite 
Med, Cesena, Italy). The speed of the treadmill was set to that determined in the exercise 
familiarisation trial to elicit 60% V̇O2 peak. Heart rate and expired air samples were collected 
by breath-by-breath analysis (MetaMax 3B, Cortex, Biophysik, Leipzig, Germany) 
throughout the treadmill session. Ratings of perceived exertion were assessed at 15, 30, 45 
and 60 min during the exercise. Energy expenditure during the exercise session was 
calculated from oxygen uptake and carbon dioxide production (Frayn, 1983). These 
measurements were also used to calculate RER (carbon dioxide production divided by 
oxygen consumption). After the run participants rested in the laboratory for 7 h (sitting, 
reading, working at a desk or watching films). Blood samples and appetite questionnaires 
were completed periodically. Set meals were provided at 1.5 h and 4 h, and a buffet meal at 
7 h. 
The procedures in the control trial were identical to the exercise trial except that no exercise 
was performed. The sole exception to this was that resting expired air samples were collected 
during the first hour to assess resting metabolic rate. These data subsequently permitted the 
calculation of net exercise energy expenditure i.e. gross exercise energy expenditure during 
exercise minus resting energy expenditure. 
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Figure 6.4. Schematic representation of the main trial protocol. VAS, visual analogue scale. 
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6.2.6. Appetite measures 
During each trial appetite perceptions (hunger, satisfaction, fullness and PFC) were assessed 
at baseline and at every 30 min thereafter, as described in Chapter 4. 
6.2.7. Food provision, standardised test meals and ad libitum buffet meal 
To assist with dietary standardisation, participants were provided with a food package to 
consume on the eve of each main trial. Food packages contained white fusilli (Tesco fusilli 
pasta twists), tomato sauce (Dolmio Express tomato and basil sauce) and chocolate biscuits 
(Kit Kat milk chocolate biscuit). The calorie content of this meal was 750 kcal for males and 
674 kcal for females, and the macronutrient content was 71% carbohydrate, 11% protein and 
18% fat. The meal was designed to provide ~35% of the estimated daily energy needs for a 
healthy weight, inactive individual. The energy needs for an inactive individual were 
calculated using the Mifflin equation and a physical activity factor of 1.4 (Mifflin et al. 1990). 
This equation was selected as it considers the participants age, height, body mass and sex 
allowing for a more accurate estimation. A 1.4 activity factor was selected to represent the 
sedentary nature of the experimental visit. The Mifflin equations for males and females are 
below: 
Male resting energy expenditure = (10 x body mass) + (6.25 x height) – (5 x age) + 5; 
Female resting energy expenditure = (10 x body mass) + (6.25 x height) – (5 x age) – 161. 
Written and verbal instructions on how to prepare the meal were given at the exercise 
familiarisation visit (as described in chapter 6.2.4.2.). Participants were instructed to consume 
the meal by 21:00 on the eve of each main trial, and that water could be consumed ad libitum 
thereafter. 
At 1.5 h (10:30) participants were provided with a standardised breakfast, which consisted of 
a jam sandwich (brown bread (Tesco wholemeal medium bread), margarine (Tesco butter me 
up original spread), and strawberry jam (Tesco strawberry jam)), banana and orange juice 
(Tesco pure orange juice smooth). The calorie content of this meal was 643 kcal for males 
and 578 kcal for females, and the macronutrient content was 72% carbohydrate, 10% protein 
and 18% fat. The meal was designed to provide ~30% of the estimated daily energy needs for 
a healthy weight, inactive individual. Participants were instructed to eat all of the meal within 
15 min. 
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At 4 h (13:00) a standardised lunch meal consisting of either a tuna (Tesco tuna chunks pole 
and line in spring water) and mayonnaise (Tesco mayonnaise) or cheese (Tesco lighter 
mature cheese) white bread (Tesco white medium bread) sandwich (depending on preference, 
determined at the screening visit), with salted crisps (Tesco ready salted crisps), golden 
delicious apple and a chocolate muffin (Tesco chocolate muffins). The calorie content of this 
meal was 750 kcal for males and 674 kcal for females, and the macronutrient content of this 
meal was 43% carbohydrate, 32% protein, 25% fat. Participants were instructed to eat all of 
the meal within 15 min. 
Energy and macronutrient intake were assessed at an ad libitum meal provided at 7 h (16:00) 
on each trial day. Acceptability of the buffet items was ensured during the preliminary trial 
via the completion of a food preference questionnaire (Appendix S). The questionnaire 
required participants to rate preselected food items on a Likert scale ranging from one (dislike 
extremely) to ten (like extremely). Participants were excluded from the study if they 
rated >20% of the items at 4 or less. The items available are listed in Appendix U. The buffet 
foods were presented identically on each occasion and were in excess of expected 
consumption. Participants were allowed up to 30 min to consume the buffet foods but 
instructed to eat until ‘comfortably full’ and informed that additional food was available if 
desired. Participants consumed meals in isolation so that social influence did not affect eating 
speed, food selection or quantity eaten. Participants were not overtly aware that their food 
intake was being measured. After the ad libitum meal leftovers were weighed and food 
consumption was determined as the weighed difference of items before and after the meal. 
The energy and macronutrient content of the items consumed were determined from 
manufacturers’ values. 
6.2.8. Blood sampling 
Upon arrival to the laboratory, participants rested in a semi-supine position and a cannula 
(Venflon, Becton Dickinson, Helsingborg, Sweden) was inserted into an antecubital vein. 
Blood samples were collected at: baseline, 1, 1.5, 2.25, 2.75, 3.25, 4, 4.75, 5.25, 5.75, 7 and 
8 h. Samples from the cannula were taken as described in Chapter 4. 
Venous blood samples were taken into two pre-chilled EDTA monovettes (4.9 and 9 mL) 
(Sarstedt, Leicester, UK) for the determination of plasma acylated and desacylated ghrelin, 
total PYY, total GLP-1, insulin, glucose, TAG and non-essential fatty acids (NEFA). To 
prevent the degradation of acylated ghrelin, blood samples collected into the 4.9 mL 
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monovette were pre-treated and processed following manufacturer instructions (see Chapter 
3). The remaining analytes were measured from the resulting plasma collected into the 9 mL 
monovette as described in Chapter 4. The plasma supernatant was aliquoted into 2 mL 
Eppendorfs and stored at -20°C, then transferred to -80°C for future analysis. Changes in 
plasma volume were estimated, as described in Chapter 4. 
6.2.9. Biochemical analysis 
Commercially available enzyme immunoassays were used to determine concentrations of 
plasma acylated ghrelin (SPI BIO, Montigny le Bretonneux, France), desacylated ghrelin 
(SPI BIO, Montigny le Bretonneux, France), total PYY (Millipore, Billerica, USA), total 
GLP-1 (Millipore, Billerica, USA) and insulin (Mercodia, Uppsala, Sweden) with the aid of a 
plate reader to measure absorbance (Varioskan Flash Multiple Mode Reader, Vantaa, 
Finland). Plasma glucose, TAG and NEFA concentrations were determined by enzymatic, 
colorimetric methods using a bench top analyser (Pentra 400; HORIBA ABX Diagnostics, 
Montpellier, France). Plasma concentrations of total ghrelin were calculated by adding 
plasma acylated ghrelin and desacylated ghrelin concentrations. Precision of analysis was 
ensured by quantification of an internal quality control exhibiting high and low values. To 
eliminate inter-assay variation, samples from each participant were analysed on the same run. 
The within-batch coefficients of variation for the assays were as follows: acylated ghrelin 
5.2%, desacylated ghrelin 4.8%, total PYY 6.1%, insulin 4.5%, total GLP-1 10.2%, glucose 
0.7%, TAG 1.5%, and NEFA 2.4%. 
6.2.10. Statistical analysis 
Data were analysed using IBM SPSS statistics, version 21.0. for Windows. Appetite 
perception (hunger, satisfaction, fullness and PFC) and appetite hormone (acylated ghrelin, 
desacylated ghrelin, total ghrelin, total PYY, total GLP-1, insulin, TAG, glucose, NEFA) 
total AUC calculations were performed using the trapezoidal method. For the purpose of 
hormone total AUC calculations, missing sample points were inputted by multiplying the 
preceding sample point by the mean change across these two time points. i.e.: 
𝑥 = (𝑥 − 1)  ∗  
𝑥
𝑥 − 1
 
where 𝑥 is the missing sample point, (𝑥 − 1) is the preceding sample, 𝑥 is the group mean 
value of the hormone at the same time point as missing sample 𝑥, and 𝑥 − 1 is the group 
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mean value of the hormone at the preceding time point to the missing sample. Given the 
behavioural and unstandardized nature of the ad libitum buffet meal at 7 h, AUC calculations 
were completed for the whole 8 h trial period, and the first 7 h of each trial. However, 
shortening the AUC period did not alter the statistical significance of the results; therefore, 
for simplicity, only the 8 h values are presented. 
Two-factor linear mixed models were used to examine participant characteristics and exercise 
responses with fixed (sex and BMI) and random (participant) factors. Three-factor linear 
mixed models were used to examine baseline measurements, appetite perception total AUC 
and appetite hormone total AUC data with fixed (sex, BMI and trial) and random (participant) 
factors. Four-factor linear mixed models were used to examine appetite perceptions and 
appetite hormones across trials with fixed (sex, BMI, trial and time) and random (participant) 
factors. Where significant trial vs. time interaction effects were found, post-hoc analysis was 
performed using Holm-Bonferroni correction for multiple comparisons (Atkinson 2002). 
Data were also plotted on graphs for clarity. Where significant trial vs. BMI and trial vs. sex 
interactions were found, data were graphically represented and written descriptions made. 
The Pearson product moment correlation coefficient was used to examine relationships 
between waist circumference and key outcomes (i.e. absolute energy intake, hunger total 
AUC, and acylated ghrelin, desacylated ghrelin, PYY and GLP-1 total AUC). Corrections of 
plasma analyte values for changes in plasma volume did not alter the statistical significance 
of the results; therefore, for simplicity, the unadjusted values are presented. Statistical 
significance was accepted at 5%. Absolute standardised effect sizes (ES) were calculated to 
supplement important findings. The differences between mean values (control vs. exercise, 
lean vs. overweight, or females vs. males) were divided by the pooled standard deviation. An 
ES of 0.2 was considered the minimum important difference for all outcome measures, 0.5 
moderate and 0.8 large (Cohen 1988). Results are shown as mean (SD) in text and tables, and 
mean (SEM) in figures (for clarity). 
6.2.11. Power calculations 
The power calculation for this study was based on its primary outcome; in particular, the 
effect of acute exercise on circulating concentrations of appetite regulatory hormones. Power 
calculations were determined by obtaining effect sizes from previous research within our 
laboratory (King et al. 2011). This study examined differences in circulating concentrations 
of acylated ghrelin and PYY3-36 between an exercise and control trial (total trial AUC). This 
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previous data revealed effect sizes of 0.6. Using this data, and assuming an alpha of 0.05 and 
acceptable power of 0.8, the present study requires a sample size of 64 participants (16 lean 
females, 16 obese females, 16 lean males and 16 obese males). 
However, it must be noted that the stated sample size was calculated using the original ethics 
documentation. It is likely that by broadening the participant inclusion criteria, i.e. wider age 
and BMI range, the sample size required to detect a meaningful result would have increased. 
However, there are no borderline statistics reported in this chapter. This would suggest there 
are no cases of type 2 error. To address the issue of under-powering, effect sizes are reported 
alongside significance values.  
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6.3. Results 
6.3.1. Exercise responses 
The exercise responses are summarised in Table 6.2. Participants completed the 60 min bout 
of treadmill exercise at 6.7 (1.2) km·h
-1
. This elicited a mean oxygen consumption equivalent 
to 59 (4) % of V̇O2 peak and a net energy expenditure of 1851 (601) kJ. The RER was 0.88 
(0.06), which reflected proportional contribution to energy provision of 62% (22%) 
carbohydrate and 38% (22%) fat. Heart rate and RPE were 135 (25) beats·min
-1
 and 12 (2), 
respectively. 
Table 6.2. Exercise responses (N=47). 
 
Lean 
Females 
(N=11)
a
 
Ow/ob 
Females 
(N=11)
b
 
Lean 
Males 
(N=11)
c
 
Ow/ob 
Males 
(N=14)
d
 
Effect Size 
Sex BMI 
Treadmill speed (km·h
-1
)
*†
 6.6 5.8 7.6 6.8 0.81 0.67 
(1.6) (0.7) (1.0) (0.8) 
Mean heart rate (beats·min
-1
) 136 118 141 142 0.55 0.24 
(31) (14) (29) (21) 
Mean relative V̇O2 (mL·kg·min
-1
)
*†
 24 17 28 23 0.77 1.00 
(6) (3) (6) (5) 
Mean absolute V̇O2 (L·min
-1
)
†
 1.4 1.3 2.0 2.1 1.87 0.06 
(0.4) (0.3) (0.4) (0.4) 
Exercise intensity (% of V̇O2 peak)
*
 61 57 59 58 0.07 0.66 
(3) (4) (3) (3) 
RPE (6-20) 11 12 12 12 0.40 0.17 
(3) (2) (1) (1) 
Net energy expenditure (kJ)
†
 1503 1350 2211 2265 1.89 0.02 
(449) (333) (507) (481) 
Mean RER 0.86 0.86 0.89 0.89 0.54 0.02 
(0.06) (0.06) (0.07) (0.07) 
Carbohydrate utilisation (%) 56.5 55.2 66.5 66.9 0.51 0.01 
(21.5) (21.9) (22.6) (21.8) 
Fat utilisation (%) 43.5 44.8 33.5 33.1 0.51 0.01 
(21.5) (21.9) (22.6) (21.8) 
*Significantly different between lean and ow/ob (P<0.01). 
†
Significantly different between 
males and females (P<0.01).
a
Mean treadmill oxygen uptake, exercise intensity, net energy 
expenditure mean RER, carbohydrate and fat utilisation only available for N=9. 
b
Mean heart 
rate only available for N=10.
c
Mean heart rate, mean treadmill oxygen uptake, exercise 
intensity, net energy expenditure mean RER, carbohydrate and fat utilisation only available 
for N=9. 
d
Net energy expenditure only available for N=13. Net energy expenditure was 
calculated as exercise energy expenditure minus energy expenditure at rest. Values are mean 
(SD). 
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Treadmill speed, mean absolute V̇O2, mean relative V̇O2, and net energy expenditure were 
significantly higher for males than females (treadmill speed, 7.2 (1.0) vs. 6.2 (1.3) km·h
-1
; 
mean absolute V̇O2, 2.0 (0.4) vs. 1.4 (0.3) L·min
-1
; mean relative V̇O2, 25 (6) vs. 20 (6) 
mL·kg·min
-1
; net energy expenditure, 2243 (481) vs. 1419 (386) kJ for males and females, 
respectively; all P≤0.01). Treadmill speed, mean relative V̇O2 and exercise intensity were 
significantly higher for lean than ow/ob individuals (treadmill speed, 7.1 (1.4) vs. 6.3 (0.9) 
km·h
-1
; mean relative V̇O2, 26 (7) vs. 20 (5) mL·kg·min
-1
; exercise intensity (% of V̇O2 peak), 
60 (3) vs. 58 (4)
 for lean and ow/ob, respectively; all P≤0.01). 
6.3.2. Resting expired air samples 
The resting expired air values are summarised in Table 6.3. There were no significant 
differences in mean RER, carbohydrate or fat utilisation between sex or BMI group. Mean 
relative V̇O2 was significantly higher for lean than ow/ob individuals (3.72 (0.62) vs. 3.18 
(0.57) mL·kg·min
-1
 for lean and ow/ob, respectively; P<0.01). Mean absolute V̇O2 and 
energy expenditure were significantly higher for males than females (mean absolute V̇O2, 
0.28 (0.05) vs. 0.23 (0.05) L·min
-1
; energy expenditure, 5.93 (0.93) vs. 4.74 (1.04) kJ·min
-1
 
for males and females, respectively; P≤0.01). 
Table 6.3. Resting expired air values. (N=46). 
 
Lean 
Females 
(N=11) 
Ow/ob 
Females 
(N=11) 
Lean 
Males 
(N=11) 
Ow/ob 
Males 
(N=13) 
Effect Size 
Sex BMI 
Mean relative V̇O2 (mL·kg·min
-1
)
*
 3.69 3.03 3.75 3.31 0.23 0.45 
(0.62) (0.49) (0.65) (0.62) 
Mean absolute V̇O2 (L·min
-1
)
†
 0.22 0.24 0.27 0.30 1.04 0.90 
(0.06) (0.05) (0.05) (0.04) 
Energy expenditure (kJ·min
-1
)
†
 4.58 4.90 5.62 6.18 1.20 0.02 
(1.16) (0.93) (0.89) (0.92) 
Mean RER 0.85 0.82 0.87 0.85 0.35 0.37 
(0.08) (0.05) (0.07) (0.05) 
Carbohydrate utilisation (%) 51.9 43.1 59.4 52.4 0.36 0.33 
(28.4) (17.9) (24.1) 17.9) 
Fat utilisation (%) 48.1 56.9 40.7 47.6 0.36 0.33 
(28.4) (17.9) (24.1) (17.9) 
*Significantly different between lean and ow/ob (P<0.01). 
†
Significantly different between 
males and females (P<0.01). Values are mean (SD). 
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6.3.3. Appetite responses 
Fasting appetite perceptions (hunger, fullness, satisfaction and PFC) did not differ between 
sex, BMI group or trial at baseline (all P≥0.10, Table 6.4). Despite this, baseline hunger was 
seen to be lower in the exercise than control trial for lean females and ow/ob males. Prior 
knowledge of the trial participants would be completing could have influenced baseline 
hunger ratings. 
Table 6.4. Baseline appetite perceptions in the control and exercise trials (N=47). 
Fasting appetite 
perception (mm) 
Trial 
Lean 
Females 
(N=11) 
Ow/ob 
Females 
(N=11) 
Lean 
Males 
(N=11) 
Ow/ob 
Males 
(N=14) 
Hunger Control 47 
(26) 
49 
(24) 
52 
(28) 
37 
(27) 
Exercise 34 
(29) 
48 
(24) 
52 
(25) 
26 
(22) 
Satisfaction Control 19 
(11) 
37 
(16) 
30 
(19) 
30 
(23) 
Exercise 29 
(28) 
24 
(10) 
38 
(29) 
40 
(22) 
Fullness Control 16 
(13) 
26 
(18) 
25 
(18) 
27 
(19) 
Exercise 26 
(29) 
23 
(13) 
28 
(21) 
35 
(24) 
PFC Control 66 
(24) 
63 
(20) 
63 
(22) 
62 
(29) 
Exercise 49 
(31) 
61 
(11) 
65 
(20) 
50 
(25) 
Values are mean (SD). 
Across trials, four-factor linear mixed modelling (sex vs. BMI vs. trial vs. time) revealed a 
significant main effect of trial for hunger and PFC (both P≤0.01; Figure 6.5), indicating 
suppressed ratings in the exercise trial for all participants. A significant trial vs. time 
interaction effect was found for hunger (P≤0.01), satisfaction (P=0.04) and PFC (P≤0.01). 
Compared with control, post-hoc analysis revealed suppressed hunger ratings at 0.5 (P=0.02) 
and 1.0 h (P=0.04) of the exercise trial. Similarly, post-hoc analysis revealed suppressed PFC 
perceptions at 0.5 (P<0.01) and 1.0 h (P=0.01). A significant trial vs. sex interaction was 
found for PFC, males showed a greater suppression of PFC than females during the exercise 
trial (11 vs. 2%, P=0.04; Appendix V). Significant trial vs. BMI interactions were found for 
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satisfaction (P=0.04; Appendix V) and PFC (P<0.01; Appendix V). For satisfaction, lean and 
ow/ob responded in opposite directions, with ow/ob being less satisfied in the exercise 
compared to control trial and lean individuals showing an increase in satisfaction in the 
exercise trial. For PFC, lean individuals showed a greater suppression of PFC than ow/ob 
during the exercise trial (12 vs. 1%, for lean and ow/ob, respectively). 
Analysis of the appetite total AUC using three-factor linear mixed modelling (sex vs. BMI vs. 
trial) did not show any differences in appetite perceptions (Table 6.5). 
Table 6.5. Total area under the curve (AUC) values (0-8 h) for hunger, satisfaction, fullness 
and prospective food consumption (PFC) during control and exercise trials (N=47). 
AUC 
(0-8h) 
Trial 
Lean 
Females 
(N=11) 
Ow/ob 
Females 
(N=11) 
Lean 
Males 
(N=11) 
Ow/ob 
Males 
(N=14) 
Hunger  Control 217 261 312 226 
(97) (117) (127) (86) 
Exercise 170 237 288 221 
(90) (117) (146) (85) 
Satisfaction Control 438 452 401 442 
(98) (133) (69) (93) 
Exercise 461 446 416 440 
(96) (112) (132) (96) 
Fullness Control 434 431 375 441 
(94) (118) (76) (99) 
Exercise 446 427 393 431 
(115) (95) (105) (85) 
PFC Control 304 318 365 311 
(111) (120) (105) (98) 
Exercise 242 310 342 317 
(88) (115) (125) (90) 
Values are mean (SD).  
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6.3.4. Energy and macronutrient intake 
Table 6.5 shows the energy and macronutrient intake data from the control and exercise trials. 
Three-factor linear mixed modelling (sex vs. BMI vs. trial) identified a main effect of sex for 
absolute energy intake (kJ), carbohydrate (g), protein (g) and fat (g) intake (all P<0.01). 
Males consumed more kilocalories and more grams of carbohydrate, protein and fat than 
females. No main effect of trial, BMI or interaction effects were found (all P≥0.18). There 
was no effect of trial order on ad libitum energy intake (P=0.12). Three-factor linear mixed 
modelling revealed a significant main effect of trial for ad libitum water intake (1071 (406) 
vs. 1366 (480) g for control and exercise, respectively; P<0.01). 
6.3.5. Relative energy intake 
Relative energy intake was calculated as ad libitum energy intake minus the net energy 
expenditure elicited by exercise (Table 6.2). A significant trial effect (P<0.01) was found, 
indicating lower REI for all participants in the exercise trial. A significant effect of sex 
(P<0.01) shows that males had a higher REI than females.  
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Table 6.6. Absolute ad libitum energy intake, relative ad libitum energy intake and 
macronutrient intake at the buffet meal (7 h) during control and exercise trials (N=47). 
 
 
Trial 
Lean 
Females 
(N=11)
a
 
Ow/ob 
Females 
(N=11) 
Lean 
Males 
(N=11)
a
 
Ow/ob 
Males 
(N=14)
b
 
Effect Size 
Sex BMI Trial 
Absolute  
energy intake 
 
(kJ)
†
 Control 2497 2830 3869 3964 1.15 0.26 0.01 
(1158) (1378) (1295) (1578) 
Exercise 2149 2525 3976 4340 
(998) (1575) (1858) (1566) 
REI 
 
(kJ)
†#
 Control 2497 2830 3869 3964 0.87 0.18 1.26 
(1158) (1378) (1295) (1578) 
Exercise 467 1155 1975 2020 
(1110) (1450) (1911) (1673) 
FAT g
†
 Control 31 34 40 45 0.73 0.29 0.06 
(17) (17) (15) (27) 
Exercise 26 29 42 48 
(16) (17) (21) (28) 
% Control 41 45 40 40 0.23 0.14 0.05 
(12) (11) (9) (12) 
Exercise 40 45 41 39 
(8) (9) (10) (10) 
CHO g
†
 Control 63 70 114 99 1.11 0.10 0.06 
(30) (39) (50) (37) 
Exercise 61 69 107 115 
(24) (49) (68) (37) 
% Control 43 42 48 43 0.09 0.18 0.16 
(9) (15) (11) (10) 
Exercise 49 43 44 47 
(8) (16) (14) (11) 
PRO g
†
 Control 20 23 26 36 1.14 0.26 0.07 
(10) (14) (11) (13) 
Exercise 18 18 36 38 
(14) (12) (27) (20) 
% Control 15 13 12 16 0.15 0.01 0.07 
(9) (6) (5) (6) 
Exercise 14 12 15 14 
(11) (9) (11) (5) 
†
Significantly different between males and females (P<0.01).
 #
Significantly different between 
control and exercise trials (P<0.01). 
a
Exercise energy intake only available for N=9. 
b
Exercise 
energy intake only available for N=13. Values are mean (SD).  
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6.3.6. Blood analyses 
Due to problems with cannulation, blood sampling data for fasting and across trial plasma 
acylated, desacylated and total ghrelin, insulin, TAG, glucose and NEFA are presented for 43 
(rather than 47) participants. Data for fasting and across trial plasma total PYY are presented 
for 42 participants, whilst data for fasting and across trial plasma total GLP-1 are presented 
for 40 participants. Of the participant blood sets presented 3% of samples could not be 
collected for acylated and desacylated ghrelin, total PYY, insulin, TAG, glucose and NEFA. 
Total ghrelin and total GLP-1 are missing 4% of sample points.  
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6.3.6.1. Acylated ghrelin concentrations (N=43) 
There were no main effects of trial, BMI or interaction effects for baseline acylated ghrelin 
concentrations (all P≥0.38; Figure 6.6). A significant main effect of sex showed females to 
have higher circulating baseline concentrations than males (143 (91) vs. 87 (79) pg·mL
-1 
for 
females and males, respectively; P<0.01). 
Across the whole trial, a four-factor mixed model showed no significant main effects of sex, 
BMI or trial (all P≥0.13). A significant trial vs. sex interaction highlights that females 
expressed 8% higher circulating acylated ghrelin concentrations in the exercise than control 
trial, whilst males showed 5% lower concentrations (P=0.01; Appendix W). 
Total area under the curve calculations revealed no significant differences (Figure 6.7 and 
Table 6.7). 
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Table 6.7. Total area under the curve (AUC) values (0-8 h) for acylated ghrelin, desacylated 
ghrelin, total ghrelin, total peptide-YY (PYY), total glucagon-like peptide-1 (GLP-1), insulin, 
triglycerides (TAG), glucose, and non-essential fatty acids (NEFA) during control and 
exercise trials (N=43). 
AUC 
(0-8h) 
Trial 
Lean 
Females 
(N=10)
a
 
Ow/ob 
Females 
(N=11)
b
 
Lean 
Males 
(N=10) 
Ow/ob 
Males 
(N=12) 
Effect Size 
Sex BMI Trial 
Acylated ghrelin 
(pg·mL-1·h-1) 
Control 708 676 396 619 0.23 0.10 0.03 
(416) (363) (150) (634) 
Exercise 766 742 372 594 
(558) (561) (169) (681) 
Desacylated 
ghrelin 
(pg·mL-1·h-1) 
Control 1581 2204 1000 1544 0.27 0.18 0.02 
(800) (1648) (636) (1324) 
Exercise 1787 2473 955 1316 
(1177) (3029) (660) (1019) 
Total ghrelin 
(pg·mL-1·h-1)† 
Control 2289 2880 1396 2163 0.28 0.17 0.03 
(1110) (1975) (752) (1763) 
Exercise 2553 3215 1327 1910 
(1645) (3571) (794) (1454) 
Total PYY 
(pg·mL-1·h-1) 
Control 947 985 1041 775 0.08 0.13 0.06 
(497) (588) (302) (570) 
Exercise 1034 1034 1080 761 
(548) (563) (393) (625) 
Total GLP-1 
(pM·h-1)# 
Control 154 178 186 178 0.12 0.11 0.28 
(99) (81) (74) (57) 
Exercise 179 219 215 244 
(122) (126) (97) (152) 
Insulin 
(pmol·L-1·h-1)# 
Control 1433 1762 1164 1425 0.21 0.27 0.22 
(962) (884) (451) (549) 
Exercise 1063 1655 1066 1240 
(388) (457) (464) (531) 
TAG 
(mmol·L-1·h-1)*† 
Control 9.29 12.26 11.71 19.07 0.43 0.47 0.02 
(2.90) (4.36) (6.27) (8.31) 
Exercise 8.96 12.57 12.27 19.39 
(2.07) (4.07) (5.79) (7.05) 
Glucose 
(mmol·L-1·h-1)* 
Control 50.12 55.76 50.54 51.02 0.15 0.31 0.01 
(4.98) (9.75) (5.19) (4.04) 
Exercise 49.95 54.96 50.37 52.41 
(3.61) (5.03) (2.61) (4.30) 
NEFA 
(mmol·L-1·h-1)# 
Control 1.78 1.99 1.53 1.84 0.12 0.13 1.04 
(0.71) (0.64) (0.82) (0.43) 
Exercise 3.09 2.98 2.64 3.12 
(1.11) (0.81) (0.86) (0.97) 
*Significantly different between lean and ow/ob (P≤0.01). †Significantly different between males and females 
(P≤0.05). #Significantly different between control and exercise trials (P≤0.05). aN=8 for total GLP-1. bN=10 for 
total PYY and total GLP-1. Values are mean (SD).  
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6.3.6.2. Desacylated ghrelin concentrations (N=43) 
There were no main effects of trial or BMI or interaction effects for baseline desacylated 
ghrelin concentrations (all P≥0.09; Figure 6.8). A significant main effect of sex showed 
females to have higher circulating baseline concentrations than males (414 (499) vs. 221 (198) 
pg·mL
-1 
for females and males, respectively; P=0.02). 
Across the whole trial, a four-factor mixed model showed no significant main effects of sex, 
BMI or trial (all P≥0.07). A significant trial vs. sex interaction highlights that females 
expressed 12% higher circulating desacylated ghrelin concentrations in the exercise than 
control trial, whilst males showed 11% lower concentrations (P=0.02; Appendix W). 
Total area under the curve calculations revealed no significant differences (Figure 6.7 and 
Table 6.7). 
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6.3.6.3. Total ghrelin concentrations (N=43) 
There were no main effects of trial or BMI or interaction effects for baseline total ghrelin 
concentrations (all P≥0.14; Figure 6.9). A significant main effect of sex showed females to 
have higher circulating baseline concentrations than males (557 (577) vs. 308 (259) pg·mL
-1 
for females and males, respectively, P=0.01). 
Across the whole trial, a four-factor mixed model showed no significant main effects of sex, 
BMI or trial (all P>0.06). A significant trial vs. sex interaction found that females expressed 
12% higher circulating total ghrelin concentrations in the exercise than control trial, whilst 
males showed 7% lower concentrations (P=0.02; Appendix W). 
Total area under the curve calculations revealed a significant main effect of sex with females 
expressing higher total AUC concentrations than males (2749 (2247) vs. 1730 (1308) 
pg·mL
-1
, for females and males, respectively; P=0.05; Table 6.7 and Figure 6.7). 
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6.3.6.4. Total peptide-YY concentrations (N=42) 
Total PYY concentrations did not significantly differ between trial or group at baseline (all 
P≥0.25; Figure 6.10). 
Across the whole trial, a four-factor mixed model showed a significant main effect of trial 
with circulating concentrations significantly higher in the exercise than control trial (119 (75) 
vs. 113 (68) pg·mL
-1
, for exercise and control, respectively; P<0.01; Appendix X). 
Total area under the curve calculations revealed concentrations to be higher in the exercise 
than control trial (967 (539) vs. 929 (500) pg·mL
-1
·h
-1
, for exercise and control, respectively; 
P=0.051; Table 6.7). 
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6.3.6.5. Total glucagon-like peptide-1 concentrations (N=40) 
Total GLP-1 concentrations did not significantly differ between trial or group at baseline (all 
P≥0.15; Figure 6.11). 
Across the whole trial, a four-factor mixed model showed a significant main effect of trial, 
with concentrations higher in the exercise than control trial (27 (20) vs. 22 (12) pM.L
-1
, for 
exercise and control, respectively; P<0.01; Appendix X). A significant trial vs. time 
interaction was also found (P<0.01). Post-hoc analysis showed total GLP-1 concentrations to 
be significantly elevated during exercise trials at 2.25 h (P<0.01) and 2.75 h (P=0.04), 
compared to control. 
Total area under the curve calculations revealed a significant effect of trial, with total AUC 
concentrations higher in the exercise than control trial (217 (128) vs. 175 (79) pM·mL
-1
·h
-1
, 
for exercise and control, respectively; P=0.01; Table 6.7). 
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6.3.6.6. Insulin concentrations (N=43) 
Insulin concentrations did not significantly differ across trial or group at baseline (all P≥0.13; 
Figure 6.12). 
Across the whole trial, a four-factor mixed model showed a significant main effect of BMI 
with concentrations higher in ow/ob than lean individuals (198 (166) vs. 150 (135) pmol.L
-1
, 
for ow/ob and lean, respectively; P=0.03). A significant main effect of trial showed 
concentrations of insulin to be higher in the control than exercise trial (186 (169) vs. 165 (137) 
pmol.L
-1
, for control and exercise, respectively; P<0.01; Appendix X). 
Total area under the curve calculations revealed a significant main effect of trial showed that 
total AUC values were higher in the control than exercise trial (1452 (743) vs. 1264 (511) 
pmol.L
-1
·h
-1
, for control and exercise, respectively; P=0.03). Concentrations were found to be 
higher in ow/ob than lean individuals (1520 (846) vs. 1181 (906) pmol.L
-1
·h
-1
,
 
for lean and 
ow/ob, respectively; P=0.051; Table 6.7). 
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6.3.6.7. Triglyceride concentrations (N=43) 
There were no main effects of trial or interaction effects for baseline TAG concentrations (all 
P≥0.62; Figure 6.13). A significant main effect of sex showed males to have higher 
circulating baseline concentrations than females (1.5 (0.8) vs. 1.1 (0.5) mmol.L
-1 
for males 
and females, respectively; P=0.01). A significant main effect of BMI showed ow/ob to have 
higher circulating baseline concentrations than lean individuals (1.5 (0.7) vs. 1.0 (0.4) 
mmol.L
-1 
for ow/ob and lean, respectively; P<0.01). 
Across the whole trial, a four-factor mixed model showed a significant main effect of sex, 
with males expressing higher concentrations of TAG than females (1.9 (1.2) vs. 1.3 (0.6) 
mmol.L
-1 
for males and females, respectively; P=0.01). A significant main effect of BMI 
showed ow/ob to express higher concentrations of TAG than lean individuals (1.9 (1.1) vs. 
1.3 (0.7) mmol.L
-1
, for ow/ob and lean, respectively; P<0.01). 
Total area under the curve calculations revealed a significant main effect of sex, with males 
having higher total AUC concentrations than females (16.0 (7.7) vs. 10.9 (3.7) mmol.L
-1
·h
-1
, 
for males and females, respectively; P<0.01; Table 6.7). A significant main effect of BMI 
showed that ow/ob had higher total AUC concentrations than lean individuals (16.0 (7.1) vs. 
10.6 (4.8) mmol.L
-1
·h
-1
, for ow/ob and lean, respectively; P<0.01). 
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6.3.6.8. Glucose concentrations (N=43) 
There were no main effects of trial or sex or interaction effects for baseline glucose 
concentrations (all P≥0.44; Figure 6.14). A significant main effect of BMI showed ow/ob to 
have higher circulating baseline concentrations than lean individuals (6.0 (0.6) vs. 5.6 (0.3) 
mmol.L
-1 
for ow/ob and lean, respectively; P<0.01). 
Across the whole trial, a four-factor mixed model showed a significant main effect of BMI 
with ow/ob expressing higher concentrations of insulin than lean individuals (6.8 (1.4) vs. 6.3 
(1.2) mmol.L
-1
, for ow/ob and lean, respectively; P=0.02).  
Total area under the curve calculations revealed a significant main effect of BMI, with ow/ob 
showing higher total AUC concentrations than lean individuals (50.2 (4.2) vs. 53.5 (6.2) 
mmol.L
-1
·h
-1
, for lean and ow/ob, respectively; P=0.03). 
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6.3.6.9. NEFA concentrations (N=43) 
There were no main effects of trial or BMI or interaction effects for baseline NEFA 
concentrations (all P≥0.18; Figure 6.15). A significant main effect of sex showed females to 
have higher circulating baseline concentrations than males (0.7 (0.3) vs. 0.5 (0.2) mmol.L
-1 
for females and males, respectively; P<0.01). 
Across the whole trial, a four-factor mixed model showed a significant main effect of trial 
with concentrations of NEFA higher in the exercise than control trial (0.3 (0.4) vs. 0.2 (0.2) 
mmol.L
-1
, for exercise and control, respectively; P<0.01; Appendix X). A significant trial vs. 
time interaction was also found (P<0.01). Post-hoc analysis showed NEFA concentrations to 
be significantly elevated during exercise trials at 1.0 and 1.5 h (both P≤0.01), compared to 
control. 
Total area under the curve calculations revealed a significant main effect of trial, with total 
AUC concentrations higher in the exercise than control trial (3.0 (0.9) vs.1.8 (0.8) 
mmol.L
-1
·h
-1
, for exercise and control trials, respectively; P<0.01).  
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6.3.7. Correlations 
A positive, but weak, relationship was found between waist circumference and ad libitum 
energy intake for both control and exercise trials (control: r= 0.32, P=0.03, exercise: r=0.39, 
P<0.01). There was no correlation between waist circumference and acylated ghrelin total 
AUC, desacylated ghrelin total AUC, GLP-1 total AUC, PYY total AUC or hunger total 
AUC.  
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6.4. Discussion 
The purpose of this investigation was to compare the effects of a single bout of aerobic 
exercise on subjective appetite perceptions, circulating concentrations of appetite regulatory 
hormones and ad libitum energy intake in lean and ow/ob males and females. The primary 
findings are that 1) exercise induced a transient suppression of subjective appetite in all 
participant groups, 2) concentrations of PYY and GLP-1 were higher in the exercise than 
control trial, 3) mean subjective appetite, acylated ghrelin, and ad libitum energy intake did 
not differ between control and exercise trial days, for all participant groups. Together, the 
findings of the current study suggest that the beneficial effects of exercise on appetite control 
are seen equally in males and females, and in lean and ow/ob individuals, i.e. acute exercise 
does not induce compensatory increases in subjective appetite in the 7 h after exercise or ad 
libitum energy intake at a buffet meal 6 h after exercise. Together this allowed for the 
maintenance of an energy deficit. If this can be sustained over longer periods of time, 
moderate intensity exercise could be useful for weight loss and management. 
Subjective ratings of hunger and PFC were suppressed for all participant groups during and 
for immediately after exercise. This suppression of subjective appetite during exercise is 
consistent with previous reports of exercise induced anorexia during exercise ≥60% V̇O2 max 
(Blundell et al. 2003; King et al. 1994). However, few have compared responses of males and 
females (Alajmi et al. 2016; Hagobian et al. 2013), or ow/ob and lean individuals (Ueda et al. 
2009b). In the present study, we found appetite responses to be similar among all participants, 
irrespective of sex or BMI group. The mechanisms that cause appetite suppression during 
exercise remain unclear; however, recent evidence suggests that exercise-induced changes in 
appetite regulatory hormones such as acylated ghrelin, PYY, GLP-1 and PP may play a role 
(Broom et al. 2009; Hazell et al. 2016; Schubert et al. 2013; Ueda et al. 2009a). The transient 
suppression of appetite after exercise seen in the present study, occurred in the absence of any 
simultaneous changes in appetite regulatory hormones. This questions the role of appetite 
regulatory hormones on subjective appetite perceptions, and suggests other mechanisms of 
appetite control may be more influential. 
In accordance with previous research, it was expected for circulating concentrations of 
acylated ghrelin to be transiently suppressed after exercise, in lean individuals. Contrary to 
this, acylated ghrelin concentrations were found to be similar between control and exercise 
trials, for all participant groups. It has been suggested that the redistribution of blood from the 
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splanchnic region to active skeletal muscle during exercise is important for suppressing 
ghrelin (Hazell et al. 2016). As blood flow redistribution is dependent on exercise intensity, it 
is possible that the exercise intensity used in the current study was not great enough to elicit 
these expected changes in acylated ghrelin. In concert with the current findings, other low 
intensity exercise, including treadmill walking and cycling at 50% of V̇O2 max, has failed to 
alter concentrations of acylated ghrelin in comparison to control trials (King et al. 2010b; 
Ueda et al. 2009a; Unick et al. 2010). However, intense exercise (~70% V̇O2 max) has been 
shown to suppress acylated ghrelin concentrations (Broom et al. 2007; Broom et al. 2009; 
King et al. 2010a; King et al. 2011a; Wasse et al 2012). 
Although there was no main effect of gender for acylated ghrelin, female participants 
expressed higher circulating concentrations of acylated ghrelin across both trials compared 
with males. This is in agreement with previous research (Alajmi et al. 2016; Burns et al. 2007; 
Hagobian et al. 2013). A significant trial by sex interaction found females to have 8% higher 
mean concentrations of acylated ghrelin in exercise than control trials, and males to have 5% 
lower concentrations in the exercise trials. These differences were predominantly driven by 
the response of ow/ob males and females during and 30 min after exercise. In particular, 
females showed increased circulating concentrations of acylated ghrelin immediately after the 
exercise bout. Males showed lower concentrations immediately and 30 min after exercise. 
This divergent response supports previous suggestions that females exhibit compensatory 
responses in appetite regulatory hormones to energy deficits to preserve energy balance and 
reproductive function (Hagobian and Braun 2010). However, despite these differences, 
concentrations were not significantly different between males and females at any time point, 
and total AUC values did not significantly differ between males and females, questioning the 
importance of this interaction. 
In the current study, both acylated and desacylated ghrelin were measured. This consequently 
allowed for the calculation of total ghrelin concentrations (acylated ghrelin plus desacylated 
ghrelin concentrations). Acylated and desacylated ghrelin responded similarly in all 
participant groups, across both trials (control, r=0.65, P<0.01; exercise, r=0.69, P<0.01). 
Acylation is considered necessary to allow ghrelin to cause its appetite regulatory effects 
(Neary et al. 2006). Previously, the measurement of total ghrelin has been shown to be 
unreliable in detecting changes seen in acylated ghrelin (Hosoda et al. 2006). The findings in 
the present study do not support this, and provide some evidence to suggest that the 
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measurement of desacylated ghrelin could summarise changes in concentrations of ghrelin. 
The measurement of acylated ghrelin is time consuming, and uses potentially toxic chemicals. 
If further research supports the findings of the current study, future studies could use quicker 
and safer methods of determining ghrelin responses (i.e. measuring desacylated ghrelin from 
EDTA plasma). 
Across trial days total PYY concentrations were found to be higher in the exercise than 
control trial, for all participant groups. To date, the majority of studies have found transient 
increases in circulating concentrations of PYY after exercise (Broom et al. 2009; Deighton et 
al. 2013a; Deighton et al. 2013b; Deighton et al. 2014; King et al. 2011a; Martins et al. 2007; 
Shorten et al. 2009; Ueda et al. 2009a; Wasse et al. 2012). However, some have found no 
change (Balaguera-Cortes et al. 2011; Shorten et al. 2009). Similar discrepancies are also 
reported when comparing the responses of lean and ow/ob individuals (Holmstrup et al. 2013; 
Martins et al. 2015; Sim et al. 2014; Ueda et al. 2009b). It is likely that the conflicting 
findings are a result of variances in study protocol and form of PYY measured. It has been 
suggested that PYY3-36 has more potent anorectic effects than total PYY (Chelikani et al. 
2005). However, after high protein, high carbohydrate and high fat meals, PYY3-36 and total 
PYY have been shown to respond similarly. This suggests that measuring either form of PYY 
is valid, and that discrepancies in research to date may be ruled by other variables. Regardless 
of these conflicting findings, a recent review found exercise to increase concentrations of 
PYY (Schubert et al. 2014). The findings of the current study are in concert with these. 
Mean concentrations of total GLP-1 were found to be higher in the exercise than control trial. 
In particular, this trial effect appeared to be driven by significantly elevated GLP-1 
concentrations immediately and 30 min after the standard breakfast meal in the exercise 
compared to the control trial, for all participant groups. Beyond this time point, all participant 
groups expressed similar GLP-1 responses in exercise and control trials. To the author’s 
knowledge, this is the first study to examine sex differences in GLP-1 responses to exercise. 
Data from the current study suggests males and females exhibit similar GLP-1 responses to 
exercise. When comparing responses of lean and ow/ob individuals, previous studies have 
also shown mixed findings. One possible reason for these discrepancies is the influence that 
weight loss has on circulating GLP-1 concentrations. In particular, after a period of weight 
loss (6 weeks), fasting GLP-1 concentrations have been shown to decrease and the release of 
GLP-1 is negated after feeding (Adam et al. 2005). Further to this, after 6 weeks of weight 
loss, concentrations of GLP-1 were shown to return to baseline after a 3 month weight-
164 
maintenance period (Adam et al. 2006). These findings suggest that the GLP-1 response to an 
acute bout of exercise was similar in lean ow/ob males and females, up to 7 h after moderate 
intensity acute exercise. 
Insulin is regarded as a tonic regulator of appetite which generates anorectic effects by 
supressing activity of NPY and AgRP neurones, stimulating POMC neurones in the ARC of 
the hypothalamus and altering the brain’s sensitivity to episodic appetite signals (McMinn et 
al. 2000; Murphy and Bloom 2004; Woods et al. 2006; Wynne et al. 2005a). Chronically, 
circulating concentrations of insulin are positively related to adiposity and insulin resistance 
in key metabolic tissues (Woods and Seeley 1998). Insulin resistance was crudely assessed in 
the current study using HOMA1-IR (Matthews et al. 1985), which suggested that none of the 
participants were insulin resistant (HOMA1-IR>2.7, Geloneze et al. 2009). However, 
individuals who were ow/ob did have higher insulin levels than those who were lean, across 
trial days. Therefore it could be expected for ow/ob individuals to report lower appetite 
sensations than their lean counterparts, however this was not seen. It is well established that 
acute exercise can increase insulin sensitivity by increasing glucose uptake into muscle cells, 
and this is seen for up to 72 h after exercise (Hawley and Lessard 2008). In the current study 
insulin AUC was reduced with exercise, whilst glucose AUC remained similar between 
control and exercise trials, for all participants. This implies that the moderate bout of exercise 
was sufficient to enhance insulin sensitivity in lean, overweight and obese individuals. 
However, it is also important to consider the role of GLP-1, an incretin hormone that 
stimulates insulin secretion (Field et al. 2009; Holst 2007; Lockie 2013).The current study 
found GLP-1 AUC to be increased in the exercise vs. control trial, for all participants. The 
between-trial difference for insulin was in the opposing direction, observing reduced 
concentrations with exercise. Therefore, it appears that the moderate exercise bout did not 
influence the insulinotropic actions of GLP-1 in this study. 
Despite finding a transient suppression of hunger, elevated concentrations of total PYY and 
total GLP-1 during exercise, there were no differences in absolute energy or macronutrient 
intake at the ad libitum meal provided 6 h after the exercise or control period. This supports 
previous evidence that exercise does not cause compensatory increases in energy intake in the 
hours after acute exercise (Schubert et al. 2013). Furthermore, this study found that lean and 
ow/ob males and females responded similarly, with no significant differences in absolute 
energy or macronutrient intake between exercise and control trials. When taking into 
consideration the energy requirements of the exercise bout, it was found that REI was 
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significantly reduced in all participant groups. This suggests that lean and ow/ob males and 
females do not exhibit compensatory food intake behaviour in the 6 h after exercise to 
recover the exercise induced energy deficit. In the present study, participants were only 
provided with the opportunity to compensate for the energy deficit 6 h after the exercise bout. 
Further research is required to determine if this deficit can be maintained over a longer period 
of time, and to help ascertain the effectiveness of exercise in weight loss and weight 
maintenance. 
Given the nature of the current study, all of the measured hormones and substrates showed 
significant effects of time (all P<0.01). However, only GLP-1 and NEFA, expressed 
significant time vs. trial interactions. Post-hoc analysis revealed the significant differences to 
be in close temporal proximity to the exercise bout. Specifically, circulating concentrations of 
NEFA were elevated at 1.0 and 1.5 h in the exercise trial, whilst circulating concentrations of 
GLP-1 were elevated at 2.25 and 2.75 h, for all participants. NEFA and GLP-1 concentrations 
were similar at all other time points. The transient increase in NEFA concentrations seen 
during and 30 min after exercise were expected. This represents the mobilisation of fat for the 
working muscles to use as fuel, during exercise (Frayn, 2010). The heightened response of 
total GLP-1 to feeding after exercise, would suggest a beneficial effect of exercise on appetite 
regulation, i.e. exercise enhances satiation after feeding. This could be especially useful to 
those who express dysfunctional appetite mechanisms. However, these changes in GLP-1 
were not concordant with alterations in appetite. 
Although there were no differences in subjective appetite ratings, appetite regulatory 
hormones, or ad libitum energy intake responses to acute exercise between lean and ow/ob 
males and females, baseline measures were found to differ between groups. Specifically, 
females expressed higher baseline values of acylated, desacylated and total ghrelin and 
NEFA, and lower baseline concentrations of TAG, than males. Lean individuals showed 
lower baseline concentrations of TAG and glucose, than ow/ob individuals. As fasting 
concentrations of appetite regulatory hormones differ between groups, this highlights the 
importance of examining relative change in appetite regulatory hormones rather than absolute 
concentrations. The observation of similar ghrelin, total PYY and GLP-1 responses to 
exercise between groups, may explain why similar subjective appetite and energy intake 
responses were seen. 
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This study is limited by the selected group cut-off criteria. In particular, relying on BMI and 
waist circumference measures to classify individuals as ‘lean’ or ‘overweight/obese’. Body 
mass index does not take into account body shape and body fat percentage when grouping 
participants. This may confound the comparisons between lean and ow/ob individuals, and 
future studies should aim to use a more vigorous set of criteria to determine body size and 
subsequently classify individuals, for example, by using measures of skinfold thickness or 
DEXA scans. Another limitation of the current study was the prescription of regular feeding 
bouts to participants. Test meals were provided at 1.5 and 4 h, and an ad libitum meal 
provided at 7 h. These eating times were often inconsistent with the self-reported eating 
habits of the participants, with participants often still feeling full at the start of the ad libitum 
meal. This could have impacted the amount of food eaten at the ad libitum meal, and reduced 
the sensitivity of the meal to detect changes in energy intake. In addition to this, participants 
were not familiarised with the ad libitum meal, potentially resulting in a ‘banquet effect’, in 
which participants over eat in response to the wide-selection of foods available. In an attempt 
to control for this, a cross over design was adopted with participants randomly assigned to 
either the control (N=23) or exercise trial (N=24) first. Furthermore, there was found to be no 
effect of trial order on ad libitum energy intake (P=0.12). Future studies using this method of 
assessment should present buffet meals to participants in preliminary visits to help prevent 
the ‘banquet effect’ from occurring and to improve the validity of this measure. The primary 
aim of this study was to determine the physiological, i.e. hormonal and subjective appetite, 
response to exercise. As a result, this study provided participants with standard and buffet 
meals at strict time intervals. This limits the study’s ability to evaluate the compensatory 
eating behaviour of participants. Future studies should incorporate ‘real world’ influences and 
less rigid experimental control to gain a greater insight into the compensatory responses to 
feeding. Finally, circulating concentrations of the hormones measured in this study are related 
to body size. Given that we grouped individuals who were overweight and obese, the 
responses seen by individuals who were overweight could have diluted the responses of those 
seen in individuals who were obese. It is therefore possible that the current study is 
underpowered to detect significant differences between the four groups. In an attempt to 
control for the effects of the menstrual cycle on appetite regulatory hormones and subjective 
appetite sensations, main trials were separated by 28 days in females. However, females 
rarely exhibit cycles lasting 28 days, and participants may have been tested in different 
phases of the menstrual cycle. Future studies should control for the between- and inter-
subject variations in menstrual cycle length. Total ghrelin concentrations were indirectly 
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measured in this study by summing concentrations of acylated and desacylated ghrelin. 
Samples used to determine acylated ghrelin concentrations were pre-treated to optimize its 
preservation, minimising its breakdown to desacylated ghrelin during storage. However, 
samples used to determine desacylated ghrelin were not pre-treated. Consequently, total 
ghrelin values may have been overestimated, as concentrations of desacylated ghrelin could 
have been higher in EDTA-plasma than in pre-treated plasma. 
In conclusion, this study has shown that an acute bout of treadmill exercise supresses appetite 
during and immediately after exercise in lean and ow/ob males and females. Circulating 
concentrations of PYY and GLP-1 are increased across the exercise trial day in comparison to 
the control trial. Despite this, energy intake remains unchanged, in all participant groups. 
These findings provide novel information regarding subjective appetite perception, appetite 
regulatory hormone and ad libitum energy intake by directly comparing responses in lean and 
ow/ob, males and females. 
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CHAPTER VII 
General Discussion 
7.1. Introduction 
Amid present concerns over the prevailing overweight and obesity epidemic there has been 
an explosion of research into the effects of exercise on appetite regulation and energy intake. 
The studies within this thesis were designed with the intention to add to this field of study by; 
(i) further characterising when compensatory subjective appetite, appetite regulatory hormone 
(acylated ghrelin, total PYY and leptin) and ad libitum energy intake responses start after 
exercise, and to (ii) compare subjective appetite, appetite regulatory hormone (acylated 
ghrelin, total PYY and total GLP-1) and ad libitum energy intake responses to acute aerobic 
exercise in lean and ow/ob males and females.  
The purpose of this chapter is to consider the main outcomes of the experimental chapters 
presented in this thesis and to consolidate these findings. Table 7.1 summarises the protocols 
and variables measured in each experimental chapter. 
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Table 7.1. Summary of the study protocols presented within the experimental chapters of this thesis. 
 
CON, control; EX, exercise; F, female; M, male; N, participant number. Values are mean (SD). 
Chapter 
Participants 
Trials 
(time, h) 
Exercise duration and intensity Measurements 
N 
BMI 
(kg·m
-2
) 
4 15 (M) 23.0 (1.9) CON 
(31h) 
60 min of treadmill running 
at 70.1 (2.5)% (Day 1) 
and 70.0 (3.2)% (Day 2) V̇O2 peak 
on two consecutive mornings 
Appetite 
Energy/macronutrient intake 
Acylated ghrelin 
Total PYY 
Leptin 
Insulin, glucose, TAG 
EX 
(31h) 
6 11 (F) 21.9 (1.6) CON 
(8h) 
60 min of treadmill exercise 
at 58.8 (3.6)% V̇O2 peak 
Appetite 
Energy/macronutrient intake 
Acylated ghrelin 
Desacylated ghrelin 
Total ghrelin 
Total PYY 
Total GLP-1 
Leptin 
Insulin, glucose, TAG and NEFA 
11 (F) 28.7 (2.8) 
11 (M) 23.0 (1.4) EX 
(8h) 
14 (M) 29.6 (3.0) 
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7.2. Appetite 
A large body of evidence supports the existence of ‘exercise induced anorexia’, a condition 
where appetite is transiently suppressed after exercise (King et al. 1994). Work in Chapter 4 
further expands on this notion by showing that on two consecutive days of acute moderately-
vigorous aerobic exercise, appetite is suppressed during and up to 30 min after each exercise 
bout. In Chapter 6 lean and ow/ob, males and females expressed an exercise induced 
suppression of subjective appetite during and immediately after acute moderate intensity 
aerobic exercise. The research in this thesis confirms that the suppression of subjective 
appetite is short-lived, returning to values reported after a period of rest within 30 min of an 
exercise bout.  
Previous research has shown that subjective appetite ratings do not exhibit compensatory 
responses in the hours after exercise (i.e. do not increase later in the trial day). The findings in 
Chapter 4 and 6 are consistent with these, showing that subjective appetite responses are 
similar to control conditions in the 7-30 h after both moderate and moderately-vigorous 
intensity exercise. Chapter 6 extends on these findings by showing that lean and ow/ob, males 
and females respond similarly in the hours after exercise. This suggests that the beneficial 
effects of exercise on appetite control (i.e. no compensatory increase in subjective appetite) 
seen in lean participants translate into ow/ob individuals. 
It has been suggested that compensatory subjective appetite responses may be delayed, 
occurring after the observation time in the laboratory (~24 h). However, recent evidence has 
found that even on the day after acute aerobic exercise, subjective appetite responses after 
exercise did not significantly differ from control conditions (Beaulieu et al. 2015; King et al. 
2015). Findings from Chapter 4 are in agreement with these, and supplement this to show 
subjective appetite responses can withstand the effects of moderately-vigorous aerobic 
exercise performed on two consecutive days. Further research should determine if this 
response is maintained after additional days of exercise, as beneficial effects of exercise on 
subjective appetite control could support the role of exercise in weight control. It is likely that 
such a study would be designed so that participants visit the laboratory on consecutive days, 
being allowed to return home overnight. It would be difficult to have full control over what 
the participants did outside of the laboratory, therefore making it difficult to objectively 
assess subjective appetite responses over long durations. 
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Few studies have compared subjective appetite responses in males and females (Alajmi et al. 
2016; Hagobian et al. 2013). Both of these studies found no difference in subjective appetite 
responses between males and females after a bout of moderate intensity exercise (~70% V̇O2 
max). The findings in Chapter 6 support these findings, and extend upon them by showing 
that appetite responds similarly, irrespective of sex, at moderate intensity exercise (~60% 
V̇O2 peak).  
To date subjective appetite responses to acute exercise in ow/ob individuals have been 
inconsistent. Reductions in appetite during and for 30 min after exercise (Tsofliou et al. 2003; 
Westerterp-Plantenga et al. 1997), and no difference in appetite (Ueda et al. 2009b; Unick et 
al. 2010) have been reported in comparison to control conditions. To the authors’ knowledge, 
no previous studies have made direct comparisons between individuals who are lean and 
ow/ob. In Chapter 6 both lean individuals and individuals who are ow/ob express suppressed 
sensations of appetite during and immediately after acute exercise. Additionally, no 
correlation was observed between waist circumference and hunger AUC. Therefore the 
findings in Chapter 6 add to the current literature, showing individuals who are lean and 
ow/ob to have similar appetite responses to moderate intensity treadmill exercise. 
7.3. Energy intake 
Currently, the majority of research is in agreement that exercise does not influence energy 
intake in the immediate hours after exercise (12-14 h, Schubert et al. 2013). The findings in 
Chapter 4 and 6 support this, showing absolute energy intake to be similar during control and 
exercise trials. It has been suggested that compensatory increases in ad libitum energy intake 
may occur outside this 12-14 h window post-exercise. However, when observation times 
have been increased to longer than 24 h, ad libitum energy intake during exercise trials 
remains indifferent to those of control trials (Beaulieu et al. 2015; King et al. 2015). Chapter 
4 expands on this, to show that two consecutive days of moderately-vigorous exercise, fails to 
provoke a difference in absolute energy intake between trials. The inability for exercise to 
influence energy intake supports the subjective appetite response seen in Chapters 4 and 6.  
It has been suggested that females, compared to males, could exhibit more potent 
compensatory responses to exercise induced energy deficits in an attempt to preserve energy 
balance and reproductive function (Hagobian and Braun 2010). However, in a recent meta-
analysis, Schubert et al. (2013) showed males and females to exhibit similar ad libitum 
energy intake responses to exercise. Specifically, both males and females display no change 
172 
in ad libitum energy intake after an acute bout of exercise (Alajmi et al. 2016; Schubert et al. 
2013). The findings in Chapter 6 confirm this and suggest that if an exercise induced energy 
deficit can be sustained over long periods of time, exercise could be equally effective for 
weight loss and maintenance in both males and females. 
Across studies, the findings for ad libitum energy intake responses of ow/ob individuals to 
acute exercise are inconsistent. Some have found ow/ob individuals to express no difference 
(Martins et al. 2015; Tsofliou et al. 2003; Unick et al. 2010) and others report reductions in 
absolute energy intake after exercise compared to rest (Sim et al. 2014; Ueda et al. 2009b). 
Discrepancies are likely due to differences in study protocol, for example, exercise intensity, 
mode and duration. In addition, trial length of these studies was short (up to 3.5 h) restricting 
assumptions about how ow/ob individuals respond later in the trial day. In particular, ad 
libitum energy intake could only be assessed approximately 1.5 h after exercise. The findings 
in Chapter 6 broaden the findings of the current literature by extending this observation to 6 h 
after exercise and by directly comparing the response of ow/ob individuals to that of lean 
individuals. The findings from this thesis, along with previous research, would suggest that 
exercise is equally effective at generating a negative energy balance in lean and ow/ob 
individuals. The failure for acute exercise to increase ad libitum energy intake 6 h after 
exercise supports a role of exercise in weight management. 
In both Chapter 4 and 6 of this thesis, participants were not familiarised with the buffet meals 
presented to them in main trials. To maintain the internal validity of buffet meals to assess 
energy intake it is important to keep all factors, other than the intervention, constant. By 
omitting buffet meal familiarisation, two factors will have been inadvertently changed at the 
buffet meals, i.e. the intervention and an unusual feeding environment on the first exposure 
vs. familiar feeding environment on subsequent exposures. This could have compromised 
internal validity, providing participants the potential to over-eat during the first exposure to 
these meals, in response to the wide-selection of foods available. However, no trial order 
effect was found for ad libitum energy intake in both Chapter 4 and 6 (P=0.77 and P=0.12, 
respectively). Future research must consider this limitation, and incorporate familiarisation to 
buffet meals, to ensure reliable and sensitive food intake assessment. 
7.4. Acylated ghrelin 
Circulating concentrations of acylated ghrelin are shown to be transiently suppressed during 
and immediately after exercise (Broom et al. 2007; Broom et al. 2009; Deighton et al. 2013a; 
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King et al. 2010a; King et al. 2011a; Wasse et al. 2012), concurrent with suppressions in 
subjective ratings of appetite. In view of ghrelin’s unique ability to stimulate hunger, studies 
have tried to determine whether exercise induced anorexia is regulated by suppressions in 
ghrelin. However, few have identified significant correlations between appetite and acylated 
ghrelin concentrations (Broom et al. 2007; Broom et al. 2009). Chapter 4 also failed to 
correlate subjective appetite and acylated ghrelin concentrations; subjective appetite was 
suppressed immediately after exercise despite acylated ghrelin concentrations being similar to 
those in the control trial. Similarly, in Chapter 6 a suppression in subjective appetite was seen 
despite no differences in acylated ghrelin concentration immediately after exercise.  
Data from this thesis questions the importance of acylated ghrelin in appetite regulation; 
transient suppressions in appetite did not coincide with suppressions in circulating 
concentrations of acylated ghrelin. Appetite control is complex, a plethora of tonic and acute 
hormones contribute to changes in appetite, amongst many other factors (i.e. behavioural, 
environmental and psychological). It is likely that the control of appetite after exercise is not 
solely regulated by one hormone, but instead the interaction of several hormones and other 
psychological, behavioural and environmental factors. 
Numerous studies, including Chapters 4 and 6 of this thesis, have shown that in the hours 
after exercise acylated ghrelin concentrations are no different to those seen in control 
conditions i.e. there are no delayed rises to attempt to compensate for the energy expended 
during the exercise bout. Chapter 4 extended upon this pool of evidence by lengthening the 
exercise period over two days, again showing no delayed compensatory increase in acylated 
ghrelin. It is possible that the second day of exercise blocked the influences of the first 
exercise bout on circulating concentrations of acylated ghrelin as King et al. (2015) found 
acylated ghrelin concentrations to be reduced 24-27 h after exercise. This finding was 
unexpected and implies an improved appetite response to feeding the day after exercise. 
Further research is required to confirm the responses of acylated ghrelin >12-14 h after 
exercise.  
To date, several studies have compared ghrelin responses in males and females. Initial 
findings suggested that males and females respond differently (Hagobian et al. 2009), 
however more recently studies suggest that there is no difference in acylated ghrelin response 
to exercise between males and females (Alajmi et al. 2016; Burns et al. 2007; Hagobian et al. 
2009; Hagobian et al. 2013). The findings of Chapter 6 confirm these.  
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Research on responses of circulating ghrelin concentrations to exercise in ow/ob individuals 
are limited, with very few studies comparing these responses to those of lean individuals 
(Ueda et al. 2009b). Chapter 6 is one of the first studies to compare acylated ghrelin 
responses in lean and ow/ob individuals. These suggest that lean and ow/ob individuals 
respond similarly to a bout of acute treadmill exercise i.e. no suppression after exercise, and 
no compensatory increase later in the trial day. This supports the findings of Ueda et al. 
(2009b), who also showed no difference in ghrelin response to exercise (60 min cycling at 50% 
V̇O2 max) between lean and ow/ob individuals. Furthermore, Chapter 6 found there to be no 
correlation between waist circumference and acylated ghrelin AUC. The data presented in 
this thesis show that ow/ob individuals do not exhibit compensatory increases in acylated 
ghrelin, responding in a similar fashion to exercise as their lean counterparts, therefore 
supporting a role for exercise in the generation of an energy deficit. 
7.5. Peptide YY 
Studies examining the responses of circulating concentrations of PYY to acute bouts of 
exercise have shown mixed findings. Transient increases (and concordant decreases in hunger; 
Broom et al. 2009; Deighton et al. 2013a; Deighton et al. 2013b; Deighton et al. 2014; King 
et al. 2011a; Martins et al. 2007; Shorten et al. 2009; Ueda et al. 2009a; Ueda et al. 2009b; 
Wasse et al. 2012) after exercise, and no difference compared to control (Balaguera-Cortes et 
al. 2011; Holmstrup et al. 2013; Martins et al. 2015; Shorten et al. 2009; Sim et al. 2014) 
have been found. When expanding these comparisons to the whole intervention period, 
circulating concentrations of PYY are higher during exercise compared to control conditions 
(Cheng et al. 2009; King et al. 2011a). Both Chapters 4 and 6 confirm these reports, and 
further this to show that these increased PYY concentrations during exercise trials are 
concordant in males, females, lean and ow/ob individuals. Although not significantly 
different, ow/ob tended to express lower fasting concentrations of total PYY in Chapter 6 (87 
(60) and 98 (56) pg·mL
-1
, for ow/ob and lean individuals, respectively). This is in concert 
with previous research, showing obese individuals to exhibit lower fasting concentrations of 
PYY (Batterham et al. 2003; le Roux et al. 2006). To date, there is little research comparing 
the responses of males vs. females and lean vs. ow/ob, making the findings of Chapter 6 
novel.  
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7.6. GLP-1 
Few have measured the responses of circulating concentrations of GLP-1 to acute exercise 
(Larson-Meyer et al. 2012; Martins et al. 2007; Martins et al. 2015; Ueda et al. 2009a; Ueda 
et al 2009b; Unick et al. 2010). A recent meta-analysis compiled these studies to show that 
GLP-1 concentrations are elevated on exercise compared to resting days (Schubert et al. 
2014). Findings from Chapter 6 confirm those of the recent review, showing GLP-1 
concentrations to be higher in the 7 h after a bout of moderate treadmill exercise than rest. 
Individuals were shown to respond similarly, irrespective of sex or BMI group. Furthermore, 
no correlation was found between waist circumference and GLP-1 AUC concentrations. This 
novel finding adds to the literature, and suggests that GLP-1 concentrations are altered in a 
way that will increase satiety after exercise. This in hand with the absence of exercise 
induced changes in ad libitum energy intake 6 h after a bout of acute exercise, suggests that 
satiety is maintained after exercise and consequently prevents a compensatory increase in 
energy intake. This could be of particular benefit to those who are using exercise as a weight 
loss or maintenance tool, but further work is required to confirm these findings. 
7.7. Leptin 
Circulating concentrations of leptin remain unaltered in the immediate hours (0-4 h) after 
acute exercise (Racette et al. 1997; Torjman et al. 1999; Weltman et al. 2000). However, in 
the 24-48 h after acute exercise circulating concentrations of leptin are seen to be reduced 
(Essig et al. 2000; King et al. 2015; Olive & Miller 2001; Yang et al. 2014). Contrary to this, 
in Chapter 4, leptin concentrations were unaltered by two consecutive days of exercise. The 
large energy requirements of each hour treadmill run (~3800 kJ) generated a significant 
difference in REI between control and exercise trials (control 29217 (4006); exercise 21394 
(3031) kJ). Previously, the delayed reduction of leptin concentrations after acute exercise has 
been attributed to the generation of a negative energy balance and low energy availability 
(Borer et al. 2009; Hilton and Louks 2000). Perhaps, the high-energy intake seen on day one 
of the exercise trial (16812 (2899) kJ) could explain why leptin concentrations were not seen 
to be lower on day two of the exercise trial, compared to control. It is possible that the energy 
consumed was sufficient to block any exercise-related decreases in leptin. Owing to the 
importance of exercise-induced disturbances in energy balance for weight loss and 
maintenance, it is important to further examine the response of leptin to exercise induced 
energy deficits. Energy intake should be strictly controlled, so that the energy availability is 
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representative of a typical diet. This will aid in the design of effective exercise strategies to 
generate weight loss. 
7.8. Limitations 
The experimental chapters presented in this thesis contain several common limitations. Firstly 
all participants were relatively young (18-60 y). Considering the ageing population and large 
percentage of the UK population living outside the healthy life expectancy, it is becoming 
increasingly important to determine the effectiveness of exercise on appetite control and 
weight management in individuals who are elderly. Although Chapter 6 added to the current 
literature by comparing responses of lean and ow/ob individuals, participants were all 
otherwise healthy i.e. no history or currently suffering from diabetes, cardiovascular disease, 
high blood pressure etc. These are all conditions associated with increases in BMI, and 
therefore it would be useful to understand how individuals suffering from these conditions 
respond to exercise. Again, the findings from Chapter 6 are limited to those who are lean, 
overweight or obese. Future studies should examine appetite related responses to exercise in 
morbidly obese individuals. Chapter 6 is also restricted by the relatively short observation 
period (8 h). This also impacts the validity of the ad libitum meal provided during Chapter 6. 
This meal was provided at 7 h (~16:00), participants may have refrained from eating until 
‘comfortably full’ knowing that they would be free to leave the laboratory one hour later, and 
subsequently be free to eat what they wish and not be confined to that available at the buffet.  
7.9. Future directions  
Further research is required to compare the responses of lean and ow/ob individuals to longer 
observation periods i.e. days after exercise and repeated bouts of exercise. This will help to 
determine if the energy deficit generated by single or repeated bouts of exercise can be 
sustained over time and ultimately aid in weight management. However, this will be difficult 
to measure objectively. In particular, it will be hard to control participant behaviour outside 
of the laboratory. Adopting a life-like study design, instead of time structured protocols (i.e. 
fixed meal times), will allow for the true determination of appetite compensation. Similarly, it 
is important to take a more holistic approach to study design, by incorporating genetic, 
psychological and environmental measures. For example, blood samples could be analysed to 
determine if participants express the FTO gene, measures of mood and anxiety could be 
collected periodically throughout trial days. Finally, with regard to the control of appetite 
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regulation, future research should look to extend upon the findings of this thesis by 
incorporating the measurement of active GLP-1 and PYY3-36, cholecystokinin and PP. 
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APPENDIX A 
 
The comparison of two methods of blood sample collection for 
determining plasma acylated ghrelin concentration in humans 
 
INFORMED CONSENT FORM 
(to be completed after Participant Information Sheet has been read) 
 
 
The purpose and details of this study have been explained to me. I understand that this study 
is designed to further scientific knowledge and that all procedures have been approved by the 
Loughborough University Ethical Approvals (Human Participants) Sub-Committee. 
 
I have read and understood the information sheet and this consent form. 
 
I have had an opportunity to ask questions about my participation. 
 
I understand that I am under no obligation to take part in the study. 
 
I understand that I have the right to withdraw from this study at any stage for any reason, and 
that I will not be required to explain my reasons for withdrawing. 
 
I understand that all the information I provide will be treated in strict confidence and will be 
kept anonymous and confidential to the researchers unless (under the statutory obligations of 
the agencies which the researchers are working with), it is judged that confidentiality will 
have to be breached for the safety of the participant or others.  
 
 
I agree to participate in this study. 
 
 
 
                    Your name 
 
              Your signature 
 
Signature of investigator 
 
                               Date 
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APPENDIX B 
 
Name/Number   ...............…….  
Health Screen Questionnaire for Study Volunteers 
As a volunteer participating in a research study, it is important that you are currently in good 
health and have had no significant medical problems in the past.  This is (i) to ensure your 
own continuing well-being and (ii) to avoid the possibility of individual health issues 
confounding study outcomes. 
 
If you have a blood-borne virus, or think that you may have one, please do not take part in 
this research. 
 
Please complete this brief questionnaire to confirm your fitness to participate: 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise ............. Yes 
 
No  
(b) attending your general practitioner .................... Yes  No  
(c) on a hospital waiting list .................................... Yes  No  
2. In the past two years, have you had any illness which required you to: 
(a) consult your GP .................................................. Yes 
 
No  
(b) attend a hospital outpatient department ............. Yes  No  
(c) be admitted to hospital  ...................................... Yes  No  
3. Have you ever had any of the following: 
(a) Convulsions/epilepsy  .........................................  Yes 
 
No  
(b) Asthma  ...............................................................  Yes  No  
(c) Eczema  ...............................................................  Yes  No  
(d) Diabetes  ..............................................................  Yes  No  
(e) A blood disorder  ................................................  Yes  No  
(f) Head injury  .........................................................  Yes  No  
(g) Digestive problems  ............................................  Yes  No  
(h) Heart problems  ...................................................  Yes  No  
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(i) Problems with bones or joints     .........................  Yes  No  
(j) Disturbance of balance/coordination  .................  Yes  No  
(k) Numbness in hands or feet  .................................  Yes  No  
(l) Disturbance of vision  .........................................  Yes  No  
(m) Ear / hearing problems  .......................................  Yes  No  
(n) Thyroid problems  ...............................................  Yes  No  
(o) Kidney or liver problems  ...................................  Yes  No  
(p) Allergy to nuts  ....................................................  Yes  No  
 
4. Has any, otherwise healthy, member of your family under the 
age of 35 died suddenly during or soon after 
exercise?  ..................................................................... 
Yes  No  
 
If YES to any question, please describe briefly if you wish (eg to confirm problem was/is 
short-lived, insignificant or well controlled.) 
......................................................................................................................................................
......................................................................................................................................................
.......................................................................................................... 
5. Allergy Information 
(a) are you allergic to any food products? Yes  No  
(b) are you allergic to any medicines? Yes  No  
(c) are you allergic to plasters? Yes  No  
 
If YES to any of the above, please provide additional information on the allergy 
…………………………………………………………………………………………………..
…………………………………………………………………………………………………... 
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6. Please provide contact details of a suitable person for us to contact in the event of any 
incident or emergency. 
 
Name: 
…………………………………………………………………………………………………... 
Telephone Number: 
…………………………………………………………………………………………………... 
 Work  Home  Mobile  
Relationship to Participant: 
…………………………………………………………………………………………............. 
 
7. Are you currently involved in any other research studies at the University or 
elsewhere? 
 Yes  No  
 
If yes, please provide details of the study 
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
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APPENDIX C 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
We are interested in finding out about the kinds of physical activities that people do as part of 
their everyday lives. The questions will ask you about the time you spent being physically 
active in the last 7 days. Please answer each question even if you do not consider yourself to 
be an active person. Please think about the activities you do at work, as part of your house 
and yard work, to get from place to place, and in your spare time for recreation, exercise or 
sport. 
Think about all the vigorous activities that you did in the last 7 days. Vigorous physical 
activities refer to activities that take hard physical effort and make you breathe much harder 
than normal. Think only about those physical activities that you did for at least 10 minutes at 
a time. 
1. During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical  activities  Skip to question 3 
 
2. How much time did you usually spend doing vigorous physical activities on one of 
those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
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Think about all the moderate activities that you did in the last 7 days. Moderate activities 
refer to activities that take moderate physical effort and make you breathe somewhat harder 
than normal. Think only about those physical activities that you did for at least 10 minutes at 
a time. 
3. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads, bicycling at a regular pace, or doubles tennis? Do not include 
walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
 
4. How much time did you usually spend doing moderate physical activities on one of 
those days? 
 
_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
Think about the time you spent walking in the last 7 days. This includes at work and at home, 
walking to travel from place to place, and any other walking that you have done solely for 
recreation, sport, exercise, or leisure. 
5. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time?  
_____ days per week 
  
   No walking    Skip to question 7 
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6. How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
The last question is about the time you spent sitting on weekdays during the last 7 days. 
Include time spent at work, at home, while doing course work and during leisure time. This 
may include time spent sitting at a desk, visiting friends, reading, or sitting or lying down to 
watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week day? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
This is the end of the questionnaire, thank you for participating. 
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APPENDIX D 
Three Factor Eating Questionnaire 
Part 1: please answer true/false 
1. When I smell a sizzling steak or see a juicy piece of meat, I find it very difficult to 
keep from eating, even if I have just finished a meal 
True □  False □ 
2. I usually eat too much at social occasions, like parties and picnics 
True □  False □ 
3. I am usually so hungry that I eat more than three times a day 
True □  False □ 
4. When I have eaten my quota of calories, I am usually good about not eating any 
more 
True □  False □ 
5. Dieting is too hard for me because I just get too hungry 
True □  False □ 
6. I deliberately take small helpings as a means of controlling my weight 
True □  False □ 
7. Sometimes things just taste so good that I keep on eating even when I am no 
longer hungry 
True □  False □ 
8. Since I am often hungry, I sometimes wish that while I am eating, an expert 
would tell me that I have had enough or that I can have something more to eat 
True □  False □ 
9. When I am anxious, I find myself eating 
True □  False □ 
10. Life is too short to worry about dieting 
True □  False □ 
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11. Since my weight goes up and down, I have been on weight reducing diets more 
than once 
True □  False □ 
12. I often feel so hungry that I just have to eat something 
True □  False □ 
13. When I am with someone who is overeating, I usually overeat too 
True □  False □ 
14. I have a pretty good idea of the number of calories in common food 
True □  False □ 
15. Sometimes when I start eating, I just can’t seem to stop 
True □  False □ 
16. It is not difficult for me to leave something on my plate 
True □  False □ 
17. At certain times of the day, I get hungry because I have gotten used to eating 
then 
True □  False □ 
18. While on a diet, if I eat food that is not allowed, I consciously eat less for a period 
of time to make up for it 
True □  False □ 
19. Being with someone who is eating often makes me hungry enough to eat also 
True □  False □ 
20. When I feel blue, I often overeat 
True □  False □ 
21. I enjoy eating too much to spoil it by counting calories or watching my weight 
True □  False □ 
22. When I see a real delicacy I often get so hungry that I have to eat it right away 
True □  False □ 
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23. I often stop eating when I am not really full as a conscious means of limiting 
what I eat 
True □  False □ 
24. I get so hungry that my stomach often feels like a bottomless pit 
True □  False □ 
25. My weight has hardly changed at all in the last ten years 
True □  False □ 
26. I am always hungry so it is hard for me to stop eating before I finish all the food 
on my plate 
True □  False □ 
27. When I feel lonely, I console myself by eating 
True □  False □ 
28. I consciously hold back at meals in order not to gain weight 
True □  False □ 
29. I sometimes get very hungry late in the evening or at night 
True □  False □ 
30. I eat anything I want, anytime I want 
True □  False □ 
31. Without even thinking about it, I take a long time to eat 
True □  False □ 
32. I count calories as a conscious means of controlling my weight 
True □  False □ 
33. I do not eat some foods because they make me fat 
True □  False □ 
34. I am always hungry enough to eat at any time 
True □  False □ 
35. I pay a great deal of attention to changes in my figure 
True □  False □ 
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36. While on a diet, if I eat a food that is not allowed, I often then splurge and eat 
other high calorie foods 
True □  False □ 
Part 2: 
37. How often are you dieting in a conscious effort to control your weight? 
1 (rarely)   2(sometimes)   3(Usually)   4(always) 
38. Would a weight fluctuation of 5 lbs affect the way you live your life? 
1(not at all)   2(slightly)   3(moderately)   4(very much) 
39. How often do you feel hungry? 
1(only at meal times)   2(sometimes between meals)   3(often between meals)   4(almost 
always) 
40. Do your feelings of guilt about overeating help you to control your food intake? 
1(never)   2(rarely)   3(often)   4(always) 
41. How difficult would it be for you to stop eating half way through dinner and not 
eat again for four hours? 
1(easy)   2(slightly difficult)   3( moderately difficult)  4(very difficult) 
42. How conscious are you of what you are eating? 
1(not at all)   2(slightly)   3(moderately)   4(extremely) 
43. How frequently do you avoid ‘stocking up’ on tempting foods? 
1 (almost never)   2(seldom)   3(usually)   4(almost always) 
44. How likely are you to shop for low calorie foods? 
1(unlikely)   2(slightly unlikely)  3(moderately likely)   4(very likely) 
45. Do you eat sensibly in front of others and splurge alone? 
1(never)   2(rarely)   3(often)   4(always) 
46. How likely are you to consciously eat slowly in order to cut down on how much 
you eat? 
1(unlikely)   2(slightly likely)   3(moderately likely)   4(very likely) 
47. How frequently do you skip desert because you are no longer hungry? 
1(almost never)   2(seldom)   3(at least once a week)   4(almost every day) 
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48. How likely are you to consciously eat less than you want? 
1(unlikely)   2(slightly likely)   3(moderately likely)   4(very likely) 
49. Do you go on eating binges though you are not hungry? 
1(never)   2(rarely)   3(sometimes)   4(at least once a week) 
50. On a scale of 0-5, where 0 means no restraint in eating (eating whatever you 
want, whenever you want it) and 5 means total restraint (constantly limiting food 
intake and never ‘giving in’), what number would you give yourself? 
0 
Eat whatever you want, whenever you want it 
1 
Usually eat whatever you want, whenever you want it 
2 
Often eat whatever you want, whenever you want it 
3 
Often limit food intake, but often ‘give in’ 
4 
Usually limit food intake, rarely ‘give in’ 
5 
Constantly limiting food intake, never ‘give in’ 
51. To what extent does this statement describe your eating behaviour? ‘I start 
dieting in the morning, but because of a number of things that happen during the 
day, by evening I have given up and eat what I want, promising myself to start 
dieting again tomorrow.’ 
1(not like me)   2(little like me)   3(pretty good description of me)   4( describes me perfectly) 
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APPENDIX E 
Food Preferences 
Please circle the number which best describes your liking of the following foods: 
Coco-Pops 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Cornflakes 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Rice Krispies 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Semi-Skimmed Milk 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Nutri-grain Bars 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
White Bread 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Brown Bread 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Tuna 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Cheese 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Ham 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
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Margarine 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Mayonnaise 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Salted Crisps 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Apple 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Orange 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Banana 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Mini-Rolls 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Chocolate Muffins 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Chocolate Chip Muffins 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Chocolate Chip Cookies 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Mars Bars 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
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Pasta 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
Tomato Sauce 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
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Visual Analogue Scale 
Time:  
How hungry do you feel? 
I am not hungry 
 at all 
I have never been 
 more hungry 
How satisfied do you 
feel? 
I am completely 
 empty 
I cannot eat 
another bite 
How full do you feel? 
Not at all full Totally full 
How much do you think you can eat? 
Nothing at 
all 
A lot 
How nauseous do you feel?  
Not at all 
nauseous 
Very nauseous 
0   1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
Not Hungry       Fairly Hungry         Hungry            Very Hungry 
Please indicate how hungry you are now by circling a relevant number 
Subject Number:    Trial:   Date: 
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APPENDIX G 
Semi-skimmed milk 
Coco Pops 
Cornflakes 
Rice Krispies 
White bread  
Brown bread 
Margarine 
Mayonnaise 
Ham 
Tuna  
Crisps 
Chocolate rolls 
 Mars bars 
Cereal bars 
Cookies 
Chocolate chip muffins 
Triple chocolate chip muffins 
Apples 
Oranges  
Bananas 
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APPENDIX H 
Crisps 
Chocolate rolls 
Mars bars 
Cereal bars 
Cookies 
Chocolate chip muffins 
Triple chocolate chip muffins 
Apples 
Oranges  
Bananas 
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APPENDIX I 
Chapter V search strategy. 
Keywords 
Study 
Population 
Intervention 
Obese Exercise; Physical exercise; Aerobic exercise  
Overweight Physical activity 
 Energy expenditure 
 Energy intake; Caloric intake 
 Food intake 
 Appetite 
 Hunger 
 Appetite hormones; Appetite regulating hormones 
 Ghrelin; Acylated ghrelin; Total ghrelin; Acyl ghrelin 
 Peptide YY; PYY; Peptide YY 3-36; PYY3-36; PYY (3-36); Total PYY 
 Glucagon like peptide 1; Glucagon-like peptide-1; GLP-1; total GLP-1; 
active GLP-1; GLP-1 (7-36); GLP-1 (9-36) 
I. Obese or overweight 
II. Exercise or physical exercise or aerobic exercise or physical activity or energy 
expenditure 
III. Energy intake or caloric intake or food intake 
IV. Appetite regulatory hormones or appetite hormones 
V. Peptide YY or PYY or Peptide YY 3-36 or PYY3-36 or PYY (3-36) or Total PYY 
VI. Ghrelin or Acylated ghrelin or Total ghrelin or Acyl ghrelin 
VII. Glucagon like peptide 1 or Glucagon-like peptide-1 or GLP-1 or total GLP-1 or active 
GLP-1 or GLP-1 (7-36) or GLP-1 (9-36) 
VIII. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure (I and II) 
IX. Obese or overweight and Energy intake or caloric intake or food intake (I and III) 
X. Obese or overweight and Appetite regulatory hormones or appetite hormones (I and 
IV) 
XI. Obese or overweight and Peptide YY or PYY or Peptide YY 3-36 or PYY3-36 or 
PYY (3-36) or Total PYY (I and V) 
XII. Obese or overweight and Ghrelin or Acylated ghrelin or Total ghrelin or Acyl ghrelin 
(I and VI) 
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XIII. Obese or overweight and Glucagon like peptide 1 or Glucagon-like peptide-1 or GLP-
1 or total GLP-1 or active GLP-1 or GLP-1 (7-36) or GLP-1 (9-36) (I and VII) 
XIV. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Energy intake or caloric intake or food intake (I 
and II and III) 
XV. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Appetite regulatory hormones or appetite 
hormones (I and II and IV) 
XVI. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Peptide YY or PYY or Peptide YY 3-36 or PYY3-
36 or PYY (3-36) or Total PYY (I and II and V) 
XVII. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Ghrelin or Acylated ghrelin or Total ghrelin or 
Acyl ghrelin (I and II and VI) 
XVIII. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Glucagon like peptide 1 or Glucagon-like peptide-
1 or GLP-1 or total GLP-1 or active GLP-1 or GLP-1 (7-36) or GLP-1 (9-36) (I and II 
and VII) 
XIX. Obese or overweight (RCT filter) 
XX. Exercise or physical exercise or aerobic exercise or physical activity or energy 
expenditure (RCT filter) 
XXI. Energy intake or caloric intake or food intake (RCT filter) 
XXII. Appetite regulatory hormones or appetite hormones (RCT filter) 
XXIII. Peptide YY or PYY or Peptide YY 3-36 or PYY3-36 or PYY (3-36) or Total PYY 
(RCT filter) 
XXIV. Ghrelin or Acylated ghrelin or Total ghrelin or Acyl ghrelin (RCT filter) 
XXV. Glucagon like peptide 1 or Glucagon-like peptide-1 or GLP-1 or total GLP-1 or active 
GLP-1 or GLP-1 (7-36) or GLP-1 (9-36) (RCT filter) 
XXVI. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure (I and II) (RCT filter) 
XXVII. Obese or overweight and Energy intake or caloric intake or food intake (I and III) 
(RCT filter) 
XXVIII. Obese or overweight and Appetite regulatory hormones or appetite hormones (I and 
IV) (RCT filter) 
XXIX. Obese or overweight and Peptide YY or PYY or Peptide YY 3-36 or PYY3-36 or 
PYY (3-36) or Total PYY (I and V) (RCT filter) 
XXX. Obese or overweight and Ghrelin or Acylated ghrelin or Total ghrelin or Acyl ghrelin 
(I and VI) (RCT filter) 
XXXI. Obese or overweight and Glucagon like peptide 1 or Glucagon-like peptide-1 or GLP-
1 or total GLP-1 or active GLP-1 or GLP-1 (7-36) or GLP-1 (9-36) (I and VII) (RCT 
filter) 
XXXII. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Energy intake or caloric intake or food intake (I 
and II and III) (RCT filter) 
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XXXIII. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Appetite regulatory hormones or appetite 
hormones (I and II and IV) (RCT filter) 
XXXIV. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Peptide YY or PYY or Peptide YY 3-36 or PYY3-
36 or PYY (3-36) or Total PYY (I and II and V) (RCT filter) 
XXXV. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Ghrelin or Acylated ghrelin or Total ghrelin or 
Acyl ghrelin (I and II and VI) (RCT filter) 
XXXVI. Obese or overweight and Exercise or physical exercise or aerobic exercise or physical 
activity or energy expenditure and Glucagon like peptide 1 or Glucagon-like peptide-
1 or GLP-1 or total GLP-1 or active GLP-1 or GLP-1 (7-36) or GLP-1 (9-36) (I and II 
and VII) (RCT filter) 
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APPENDIX J 
Individual study characteristics for studies evaluating acylated ghrelin. 
Study Category 
Standard 
difference in 
means 
Standard 
error 
Variance 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Z- 
value 
p-
value 
Weight 
(%) 
Gholipour, M. ow/ob -1.517 0.183 0.033 -1.876 -1.159 -8.295 0.000 8.303 
Martins, S. A ow/ob -0.468 0.114 0.013 -0.691 -0.245 -4.115 0.000 10.064 
Martins, S. B ow/ob -0.456 0.113 0.013 -0.678 -0.234 -4.019 0.000 10.070 
Martins, S. C ow/ob -0.284 0.110 0.012 -0.500 -0.069 -2.582 0.010 10.148 
Sim, A. A ow/ob  -0.032 0.091 0.008 -0.210 0.146 -0.353 0.724 10.578 
Sim, A. B ow/ob -0.201 0.092 0.008 -0.381 -0.021 -2.193 0.028 10.559 
Sim, A. C ow/ob -0.325 0.093 0.009 -0.507 -0.142 -3.490 0.000 10.529 
Tiryaki-Sonmez, G. ow/ob -0.367 0.129 0.017 -0.619 -0.114 -2.847 0.004 9.697 
Ueda, S.-y. ow/ob 0.082 0.142 0.020 -0.196 0.359 0.577 0.564 9.374 
Unick, J.L. ow/ob  -0.047 0.086 0.007 -0.216 0.121 -0.552 0.581 10.678 
Mean  -0.340 0.099 0.010 -0.533 -0.146 -3.443 0.001 100 
Broom et al. 2007 Lean -0.253 0.127 0.016 -0.501 -0.004 -1.994 0.046 4.290 
Broom et al. 2009 Lean -0.085 0.113 0.013 -0.307 0.136 -0.753 0.451 4.427 
Broom et al. 2009-1 Lean -0.125 0.113 0.013 -0.347 0.097 -1.104 0.269 4.424 
Shorten et al. 2009 Lean -0.172 0.114 0.013 -0.395 0.051 -1.512 0.131 4.421 
Ueda et al. 2009a Lean 0.701 0.158 0.025 0.391 1.010 4.439 0.000 3.960 
King et al. 2010b Lean -0.620 0.136 0.019 -0.887 -0.353 -4.553 0.000 4.192 
King et al. 2010a Lean -0.023 0.100 0.010 -0.219 0.173 -0.233 0.816 4.549 
Balaguera-Cortes et al. 
2011 
Lean 0.023 0.118 0.014 -0.209 0.255 0.197 0.844 4.374 
Balaguera-Cortes et al. 
2011-1 
Lean -0.476 0.125 0.016 -0.721 -0.231 -3.813 0.000 4.309 
King et al. 2011a Lean -0.100 0.108 0.012 -0.312 0.112 -0.924 0.355 4.472 
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King et al. 2011b Lean -0.047 0.100 0.010 -0.243 0.149 -0.468 0.640 4.549 
Vatansever-Ozen, 2011 Lean -0.672 0.131 0.017 -0.929 -0.415 -5.129 0.000 4.246 
Becker et al. 2012 Lean -0.437 0.138 0.019 -0.708 -0.165 -3.155 0.002 4.168 
Kelly et al. 2012 Lean -0.106 0.119 0.014 -0.339 0.126 -0.896 0.370 4.371 
Larson Meyer et al. 
2012 
Lean 0.631 0.137 0.019 0.363 0.899 4.621 0.000 4.187 
Larson Meyer et al. 
2012a 
Lean 0.123 0.119 0.014 -0.110 0.356 1.036 0.300 4.370 
Wasse et al. 2012 Lean -0.181 0.119 0.014 -0.415 0.053 -1.515 0.130 4.365 
Wasse et al. 2013-1 Lean -0.407 0.117 0.014 -0.637 -0.176 -3.463 0.001 4.384 
Wasse et al. 2013 Lean -0.412 0.117 0.014 -0.642 -0.181 -3.502 0.000 4.383 
Deighton et al. 2013 Lean -0.427 0.113 0.013 -0.648 -0.206 -3.785 0.000 4.428 
Deighton et al. 2013-1 Lean -0.700 0.121 0.015 -0.936 -0.464 -5.808 0.000 4.353 
Hagobian et al. 2013 Lean 0.270 0.115 0.013 0.044 0.495 2.347 0.019 4.409 
Hagobian et al. 2013-1 Lean -0.119 0.119 0.014 -0.352 0.113 -1.004 0.315 4.370 
Mean  -0.159 0.067 0.005 -0.291 -0.027 -2.358 0.018 100 
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APPENDIX K 
Individual study characteristics for studies evaluating total PYY. 
Study Category 
Standard 
difference 
in means 
Standard 
error 
Variance 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Z- 
value 
p-
value 
Weight 
(%) 
Sim, A. A ow/ob 0.034 0.185 0.034 -0.328 0.396 0.186 0.853 29.296 
Sim, A. B ow/ob -0.052 0.185 0.034 -0.414 0.310 -0.281 0.779 29.280 
Sim, A. C ow/ob 0.078 0.185 0.034 -0.285 0.441 0.422 0.673 29.245 
Ueda, S.-y. ow/ob 0.666 0.318 0.101 0.042 1.289 2.092 0.036 12.179 
Mean  0.099 0.118 0.014 -0.133 0.331 0.835 0.404 100 
Martins et al. 2007 Lean 0.056 0.311 0.097 -0.553 0.666 0.181 0.856 4.857 
Broom et al. 2009a Lean 0.647 0.253 0.064 0.152 1.142 2.564 0.010 7.373 
Broom et al. 2009b Lean -0.086 0.230 0.053 -0.537 0.365 -0.375 0.707 8.885 
Shorten et al. 2009 Lean 0.165 0.231 0.053 -0.288 0.619 0.716 0.474 8.798 
Ueda et al. 2009a Lean 0.465 0.303 0.092 -0.129 1.058 1.533 0.125 5.122 
Balaguera-Cortes et al. 
2011a 
Lean 0.085 0.241 0.058 -0.388 0.558 0.354 0.723 8.078 
Balaguera-Cortes et al. 
2011b 
Lean -0.133 0.242 0.059 -0.607 0.341 -0.549 0.583 8.037 
Kelly et al. 2012 Lean 0.153 0.242 0.059 -0.321 0.628 0.633 0.527 8.013 
Larson Meyer et al. 
2012a 
Lean 0.023 0.254 0.064 -0.474 0.521 0.093 0.926 7.295 
Larson Meyer et al. 
2012b 
Lean 0.553 0.259 0.067 0.046 1.059 2.137 0.033 7.034 
Wasse et al. 2013 Lean 0.236 0.244 0.060 -0.242 0.715 0.968 0.333 7.888 
Deighton et al. 2012a Lean 0.337 0.226 0.051 -0.106 0.780 1.493 0.135 9.205 
Deighton et al. 2012b Lean 0.259 0.223 0.050 -0.179 0.697 1.158 0.247 9.414 
Mean  0.204 0.069 0.005 0.070 0.339 2.979 0.003 100 
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APPENDIX L 
Individual study characteristics for studies evaluating total GLP-1. 
Study Category 
Standard 
difference 
in means 
Standard 
error 
Variance 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Z- 
value 
p-
value 
Weight 
(%) 
Martins, S. A ow/ob 0.066 0.100 0.010 -0.131 0.262 0.655 0.512 24.108 
Martins, S. B ow/ob  0.146 0.101 0.010 -0.051 0.343 1.450 0.147 24.033 
Martins, S. C ow/ob -0.087 0.100 0.010 -0.284 0.109 -0.872 0.383 24.093 
Unick, J.L. ow/ob -0.200 0.080 0.006 -0.358 -0.043 -2.497 0.013 27.765 
Mean         100 
Martins et al. 2007 Lean 0.628 0.155 0.024 0.325 0.932 4.060 0.000 13.908 
Ueda et al. 2009a Lean 0.381 0.136 0.018 0.116 0.647 2.813 0.005 15.608 
Ueda et al. 2009b Lean 0.518 0.117 0.014 0.290 0.747 4.442 0.000 17.441 
Ueda et al. 2009b-1 Lean 0.518 0.117 0.014 0.290 0.747 4.443 0.000 17.441 
Larson Meyer et al. 
2012 
Lean 0.155 0.116 0.013 -0.072 0.383 1.336 0.182 17.492 
Larson Meyer et al. 
2012a 
Lean 0.136 0.110 0.012 -0.079 0.352 1.239 0.215 18.109 
Mean         100 
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APPENDIX M 
Study Protocol 
Full title 
The acute effects of exercise on appetite regulatory hormones, appetite perceptions and ad 
libitum energy intake in lean vs. obese men and women. 
Short title 
Acute exercise & appetite regulation in lean vs. obese men and women (INTAKE). 
Ethics ref:  
Chief Investigator 
Professor Melanie Davies – Professor in Diabetes Medicine and Honorary Consultant 
Physician (University Hospitals of Leicester and University of Leicester) 
Investigators 
Ms Jessica Douglas – PhD student (Leicester-Loughborough Diet, Lifestyle & Physical 
Activity BRU) 
Dr David Stensel - Reader in Exercise Metabolism (Loughborough University) 
Dr James King – Senior Research Associate (Leicester-Loughborough Diet, Lifestyle & 
Physical Activity BRU) 
Professor Myra Nimmo – Professor in Exercise Physiology (Loughborough University) and 
Leicester-Loughborough Diet, Lifestyle & Physical Activity BRU theme lead 
Andrew Jackson - Grade 7 Biochemist (Loughborough University)  
Dr David Webb – Clinical Senior Lecturer in Diabetes Medicine (University of Leicester) 
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Research sponsor 
University of Leicester 
Funder 
The NIHR Leicester-Loughborough Biomedical Research Unit in Diet, Lifestyle & Physical 
Activity 
Confidentiality statement 
This document contains confidential information that must not be disclosed to anyone other 
than the sponsor, investigator team, NHS trust, regulatory authorities, or members of the 
Research Ethics Committee.  
Study Summary 
Energy balance and body weight control are mediated by the interplay between energy intake 
(food and drink) and energy expenditure through metabolic processes and physical activity. 
Evidence has shown that exercise can favourably influence body weight regulation, most 
notably by augmenting daily energy expenditure. Additionally, recent research has shown 
that exercise may also facilitate healthy body weight control by improving appetite regulation. 
Specifically, it has been demonstrated that exercise can improve the ability to sense the 
energy/nutrient content of meals and this is associated with an improved capacity to match 
energy intake to energy requirement. One of the key mechanisms by which exercise mediates 
this effect appears to be related to favourable changes in circulating concentrations of several 
gut hormones which are known to be critical regulators of appetite control and energy 
balance. 
The physiological regulation of appetite and energy homeostasis is orchestrated by several 
neuro-endocrine mediators that are released from the pancreas/gastrointestinal tract and 
which travel to the brain and exert their influence by targeting receptors on key appetite 
regulatory neuronal populations. Importantly, we now know that this regulatory system is 
dysfunctional in obese individuals with the most notable characteristics being an attenuated 
meal related increase in appetite inhibiting signals and a reduced post-meal suppression of 
appetite stimulating signals. The proposed investigation seeks to determine whether the 
beneficial effects of exercise on appetite control observed in lean participants translates into 
the obese. Specifically, the proposed investigation will examine the acute effects of a single 
bout of exercise on subjective perceptions of appetite, energy intake and appetite regulatory 
hormones (ghrelin, peptide YY3-36 and GLP-1). Comparisons will be made between lean and 
overweight/obese men and women. 
To accomplish this we will recruit 16 overweight/obese and 16 normal weight men and 16 
overweight/obese and 16 normal weight women, aged 18-65 years (64 participants in total). 
All participants will be inactive and non-diabetic. Each participant will complete one 
screening visit, one exercise familiarisation session and two, 8 hour main experimental trials 
(control and exercise). The order of main trials will be counterbalanced. In the control trial 
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individuals will be required to rest for 8 hours and 12 blood samples will be drawn from an 
intravenous cannula during the trial. A standardised breakfast, lunch and a buffet evening 
meal will be provided during trials. Subjective appetite ratings will be determined at 30 
minute intervals throughout. Identical procedures will be completed in the exercise trial 
except that during the first trial hour participants will complete 60 minutes of moderate 
intensity treadmill walking/running (60% of maximum oxygen uptake). 
This research will determine the acute impact of exercise on appetite and its key 
physiological regulators. Critically, this investigation will compare the short-term effects of 
exercise on appetite control in lean vs. obese men and women and in doing so will enhance 
knowledge regarding the interaction between obesity, appetite regulation, energy homeostasis 
and exercise. 
Background and rationale 
Globally the prevalence of obesity has reached epidemic levels and continues to escalate. 
Current World Health Organisation (WHO) estimates indicate that 1.5 billion adults are 
overweight, of which 500 million individuals also qualify as obese (WHO, 2012). 
Furthermore, levels of obesity in children and adolescents are now significant and this may 
drive up rates of adult obesity in the future. The adverse health and economic consequences 
associated with being overweight make these statistics a significant cause for concern. 
Consequently there is an urgent need to identify effective preventative and/or management 
strategies. This feat relies upon possessing a comprehensive understanding of the critical 
mechanisms and influences governing energy homeostasis. 
Energy balance and body weight are controlled physiologically by a network of gut, adipose 
and pancreatic derived hormones which regulate energy intake and energy metabolism 
homeostatically on both an acute and chronic basis (Murphy & Bloom, 2006). Specifically, 
on a meal-to-meal basis appetite and food intake are mediated by several circulating gut 
peptides (e.g. ghrelin, peptide YY, GLP-1) which rhythmically control perceptions of pre-
meal hunger and post-meal satiation and satiety. Furthermore, within the long-term, appetite 
and energy homeostasis are also influenced by insulin and leptin, two potent long-term 
signals which suppress appetite and increase energy expenditure. Collectively these signals 
serve to prevent large perturbations in energy balance and therefore help to maintain body 
weight/composition within a healthy/ ‘evolutionally fit’ range. 
Obesity is the result of chronic positive energy balance whereby over-time the energy 
consumed as food and drink surpasses that expended through metabolic processes and 
physical activity. Research has shown that the physiological appetite control system is 
dysfunctional in obese individuals and this predisposes to overconsumption (Batterham et al., 
2006; Cummings et al., 2002; le Roux et al., 2006). In particular, in recent years it has been 
identified that circulating levels of ghrelin, an appetite stimulating hormone, are not 
effectively suppressed after meals in obese individuals (Morpurgo et al., 2003). Moreover, it 
has also been demonstrated that postprandial levels of PYY and GLP-1, two important 
appetite inhibiting signals and mediators of satiation and satiety, are significantly attenuated 
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in comparison with responses in lean individuals (Batterham et al., 2006; le Roux et al., 
2006). In concert, these derangements result in impaired feelings of fullness and satisfaction 
and promote increased food consumption which ultimately perpetuates the obese state. This 
knowledge has fuelled an explosion of research and development activity into a subset of 
obesity pharmacotherapy with the aim of mimicking the body’s own appetite regulatory 
signals/pathways (Field, Chaudhri, & Bloom, 2009). Unfortunately, to date the development 
of drug treatments within this sphere have been unsuccessful due to a combination of lack of 
efficacy and safety concerns. The identification of more natural solutions to this problem is 
therefore welcomed. 
Over half a century ago it was first recognised that being active is important for individuals to 
successfully match energy intake to energy requirements and therefore maintain a healthy 
body weight (Mayer, Roy, & Mitra, 1956). More recently it has been shown that sedentary 
individuals, when compared with their active counterparts, suffer from an impaired appetite 
regulatory system which manifests as an inability to sense and respond to the energy content 
of ingested foods (Long, Hart, & Morgan, 2002). This notion has been confirmed in a six 
week exercise intervention in previously sedentary men and women (Martins, Morgan, 
Bloom, & Robertson, 2007). These researchers observed that exercise training led to an 
improved ability to detect the energy content of ingested foods (preloads) and to subsequently 
respond by altering energy intake at following meals. These findings indicate that exercise 
improves the sensitivity of the appetite control system. Preliminary data suggests that the 
mechanism responsible for these changes is at least partly due to alterations in the circulating 
concentrations of appetite regulatory hormones (acylated ghrelin, PYY and GLP-1) (Martins, 
Robertson, & Morgan, 2010). As yet it is unknown whether such benefits translate into obese 
populations who demonstrate an impaired appetite control system. 
In healthy volunteers several studies have examined the acute impact of single bouts of 
exercise on circulating appetite regulatory hormones (Broom, Batterham, King, & Stensel, 
2009; King, Miyashita, Wasse, & Stensel, 2010; King et al., 2011; King, Burley, & Blundell, 
1994; Martins et al., 2007; Ueda et al., 2009). The consensus from this research suggests that 
acute exercise transiently suppresses appetite and that this is associated with suppressed 
circulating concentrations of ghrelin and increased levels of PYY and GLP-1. To date, very 
little of this research has been conducted in those who are overweight or obese. One study 
has shown that high intensity exercise suppressed ghrelin in obese men to the same extent as 
in lean individuals however ghrelin assessments in this study were limited to merely during 
and immediately after exercise (Marzullo et al., 2008). Another investigation showed that 
circulating levels of PYY and GLP-1 increase during exercise with levels of GLP-1, but not 
PYY, remaining higher for 60 minutes afterwards (Ueda et al., 2009). Both of these studies 
are limited by the brief duration of assessment and most importantly the failure to determine 
post-exercise effects on prandial hormone changes.  
The proposed investigation seeks to compare the effects of a single bout of aerobic exercise 
on appetite perceptions, ad libitum energy intake and circulating levels of key appetite 
regulatory hormones in lean vs. overweight/obese men and women. Subjective appetite 
perceptions will be examined during exercise and for seven hours after. Circulating levels of 
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acylated ghrelin, PYY and GLP-1 will be measured in response to exercise and two 
standardised meals during seven hours after exercise. The effects of exercise on food intake 
will be ascertained by examining energy intake at an ad libitum meal provided six hours after 
exercise. 
This research will extend knowledge about the impact of exercise on appetite regulation and 
energy balance. In particular, this study will determine whether previously reported 
favourable effects translate into real benefits in a population who suffer from impaired 
appetite regulation.  
Objectives 
Primary objective: to investigate the effect of a single bout of exercise on appetite 
regulatory hormones (i.e. acylated ghrelin, PYY3-36, GLP-1) in lean vs. overweight/obese 
men and women. 
Secondary objective: to investigate the effect of a single bout of exercise on subjective 
appetite perceptions and ad libitum energy intake in lean vs. overweight/obese men and 
women.  
Trial design 
This study is a randomised crossover intervention which will require participants to visit the 
laboratory on four occasions. Participants will be recruited and pre-assessed according to the 
‘Risk Definition and Standard Operating Procedures for Exercise Testing’ document (Version 
2, 28/05/2013) and will be tested at either Leicester Diabetes Centre or Loughborough 
University. The four visits will include: 
1. Preliminary visit - ~90 minute visit 
2. Exercise familiarisation - ~90 minute visit 
3. Main experimental trial 1 - ~8.5 h visit 
4. Main experimental trial 2 - ~8.5 h visit 
Each participant will complete two main experimental trials (exercise and control) in a 
counterbalanced order. Each main experimental trial will be separated by at least one-week. 
Participant Flow 
Study visit 1 – Leicester Diabetes Centre or Loughborough University 
Informed consent 
Informed consent will be obtained before any study related procedures commence and only 
after participants have had sufficient time to thoroughly read the participant information sheet 
(always > 48 h). At this point participants will be reminded of the importance to comply with 
dietary and physical activity standardisation. Informed consent will be obtained by a 
designated researcher involved in this study who has undergone consent training and who 
holds an up to date Good Clinical Practice Certificate. Written informed consent will be 
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obtained by means of participant dated signature and dated signature of the individual who 
presented and obtained informed consent. A copy of the signed informed consent form will be 
given to the participants along with a copy of the participant information sheet. The original 
signed form will be retained in the study site file. The informed consent process will be 
undertaken in privacy. 
 
Study questionnaires 
Participants will also be required to complete a set of questionnaires at their first visit. 
Questionnaires will assess participants’ health status (non-validated questionnaire), habitual 
physical activity level (IPAQ, validated questionnaire), physical activity readiness 
questionnaire (PAR-Q, validated questionnaire), food preference and breakfast pattern 
questionnaire (in house – non-validated questionnaire), and dietary habits (Three-Factor 
Eating Questionnaire, validated questionnaire). Participants will also be asked about their 
medical history and consequently a risk SCORE assessment will be calculated. Results from 
these will determine if the participant will need to complete the subsequent exercise test with 
an ECG. Details of this can be found in the ‘Risk Definition and Standard Operating 
Procedures for Exercise Testing’ (Version 2 , 28/05/2013). 
 
Anthropometric Measures and Physical Exam 
Participants’ height, body weight, blood pressure and waist circumference will be measured 
using standard techniques. A suitably qualified member of the research team will complete a 
physical exam on the participant. 
Fasting blood sample 
A fasting venous blood sample to confirm that participants are non-diabetic (fasting glucose 
concentrations < 7 mmol/L, HbA1c <6.5%) will be taken. A cholesterol measurement will 
also be taken. 
Resting ECG 
A suitably qualified member of the research team will perform a 12 lead resting ECG.  
The results from the resting ECG will determine whether the participant is suitable to 
continue in the study.  
Submaximal-incremental treadmill walking/running test 
Participants will complete a submaximal-incremental walking/running test on a motorised 
treadmill. The test will last for 16 minutes and will consist of four, four minute stages. Initial 
treadmill speed will be set according to the fitness of the participant. Treadmill speed will be 
increased every four minutes by 0.5-1.5 km/h (depending on the individual). The treadmill 
gradient will remain at zero throughout the test. Expired air samples will be collected 
continuously throughout the test using an online breath-by-breath gas analysis system. Heart 
rate will be monitored throughout and ratings of perceived exertion (RPE) will be measured 
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at the end of each stage using the Borg scale (Borg, 1973). This test will be used to determine 
the relationship between walking/running speed and oxygen consumption.  
Maximum oxygen uptake test 
Participants’ maximum oxygen uptake will be determined using an incremental treadmill 
protocol whereby participants continue to exercise until volitional exhaustion. During this test 
the speed of the treadmill will remain constant throughout with this being determined by the 
fitness level of the participant. The test will begin with the treadmill gradient set at 1% and 
this will be increased by one per cent at intervals of one minute. The duration of this test will 
be approximately 12 minutes. After the test participants will relax for five minutes before a 
verification procedure is undertaken. For this procedure, participants will be asked to exercise 
at the gradient attained one stage prior to the last stage completed in the maximum oxygen 
uptake test. The test will then continue as per the maximum oxygen uptake test with the 
purpose being to verify that participants obtained a true maximum oxygen uptake value 
(Midgley & Carroll, 2009; Pettitt, Clark, Ebner, Sedgeman, & Murray, 2012). Expired air 
samples will be collected continuously throughout the test using an online breath-by-breath 
gas analysis system. Heart rate, expired air samples and RPE will be taken throughout.  
The information gathered from the submaximal-incremental treadmill walking/running test 
and the maximum oxygen uptake test will allow us to calculate the treadmill speed necessary 
to elicit the desired exercise intensity (60% of maximum oxygen uptake) during the main 
experimental (exercise) trial. 
Following the exercise tests, participants will be provided with refreshments to break the 
overnight fast required for the fasting blood sample. 
The information gathered from the pre-assessment will determine if the participant matches 
all the inclusion criteria, and confirm if they can continue in the study. 
Study visit 2 – Leicester Diabetes Centre or Loughborough University 
Exercise Familiarisation 
In order to ensure that participants can complete the bout of exercise required during the 
exercise main trial, and to familiarise participants with the associated procedures, each 
participant will complete 60 minutes of walking/running on a treadmill at the speed 
calculated to elicit 60% of their maximum aerobic capacity. During this procedure we will 
familiarise participants with the expired gas analysis collection procedures and ratings of 
perceived exertion assessments. 
Dietary and physical activity standardisation 
In order to ensure that strict dietary and physical activity standardisation occurs in the 48 h 
before each main experimental trial a member of the research team will talk participants 
through all of the procedures for recording and subsequently replicating their diet using a 
weighed food record. To assist with this they will then be provided with a set of weighing 
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scales and food record diary. Participants will also be provided with food to consume the 
night before each main trial. This will be a food package containing dried pasta shapes, 
tomato pasta sauce, and chocolate biscuits. The calorie content of this meal will be 
standardised (approximately 750 kcal for males and 674 kcal for females). Instructions on 
how to prepare the meal will be provided.  
Study visit 3 and 4 (main experiment trials) – Leicester Diabetes Centre or 
Loughborough University 
Visits 3 and 4 will be for participants’ main experimental trials (exercise and control) which 
will each last for 8 h (~9am – 5pm). Appendix one provides a schematic illustration of the 
main trial protocol. Prior to each main trial participants will refrain from completing any 
structured form of physical activity or from consuming alcohol or caffeine. Participants will 
also standardise their dietary intake during this period using a weighed food record. Female 
participants with regular menstrual cycles will be tested during days one to eight of the 
follicular phase. All participants will complete both trials on the same day of the week, and 
will not have been overseas for one week prior to the trial days.   
On the control trial participants will arrive at the laboratory at ~8:30am having not eaten 
since 9:00pm the prior evening. An intravenous cannula will then be inserted into an 
antecubital vein to allow repeated blood sampling to occur over the duration of the trial. 
Participants will then rest for ~20 minutes before a baseline blood sample is taken (~9:00am, 
t = 0). Participants will continue to rest in a participant waiting room for the subsequent 8 h, 
the only exception being that during the first trial hour measurements of resting metabolic 
rate will be performed. During the trial participants will be provided with a standardised 
breakfast (t = 1.5 h, energy = 643 kcal for males, 578 kcal for females) and lunch (t = 4 h, 
energy = 750 kcal for males, 674 kcal for females). Breakfast will consist of jam sandwiches, 
fruit and fruit juice. The macronutrient content of this meal will be 72% carbohydrate, 10% 
protein and 18% fat. Lunch will consist of either a tuna and mayonnaise or cheese sandwich, 
with salted crisps, apple and a chocolate muffin. The macronutrient content of this meal will 
be 43% carbohydrate, 32% protein, 25% fat. Seven hours into the trial participants will be 
provided with the opportunity to eat ad libitum from a selection of cold buffet foods over 30 
minutes and food intake will be monitored (See Appendix 2 for a list of foods available to the 
participant). The type and amount of food provided at this meal will be identical between 
main trials and participants will consume this meal within isolation. Food intake at this meal 
will be determined by weighing the amount of food initially provided and that remaining at 
the end of the meal. Manufacturer values will be used to translate this information into actual 
energy intake data. 
 
At 30 minute intervals throughout trials participants will complete a set of appetite rating 
scales to assess subjective perceptions of hunger, fullness, satisfaction and prospective food 
consumption. Scales for meal palatability will also be included at 2 h, 4.5 h and 7.5 h. 
 
Across each main trial visit 12 blood samples will be withdrawn from the cannula. A total of 
208 mL will be collected across the duration of each trial. Blood will be collected into pre-
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cooled monovettes and syringes containing necessary preservatives to ensure sample viability 
for hormone/metabolite biochemical analysis. After each blood withdrawal cannulas will be 
flushed with saline in order to maintain patency. Once blood samples have been collected 
they will immediately be spun in a refrigerated centrifuge (4
o
C) and the plasma will be 
obtained and aliquoted into eppendorf tubes. These samples will then be frozen (initially at -
20
 o
C but then transferred to -80
 o
C) until required for analysis. 
 
Identical procedures will be completed in the exercise trial with the exception that during the 
first trial hour participants will complete 60 minutes of moderate intensity (60% of maximum 
oxygen uptake) walking/running. During exercise heart rate will be monitored continuously 
throughout and ratings of perceived exertion will be ascertained. Expired air samples will 
also be obtained periodically during exercise to monitor the intensity (4 x 1 minute air 
samples). Adjustments to the treadmill speed will be made if necessary. 
Biochemical analysis 
Biochemical analysis of plasma samples will take place at Loughborough University. 
Consequently, samples collected at the Leicester Diabetes Centre (UHL) will be transported 
to the analytical laboratories at Loughborough via a commercial courier. Samples will be 
analysed for hormones known to be important in the neuro-endocrine control of appetite and 
energy balance, as well as a selection of hepatokines. Specifically, acylated and non-acylated 
ghrelin (hunger stimulating) and GLP-1 (appetite inhibiting) will be measured using 
commercially available ELISA kits. PYY3-36 (appetite inhibiting) will be measured using 
radio-immunoassay. Plasma insulin (ELISA) and glucose (colorimetry) will also be measured.  
Statistical analysis 
The statistical aspects of this study have been reviewed by a statistician within our BRU. The 
statistical analysis for this study will be undertaken by members of the research team with 
support being provided by our BRU statistician, Danielle Morris and Laura Gray. 
The power calculation for this study is based on our primary outcome which relates to 
changes in circulating levels of appetite hormones in response to acute exercise. Data 
collected from the present study will be analysed using factorial analysis of variance with two 
important comparisons – BMI (lean vs. overweight/obese) and exercise (or control). To 
perform our power calculation we first obtained effect sizes from previous research of ours 
(King et al., 2011) which examined differences in circulating levels of gut hormones 
(acylated ghrelin and PYY3-36) between an exercise and a control trial (total trial AUC). 
This previous data revealed effect sizes of 0.6. Using this data, and assuming an alpha of 0.05 
and acceptable power of 0.8, the present investigation will require us to recruit 32 males (16 
lean, 16 overweight/obese) and 32 females (16 lean, 16 overweight/obese).  
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Trial participants 
For this study we will recruit 64 participants to the groups identified below. All participants 
will be inactive or moderately active (defined by IPAQ) and between the age of 18 – 50 years.  
 N = 16 Males – lean (BMI 18.5 – 24.9 kg·m2 and waist circumference < 102 cm) 
 N = 16 Males – overweight/obese (BMI 25.0 – 39.9 kg·m2 and waist circumference ≥ 
102cm) 
 N = 16 Female – lean (BMI 18.5 – 24.9 kg·m2 and waist circumference < 88 cm) 
 N = 16 Female – overweight/obese (BMI 25.0 – 39.9 kg·m2 and waist circumference 
≥ 88cm) 
All participants will meet the following inclusion/exclusion criteria. 
Key inclusion criteria 
 18 - 65 years of age 
  Inactive to moderately inactive (Category 1 and Category 2 on IPAQ) 
  Non-diabetic (fasting whole blood capillary glucose < 7.0 mmol/L) and no history of 
diabetes (HbA1c <6.5%) 
 Blood pressure < 160/100 mmHg 
 Weight stable (weight change less than 2kg in last 3 months) 
 If female: 
o Not pregnant 
 
Exclusion criteria 
 Less than 18 or more than 65 years of age 
 Diabetic (fasting whole blood capillary glucose ≥ 7.0 mmol/L, HbA1c ≥6.5%) 
 Smokers 
 Currently following any special diets e.g. low carbohydrate 
 Recent history of infectious disease 
 Presence of gastrointestinal, inflammatory, metabolic, cardiovascular or psychological 
disease 
 Presence of a blood borne virus 
 Abnormal psychological eating tendencies (as determined by the three-factor eating 
questionnaire) 
 Highly active (Category 3 on IPAQ) 
 Shift workers 
 If female: 
o Pregnant 
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Recruitment Strategy 
There will be two opportunities at which potential participants may be identified and 
recruited into the study as follows: 
1) Advertisement within the local community. Study posters and leaflets will be displayed 
in public places and sent to local companies and health care practises. Information on these 
will include a brief overview of the study, key inclusion/exclusion criteria and further contact 
information. After reading these publications, if individuals feel they are eligible to 
participate and would like to know more about the study they will be asked to express their 
interest by telephoning/emailing the research team. 
When contacting the research team, potential participants will be asked to provide contact 
details (email/postal address and telephone number) so that they can be sent a formal study 
invitation letter and participant information sheet. A pre-paid envelope addressed to the 
research team will also be sent to prospective participants. These individuals will be asked to 
complete, tear off, and send back a reply slip to the research team, indicating whether they 
would like to take part in the study.  
2) Recruitment from NHS participant databases. Individuals, who have previously 
consented to be contacted for future diabetes studies within the department, will be contacted 
to take part in INTAKE. Only researchers working on the relevant studies will have access to 
participants' information. These researchers will inform potential participants about the study 
(via telephone/email/mail) and if desired will be sent a study invitation letter and participant 
information sheet. The participant information sheet will ask participants to contact the 
research team (telephone/email/mail) if they are interested in taking part and to return the 
reply slip in a pre-paid envelope that will also be sent to the participants.  
Trial Management 
Definition of end of trial 
The end of trial will be when the last participant has completed the study. 
Discontinuation/withdrawal of study participants 
Each participant has the right to withdraw from the study at any time without giving a reason. 
The research team may also discontinue a participant if they consider necessary e.g. adverse 
event, consent withdrawal, incomplete data collection. 
Source data, data handling and record keeping 
Email correspondence between study investigators and patients, patient reply slips, and notes 
made during telephone correspondence will be considered as source data in this study. Data 
collected at participant study visits will be recorded directly onto a case report form (CRF) 
and this information will be uploaded onto an electronic database. On all study specific 
documents, other than the signed consent form, the participant will be referred to by their 
study ID number, and not by name. Source data will be stored securely in a lockable filing 
247 
cabinets at the Leicester Diabetes Centre/Loughborough University. Only members of the 
research team will have access to these documents. Once the study has been completed data 
will be archived in accordance with local R&D procedures. 
Report writing/publication 
Results from this investigation will be published within internal reports necessary to fulfil the 
requirements of the funding body. Results will also be presented at international conferences 
and published in peer-reviewed academic journals. The chief investigator and lead 
researchers will determine the most appropriate place to publish findings depending on the 
outcomes of the study. Manuscripts will be written by the lead researchers and refined by all 
members of the research team. Authorship will be determined by the chief investigator. 
Definitions and reporting of serious adverse events 
We will follow the University of Leicester guidelines for managing and reporting a SAE or 
SUSAR, which follow those outlined in Good Clinical Practice guidance.  
The following standard definitions will be used in the INTAKE Study. 
Adverse event (or adverse experience): any untoward medical occurrence in a trial subject 
to whom a medicinal product has been administered, including occurrences which are not 
necessarily caused by or related to that product. 
Serious adverse event (SAE) or serious adverse reaction (SDR) is: any adverse event, 
adverse reaction or unexpected adverse reaction, respectively, that: 
(a) results in death 
(b) is life-threatening  
(c) requires hospitalisation or prolongation of existing hospitalisation 
(d) results in persistent or significant disability or incapacity 
(e) consists of a congenital anomaly or birth defect 
Additionally we will also define an event as serious if it is an important and significant 
medical event that may not be immediately life threatening or resulting in death or 
hospitalisation but, based upon appropriate medical judgement may jeopardise the patient or 
may require intervention to prevent one or more outcomes listed above. 
Adverse events which do not fall into these categories are defined as non-serious. 
A Suspected Unexpected serious adverse reaction: an adverse reaction the nature and 
severity of which is not consistent with the information about the medicinal product in the 
summary of product characteristics. 
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Reporting of SAE and timelines 
All SAEs will be reported internally to the R+D office and the sponsor (University of 
Leicester) using appropriate reporting forms, within 24 hours of the study team becoming 
aware of the event. The immediate report may be made orally or in writing and shall be 
followed by a detailed written report of the event. Additional information can be provided if 
requested to the sponsor, main Research Ethics Committee (REC), or R+D (e.g. in the event 
of a death). The principal investigator is responsible for the review and sign off the SAE, or 
in their absence, another member of the team (in order to avoid a delay). 
The sponsor and/or R+D personnel will ensure that all relevant information about a SUSAR 
which occurs during the course of the ACUTE Study and is fatal or life-threatening is 
reported as soon as possible to the main REC not later than seven calendar days after they 
were first aware of the reaction. Any additional relevant information will be sent within eight 
days of the report. The sponsor and/ or R+D will ensure that a SUSAR which is not fatal or 
life-threatening is reported to the main REC no later than 15 calendar days after they were 
first aware of the reaction. 
The investigator site file will contain documentation for: 
- SAE, SAR and SUSAR reports 
- Evidence of submission of SAEs to the sponsor within 24 hours of the team becoming 
aware of an event 
- Evidence of timely SUSAR submission to the main REC.  
Ethics 
Declaration of Helsinki 
The Investigators will ensure that this study is conducted in full conformity with the current 
revision of the Declaration of Helsinki (last amended October 2000, with additional footnotes 
added 2002 and 2004). 
ICH Guidelines for Good Clinical Practice 
The Investigator will ensure that this study is conducted in full conformity with relevant 
regulations and with the ICH Guidelines for Good Clinical Practice (CPMP/ICH/135/95) July 
1996. 
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Approvals 
The protocol, informed consent form, study invitation letter, participant information sheet and 
any proposed advertising material will be submitted to an appropriate Research Ethics 
Committee and host institution(s) for written approval. The Investigator will submit and, 
where necessary, obtain approval from the above parties for all substantial amendments to the 
original approved documents.    
Participant Confidentiality 
The trial staff will ensure that the participants’ anonymity is maintained at all times. The 
participants will be identified only by participant ID number on participant result sheets and 
any electronic database. All documents will be stored securely and only accessible by trial 
staff and authorised personnel. The study will comply with the Data Protection Act which 
requires data to be anonymised as soon as it is practical to do so.  
Finance 
The NIHR Biomedical Research Unit at University Hospitals of Leicester and Loughborough 
University is funded by the National Institute for Health Research and this investigation is 
being carried out as part of our BRU. 
The total costs for this study are displayed below. 
Assay costs (acylated ghrelin, PYY3-36, 
GLP-1) 
£24,171 
Consumables (blood collection equipment 
and blood tubes) 
£2,007 
Sample transportation £500 
Study food costs £1600 
Participant transport costs £3840 
Total £32,118 
Insurance 
NHS insurance/indemnity scheme will apply to this trial to meet the potential legal liability of 
investigators arising from harm to participants in the conduct of the research. 
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Appendices 
Appendix 1: Trial Visit Summary 
 
 
 
 
 
 
 
 
Appendix 2: Buffet food items 
White bread 
Brown bread 
Cheddar cheese 
Ham 
Tuna 
Salted crisps 
Mayonnaise 
Margarine 
Apple 
Orange 
Banana 
Chocolate rolls (Mini-rolls) 
Muffins (chocolate, chocolate chip) 
Cookies 
Cereal bars (Nutrigrain) 
 
B B B B B 
0 1 2 3 4 5 6 7 8 
(9am) (5pm) Time in hours (time of day) 
B B B B B B B 
Exercise or rest 
Test meal 
Ad Libitum meal 
B Blood sample 
* 
VAS to be completed every 30 minutes 
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APPENDIX N 
 
 
Does an acute bout of exercise alter appetite hormones, appetite perceptions and energy 
intake? 
Chief Investigator: Professor Melanie Davies 
Investigators: Ms Jessica Douglas, Dr David Stensel, Dr James King, Professor Myra 
Nimmo, Mr Andrew Jackson, Dr David Webb 
 
This work is being carried out as part of a research project supported by the School of Sport, 
Exercise and Health Sciences, Loughborough University and the NIHR Leicester-
Loughborough Biomedical Research Unit in Diet, Lifestyle & Physical Activity. Additionally 
this work will contribute to the partial fulfilment of Jessica Douglas’ PhD.  
 
You have been invited to take part in a research study. Before you decide whether to take part 
it is important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with friends and 
relatives if you wish to. If anything is not clear or you would like more information, please do 
not hesitate to contact us. Take time to decide whether or not you wish to take part. If you 
decide to take part you will be given a copy of your consent form and this leaflet. 
 
What is the purpose of the study? 
Energy balance is the difference between the energy we take in, and the energy we use over 
the course of a day. When the energy we take in is more than the energy we use up, it results 
in weight gain. To lose weight we can either increase the amount of exercise we do or 
decrease the amount of food we eat. It has been suggested that there is an interaction between 
the amount of exercise we do and what we eat. One off exercise sessions in healthy weight 
individuals have previously been shown to alter how hungry we feel and how much we eat. 
As exercise is often prescribed as a method for weight management it is important to know in 
what way it affects what we eat, and if this will lead to weight loss. 
The purpose of this study is to see how a single exercise session influences energy balance in 
both lean and non-lean individuals.   
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What does the study involve? 
Preliminary Visit 
Before you formally enter the study, you will be asked to attend either Loughborough 
University or the Leicester Diabetes Centre, in the morning, for a screening visit to ensure 
that you are eligible to participate. We will ask you not to eat or drink anything, other than 
water for 10 hours before this visit. This is in preparation for your visit and does not mean 
you have to take part. During this screening visit, which will take approximately 90 minutes, 
we will (i) ask you to sign a consent form following an explanation of the study, (ii) ask you 
to complete a set of questionnaires regarding your health status and history, physical activity 
habits and ability to exercise, food preference and breakfast patterns, and dietary habits (iii) 
take measurements of height, weight, waist circumference and blood pressure (iv) complete a 
physical examination (v) take a blood sample from your arm to measure sugar and cholesterol 
levels (vi) complete a resting and/or exercising electrocardiogram (vii) complete two 
walking/running exercise tests to determine your fitness. The results of your blood test, 
resting and/or exercising electrocardiogram, and information collected from the 
questionnaires during this screening visit will help to determine if you are suitable to take 
part in the study.  
 
Familiarisation Visit 
If you are suitable to participate, you will then be invited to return for a ‘familiarisation visit’ 
at either Loughborough University or the Leicester Diabetes Centre. Here you will be 
familiarised with the main trial procedures. This will include a 60 minute walk/run on a 
treadmill at moderate intensity. You will also be familiarised with expired air collection 
procedures and perceived exertion assessment. 
 
During this visit you will also be shown how to record and replicate your diet for the 48 
hours before the main trial visits using a weighed food diary. You will also be provided 
with food and instructions on how to cook a meal to eat the night before each main trial. 
 
Main Trial Visits 
Following the preliminary visits you will be invited back to either Loughborough University 
or the Leicester Diabetes Centre to complete two main experimental trials. These will include 
an exercise trial and control trial. Each visit will require a time commitment of 8.5 h. 
 
For the exercise trial you will report to a lab at 8.30 am after consuming your standardised 
evening meal at 9.00 pm and having fasted overnight and not consumed breakfast. At 9.00 
am you will perform 60 minutes of continuous walking/running at moderate intensity. You 
will be provided with a breakfast meal at 10:30 am and lunch at 1.00 pm. A free choice cold 
buffet meal will be provided at 4.00 pm. For the remainder of the trial you will rest within the 
laboratory (reading, watching TV/DVDs, playing computer games, working at a computer 
etc.). Over the course of the day we will ask you to complete some questionnaires about your 
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0 1 2 3 4 5 6 7 
B B B B B B B 
8 
(9 am) (5 pm) Time in hours (time of day) 
Exercise or rest 
Breakfast 
or lunch 
Buffet meal 
B Blood sample 
* 
Appetite questionnaires to be completed every 30 minutes 
 
appetite. We will also collect twelve blood samples from a cannula positioned in the arm 
(approximately 41 teaspoons / 208mls of blood in total). 
In the control trial procedures will be identical to the above trials but there will be no 
exercise. 
Summary 
In total the time commitment for this study will be; 
Preliminary Visit ~1.5 hours 
Exercise Familiarisation ~1.5 hours 
Main Experimental Trial # 1 ~8.5 hours 
Main Experimental Trial # 2 ~8.5 hours 
Throughout the study you should carry on your everyday life as normal. However, we will 
ask you not to take part in any other research studies, or give a blood donation over this time. 
The preliminary visits and experimental trials will be arranged at a time to suit you.  
 
You will also be asked to fast 10 hours the night before the ‘Preliminary’ visit, and from 9 
pm the night before each main trial. You will also be asked to refrain from strenuous physical 
activity, alcohol and caffeine for the 48 hours before the main experimental trials. 
 
Trial Visit summary 
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What will happen to the samples that are collected from me? 
The samples collected from you will be analysed for a number of hormones involved in the 
regulation of energy balance. These samples will be kept frozen in anonymised form until the 
analysis is completed. After this point your samples will either be discarded or will be stored 
frozen for potential use in future research if you consent to this additional aspect. This option 
will be provided on the study informed consent form. 
 
Why have I been asked to take part? 
You may be suitable to take part in the study if you are between the age of 18 and 65; you 
have a body mass index between 18.5 – 24.9 or 25.0 – 39.9 kg/m2, are either not active or 
moderately active and can commit to attending the laboratory for all the study visits.  
 
Do you have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason.  
 
The data that we collect during the course of this study will be kept for 10 years. Our records 
of your personal information e.g. contact details, will be deleted 3-6 months after the study.  
 
What are the side effects of any treatment or procedures received when taking part? 
Research studies can involve some risks, not all of which may be currently known. The 
insertion of a cannula can be uncomfortable. Blood sampling also carries a small risk of 
causing inflammation of the vein, tenderness of the surrounding area and bruising, however 
the likelihood of these occurring are minimal.  
 
The exercise bouts are performed at a moderate intensity and your heart rate will be 
monitored throughout. As you are healthy there is unlikely to be any side effects. All study 
procedures are carried out by experienced staff within our research group. At all times staff 
(doctors, other suitably trained healthcare practitioner, or member of research staff) fully 
trained in basic first aid and cardiac life support will be on hand.  
 
If you do suffer any other symptoms or side-effects outside of the lab you should report them 
to Jessica Douglas immediately (contact details below), or another member of the research 
team. 
 
What are the exclusion criteria for this study? 
Unfortunately you would not be suitable to take part if you are very active, have any medical 
problems including diabetes or have a blood borne virus (e.g. AIDs, Hepatitis B), take certain 
regular medication, smoke or could be pregnant (pregnancy tests can be provided if there is a 
possibility of this). 
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What are the possible disadvantages and risks of taking part? 
Healthy volunteers have been chosen for this study. However, if during the screening or study 
visits we find any abnormal results or a medical condition of which you were unaware, we 
will discuss the findings with you and all the relevant information will be made available to 
you. Contact with your GP will be made with your permission. We will be measuring your 
blood glucose levels during the study and it is possible that we could discover that you have 
diabetes. In the event that this occurs, a medical doctor who specialises in diabetes will be 
available to discuss this condition with you, if you so wish. Be advised, that future insurance 
status e.g. for life insurance or private medical insurance, could be affected by these 
diagnoses. 
 
Confidentiality: 
All data will be dealt with under the strictest of guidelines and according to the Data 
Protection Act (1998). All of your data will be anonymised and will only be discussed 
amongst the lead investigators. 
 
Will I get any payment and/or expenses? 
You will be reimbursed for any travel costs incurred by you throughout the study. Please 
keep any receipts. 
 
Further Information: 
If you require any further information or you would like to discuss the study further please 
contact: 
Jessica Douglas – J.Douglas@lboro.ac.uk 01509 226352 
 
The University has a policy relating to Research Misconduct and Whistle Blowing which is 
available online at: 
http://www.lboro.ac.uk/admin/committees/ethical/Whistleblowing(2).html 
Who has reviewed this study? 
Top protect your safety, rights, well-being and dignity, all research involving patients is 
looked at by an independent group of people, called a Research Ethics Committee. This study 
has been reviewed by East Midlands – Nottingham 1 National Research Ethics committee in 
accordance with local regulations. 
 
What if I am harmed by the study? 
It is very unlikely that you would be harmed by taking part in this type of research study. 
However, if you wish to complain or have any concerns about the way you have been 
approached or treated in connection with the study, you should ask to speak to Professor 
Melanie Davies (01162 586481) who will do their best to answer your questions. If you 
remain unhappy and wish to address your concerns or complaints on a formal basis, you 
should contact Patient Information & Liaison Service at pils.complaints.compliments@uhl-
tr.nhs.uk, The Firs, c/o Glenfield Hospital, Groby Road, Leicester, LE 3 9QP. Freephone: 
0808 1788337. 
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Consent Form 
Participant ID: _________________ 
Please read this form carefully before initialling each box and signing at the end. 
 
By initialling the box at the end of each statement: 
 I confirm that I have read and understood the Participant Information 
Sheet (Version 4 - 15/09/2014) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
 I understand that following the consent procedure I may be excluded from 
the study if I do not meet the inclusion criteria. 
 
 I understand that my participation is voluntary and I am free to withdraw 
at any time without giving a reason, without my medical care or legal 
rights being affected. 
 
 I understand that relevant sections of my medical notes and/or study data 
may be looked at by responsible individuals from the research team, from 
regulatory authorities, the sponsor or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
 I agree to being contacted with details of future research into diabetes and 
for my details to be stored on a NHS computer for this purpose. 
 
 I consent for my samples to be transported to Loughborough University in 
anonymised form for biochemical analysis. 
 
 I consent for my identifiable details i.e. name, address, email, telephone 
number to be stored on secure computers at Loughborough 
University/UHL during the course of this research.  
Yes No 
Yes No 
Please initial box 
Yes No 
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 I consent for my blood samples to be used in future research and 
understand that if they are used for this purpose my samples will be fully 
anonymised. 
 
 I agree to my GP being informed of my results. 
  
 I agree to take part in the above study. 
 
 
Participant Name: ____________ Date: DD/MM/YYYY Signature: _____________ 
Name of person     
taking consent:    ____________ Date: DD/MM/YYYY Signature: _____________ 
  
Yes No 
Yes No 
Yes No 
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APPENDIX P 
Dear FIRST NAME, 
Re: Invitation to participate in the INTAKE study. 
I am enclosing an information sheet giving details of the INTAKE study. Please take the time to read 
through this as it explains what the study involves. 
If you would like to participate in the study, please complete and sign the enclosed reply slip and 
return it in the pre-paid envelope provided. The study team will then contact you directly to arrange a 
preliminary visit. 
If you feel that you would like any further information before completing the documentation, please 
contact the team on the email address or phone number provided above. 
Yours Sincerely 
 
 
Jessica Douglas 
  
Leicester-Loughborough Diet, Physical Activity 
 & Lifestyle Biomedical Research Unit 
Loughborough University,  
Ashby Road, Loughborough, LE11 3TU 
Tel : +44 (0) 1509 226445 
Email: J.Douglas@lboro.ac.uk 
Web: http://www.ll.dlpa.bru.nihr.ac.uk/ 
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APPENDIX Q 
[Insert name] 
[Insert 1st line address] 
[Insert 2
nd
 line address] 
[Insert town] 
[Insert postcode] 
[Insert date] 
 
Dear [Insert Name], 
 
Re: The acute effects of exercise on appetite regulatory hormones, appetite perceptions and ad libitum 
energy intake in lean vs. obese men and women (INTAKE). 
Thank you for agreeing to take part in our study. 
Please find below details for your preliminary appointment. If for any reason you cannot keep the 
appointment (or if you would like to change the date or time) please contact us on the number above. 
Appointment Date:  [Insert day, date] 
Time:  [Insert time] 
Location: [Clyde Williams Building, Loughborough University, Epinal Way, Loughborough, 
LE11 3TU / Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, LE5 
4PW] (delete as appropriate/insert relevant map) 
 
Please find enclosed a map. 
Your appointment will take approximately 90 minutes. 
Leicester-Loughborough Diet, Physical Activity 
 & Lifestyle Biomedical Research Unit 
Loughborough University,  
Ashby Road, Loughborough, LE11 3TU 
Tel : +44 (0) 1509 …… 
Fax : +44 (0) 1509 …… 
Email: …@lboro.ac.uk 
Web: http://www.ll.dlpa.bru.nihr.ac.uk/ 
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You will need to fast from the night before, so we would ask that no food be eaten after 11.00 pm the 
night before the preliminary appointment and that only water is consumed before your visit. This is in 
preparation for your first visit and does not mean that you have to take part. 
Drinks and biscuits will be provided for you after the appointment. Could we please ask you to bring 
along a list of any current medication that you are taking.  
Yours faithfully 
 
 
Study Co-Ordinator 
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[Insert name] 
[Insert 1st line address] 
[Insert 2
nd
 line address] 
[Insert town] 
[Insert postcode] 
[Insert date] 
 
Dear [Insert Name], 
 
Re: The acute effects of exercise on appetite regulatory hormones, appetite perceptions and ad libitum 
energy intake in lean vs. obese men and women (INTAKE). 
 
Thank you for taking part in our study. 
 
Please find below details for your familiarisation appointment. If for any reason you cannot keep the 
appointment (or if you would like to change the date or time) please contact us on the number above. 
 
Appointment Date:  [Insert day, date] 
Time:  [Insert time] 
Location: [Clyde Williams Building, Loughborough University, Epinal Way, Loughborough, 
LE11 3TU / Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, LE5 
4PW] (delete as appropriate/insert relevant map)  
 
Please find enclosed a map. 
 
Your appointment will take approximately 90 minutes. 
 
Leicester-Loughborough Diet, Physical Activity 
 & Lifestyle Biomedical Research Unit 
Loughborough University,  
Ashby Road, Loughborough, LE11 3TU 
Tel : +44 (0) 1509 …… 
Fax : +44 (0) 1509 …… 
Email: …@lboro.ac.uk 
Web: http://www.ll.dlpa.bru.nihr.ac.uk/ 
 
264 
Drinks and biscuits will be provided for you after the appointment. Please bring with you a set of 
clothes comfortable to exercise in. Showers will be available for you to use following the trial, so 
please bring a towel if you would like to shower before leaving.  
 
 
Yours faithfully 
 
 
Study Co-Ordinator 
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[Insert name] 
[Insert 1st line address] 
[Insert 2
nd
 line address] 
[Insert town] 
[Insert postcode] 
[Insert date] 
 
Dear [Insert Name], 
 
Re: The acute effects of exercise on appetite regulatory hormones, appetite perceptions and ad libitum 
energy intake in lean vs. obese men and women (INTAKE). 
 
Thank you for taking part in our study. 
 
Please find below details for your resting trial appointment. If for any reason you cannot keep the 
appointment (or if you would like to change the date or time) please contact us on the number above. 
 
Appointment Date:  [Insert day, date] 
Time:  [Insert time] 
Location: [Clyde Williams Building, Loughborough University, Epinal Way, Loughborough, 
LE11 3TU / Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, LE5 
4PW] (delete as appropriate/insert relevant map) 
 
Please find enclosed a map. 
 
Your appointment will take approximately 8.5 hours. 
 
You will need to fast the night before this visit, so we would ask that you eat the provided meal before 
9.00 pm and no other food be consumed after this time. Only water should be drunk before your visit.  
Leicester-Loughborough Diet, Physical Activity 
 & Lifestyle Biomedical Research Unit 
Loughborough University,  
Ashby Road, Loughborough, LE11 3TU 
Tel : +44 (0) 1509 …… 
Fax : +44 (0) 1509 …… 
Email: …@lboro.ac.uk 
Web: http://www.ll.dlpa.bru.nihr.ac.uk/ 
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Could we please ask you to record your diet and physical activity levels for 48 hours before this visit. 
This is to ensure that you can replicate your diet for 48 hours before both main trials. Your evening 
meal will have been provided to you at the familiarisation appointment. Please refrain from alcohol, 
caffeine and strenuous physical activity in the 48 hours before this visit. These points are very 
important in order to prevent variables influencing the study findings and these will be discussed in 
depth at the familiarisation trial. 
 
If you live within one mile of the laboratory you should walk in slowly on the morning of the 
appointment. Please do not run or cycle. If you live more than one mile from the laboratory then you 
should drive in. If you do not have access to a car please tell us and we will arrange for you to be 
collected. 
 
We ask that you bring with you, your completed food diary [and weighing scales] (delete as 
appropriate). 
 
 
Yours faithfully 
 
 
Study Co-Ordinator 
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[Insert name] 
[Insert 1st line address] 
[Insert 2
nd
 line address] 
[Insert town] 
[Insert postcode] 
[Insert date] 
 
Dear [Insert Name], 
 
Re: The acute effects of exercise on appetite regulatory hormones, appetite perceptions and ad libitum 
energy intake in lean vs. obese men and women. 
 
Thank you for taking part in our study. 
 
Please find below details for your exercise trial appointment. If for any reason you cannot keep the 
appointment (or if you would like to change the date or time) please contact us on the number above. 
 
Appointment Date:  [Insert day, date] 
Time:  [Insert time] 
Location: [Clyde Williams Building, Loughborough University, Epinal Way, Loughborough, 
LE11 3TU / Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, LE5 
4PW] (delete as appropriate) 
 
Your appointment will take approximately 8.5 hours. 
 
You will need to fast the night before this visit, so we would ask that you eat the provided meal before 
9.00 pm and no other food be consumed after this time. Only water should be drunk before your visit.  
Leicester-Loughborough Diet, Physical Activity 
 & Lifestyle Biomedical Research Unit 
Loughborough University,  
Ashby Road, Loughborough, LE11 3TU 
Tel : +44 (0) 1509 …… 
Fax : +44 (0) 1509 …… 
Email: …@lboro.ac.uk 
Web: http://www.ll.dlpa.bru.nihr.ac.uk/ 
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Could we please ask you to record your diet and physical activity levels for 48 hours before this visit. 
This is to ensure that you can replicate your diet for 48 hours before both main trials. Your evening 
meal will have been provided to you at the familiarisation appointment. Please refrain from alcohol, 
caffeine and strenuous physical activity in the 48 hours before this visit. These points are very 
important in order to prevent variables influencing the study findings and these will be discussed in 
depth at the familiarisation appointment. 
 
If you live within one mile of the laboratory you should walk in slowly on the morning of the 
appointment. Please do not run or cycle. If you live more than one mile from the laboratory then you 
should drive in. If you do not have access to a car please tell us and we will arrange for you to be 
collected. 
We ask that you bring with you, your completed food diary [and weighing scales] (delete as 
appropriate), a set of clothes comfortable to exercise in and a towel as showers are available for you to 
use following the exercise. 
 
 
Yours faithfully 
 
 
Study Co-Ordinator 
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APPENDIX S 
 
Health Screen Questionnaire for Study Volunteers 
As a volunteer participating in a research study, it is important that you are currently in good 
health and have had no significant medical problems in the past. This is (i) to ensure your 
own continuing well-being and (ii) to ensure study data collected is valid. 
If you have a blood borne virus, or think that you may have one, please do not take part in 
this research. 
 
Please complete this brief questionnaire to confirm your fitness to participate: 
 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise Yes  No  
(b) attending your general practitioner Yes  No  
(c) on a hospital waiting list Yes  No  
 
2. In the past two years, have you had any illness which required you to: 
(a) consult your GP .................................................. Yes 
 
No  
(b) attend a hospital outpatient department ............. Yes  No  
(c) be admitted to hospital  ...................................... Yes  No  
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3. Have you ever had any of the following: 
(a) Convulsions/epilepsy Yes  No  
(b) Asthma Yes  No  
(c) Eczema Yes  No  
(d) Diabetes Yes  No  
(e) A blood disorder Yes  No  
(f) Head injury Yes  No  
(g) Digestive problems Yes  No  
(h) Heart problems Yes  No  
(i) Problems with bones or joints Yes  No  
(j) Disturbance of balance/coordination Yes  No  
(k) Numbness in hands or feet Yes  No  
(l) Disturbance of vision Yes  No  
(m) Ear / hearing problems Yes  No  
(n) Thyroid problems Yes  No  
(o) Kidney or liver problems Yes  No  
(p) Allergy to nuts Yes  No  
 
4. Has any, otherwise healthy, member of your family under the 
age of 35 died suddenly during or soon after 
exercise?  ..................................................................... 
Yes  No  
 
If YES to any question, please describe briefly if you wish (e.g. to confirm problem 
was/is short-lived, insignificant or well controlled.) 
......................................................................................................................................................
......................................................................................................................................................
......................................................................................................... 
5. Allergy Information 
(a) are you allergic to any food products? Yes  No  
(b) are you allergic to any medicines? Yes  No  
(c) are you allergic to plasters? Yes  No  
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If YES to any of the above, please provide additional information on the allergy 
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
 
6. Additional questions for female participants 
(a) are your periods normal/regular?  .......................  Yes  No  
(b) are you on “the pill”?  .........................................  Yes  No  
(c) could you be pregnant?    ....................................  Yes  No  
(d) are you taking hormone replacement therapy 
(HRT)? 
Yes  No  
 
7. Please provide contact details of a suitable person for us to contact in the event of any 
incident or emergency. 
 
Name:……………………………………………………………………………………….… 
 
Telephone Number:………………………………………………………………………… 
 
Work  Home  Mobile  
 
Relationship to Participant:…………………………………………………………………. 
 
8. Are you currently involved in any other research studies at the University or 
elsewhere? 
 Yes  No  
 
If yes, please provide details of the study 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
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Physical Activity Readiness Questionnaire (PAR-Q) 
For most people, physical activity should not pose any problems or hazard. PAR-Q has been 
designed to identify the small number of adults for whom physical activity might be 
inappropriate or those who should have medical advice concerning the type of activity most 
suitable for them. 
Common sense is your best guide in answering these few questions. Please read carefully and 
check YES or NO opposite the question if it applies to you. If yes, please explain. 
QUESTION YES NO 
1. Has your doctor ever said you have heart trouble? If yes, please state:  
 
 
  
2. Do you frequently have pains in your heart and chest? If yes, please state: 
  
 
  
3. Do you often feel fain or have spells of severe dizziness? If yes, please state:  
 
 
  
4. Has a doctor ever said your blood pressure was too high? If yes, please state:  
 
 
  
5. Has your doctor ever told you that you have a bone or joint problem(s), such as 
arthritis that has been aggravated by exercise, or might be made worse with exercise? 
If yes, please state:  
 
  
6. Is there a good physical reason, not mentioned here, why you should not follow an 
activity program even if you wanted to? If yes, please state:  
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7. Are you or have you been pregnant in the last 6 months? 
 
  
8. Do you suffer from any problems of the lower back, i.e., chronic pain, or 
numbness? 
If yes, please state:  
 
  
9. Are you currently taking any medications? If Yes, please specify. 
 
  
10. Do you currently have a disability or a communicable disease? If yes, please 
state:  
 
  
 
If you answered NO to all questions above, it gives a general indication that you may 
participate in physical and aerobic fitness activities. The fact that you answered NO to the 
above questions, is no guarantee that you will have a normal response to exercise. If you 
answered Yes to any of the above questions, then you may need written permission from a 
physician before participating in physical and aerobic fitness activities. 
 
 
__________________        __________________       __________________ 
Print Name                   Signature                                  Date                 
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Food Preferences and Breakfast Pattern Questionnaire 
 
Food Preferences 
Please circle the number which best describes your liking of the following foods: 
 
Wholemeal Bread 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Margarine 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Strawberry Jam 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Banana 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Orange Juice 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
White Bread 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Tuna 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
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Mayonnaise 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Cheddar Cheese 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Ready Salted Crisps 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Apple 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Chocolate Muffin 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Ham 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Orange 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Mini-Rolls 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Double Chocolate Muffins 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Chocolate Chip Muffins 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Chocolate Chip Cookies 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
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Nutrigrain Cereal Bars 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Pasta 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
Tomato Pasta Sauce 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
 
KitKat 
(Dislike extremely)    1    2    3    4    5    6    7    8    9    10     (Like extremely) 
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Breakfast Patterns 
Please answer the following questions regarding your breakfast eating habits: 
 
 
Do you normally consume breakfast? 
 
 
What do you normally consume for breakfast? 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
  
Yes No 
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Three Factor Eating Questionnaire 
 
Part 1 - please answer true/false: 
1. When I smell a sizzling steak or see a juicy piece of meat, I find it very difficult to 
keep from eating, even if I have just finished a meal 
True □  False □ 
2. I usually eat too much at social occasions, like parties and picnics 
True □  False □ 
3. I am usually so hungry that I eat more than three times a day 
True □  False □ 
4. When I have eaten my quota of calories, I am usually good about not eating any 
more 
True □  False □ 
5. Dieting is too hard for me because I just get too hungry 
True □  False □ 
6. I deliberately take small helpings as a means of controlling my weight 
True □  False □ 
7. Sometimes things just taste so good that I keep on eating even when I am no 
longer hungry 
True □  False □ 
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8. Since I am often hungry, I sometimes wish that while I am eating, an expert 
would tell me that I have had enough or that I can have something more to eat 
True □  False □ 
9. When I am anxious, I find myself eating 
True □  False □ 
10. Life is too short to worry about dieting 
True □  False □ 
11. Since my weight goes up and down, I have been on weight reducing diets more 
than once 
True □  False □ 
12. I often feel so hungry that I just have to eat something 
True □  False □ 
13. When I am with someone who is overeating, I usually overeat too 
True □  False □ 
14. I have a pretty good idea of the number of calories in common food 
True □  False □ 
15. Sometimes when I start eating, I just can’t seem to stop 
True □  False □ 
16. It is not difficult for me to leave something on my plate 
True □  False □ 
17. At certain times of the day, I get hungry because I have gotten used to eating 
then 
True □  False □ 
18. While on a diet, if I eat food that is not allowed, I consciously eat less for a period 
of time to make up for it 
True □  False □ 
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19. Being with someone who is eating often makes me hungry enough to eat also  
True □  False □ 
20. When I feel blue, I often overeat 
True □  False □ 
21. I enjoy eating too much to spoil it by counting calories or watching my weight 
True □  False □ 
22. When I see a real delicacy I often get so hungry that I have to eat it right away 
True □  False □ 
23. I often stop eating when I am not really full as a conscious means of limiting 
what I eat 
True □  False □ 
24. I get so hungry that my stomach often feels like a bottomless pit 
True □  False □ 
25. My weight has hardly changed at all in the last ten years 
True □  False □ 
26. I am always hungry so it is hard for me to stop eating before I finish all the food 
on my plate 
True □  False □ 
27. When I feel lonely, I console myself by eating 
True □  False □ 
28. I consciously hold back at meals in order not to gain weight 
True □  False □ 
29. I sometimes get very hungry late in the evening or at night 
True □  False □ 
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30. I eat anything I want, anytime I want 
True □  False □ 
31. Without even thinking about it, I take a long time to eat 
True □  False □ 
32. I count calories as a conscious means of controlling my weight 
True □  False □ 
33. I do not eat some foods because they make me fat 
True □  False □ 
34. I am always hungry enough to eat at any time 
True □  False □ 
35. I pay a great deal of attention to changes in my figure 
True □  False □ 
36. While on a diet, if I eat a food that is not allowed, I often then splurge and eat 
other high calorie foods 
True □  False □ 
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Part 2 - Please circle the appropriate answer: 
37. How often are you dieting in a conscious effort to control your weight? 
1 (rarely)   2(sometimes)   3(usually)   4(always) 
38. Would a weight fluctuation of 5 lbs affect the way you live your life? 
1(not at all)   2(slightly)   3(moderately)   4(very much) 
39. How often do you feel hungry? 
1(only at meal times)   2(sometimes between meals)   3(often between meals)   4(almost 
always) 
40. Do your feelings of guilt about overeating help you to control your food intake? 
1(never)   2(rarely)   3(often)   4(always) 
41. How difficult would it be for you to stop eating half way through dinner and not 
eat again for four hours? 
1(easy)   2(slightly difficult)   3(moderately difficult) 4(very difficult) 
42. How conscious are you of what you are eating? 
1(not at all)   2(slightly)   3(moderately)   4(extremely) 
43. How frequently do you avoid ‘stocking up’ on tempting foods? 
1 (almost never)   2(seldom)   3(usually)   4(almost always) 
44. How likely are you to shop for low calorie foods? 
1(unlikely)   2(slightly unlikely) 3(moderately likely)   4(very likely) 
45. Do you eat sensibly in front of others and splurge alone? 
1(never)   2(rarely)   3(often)   4(always) 
46. How likely are you to consciously eat slowly in order to cut down on how much 
you eat? 
1(unlikely)   2(slightly likely)   3(moderately likely)   4(very likely) 
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47. How frequently do you skip desert because you are no longer hungry? 
1(almost never)   2(seldom)   3(at least once a week)   4(almost every day) 
48. How likely are you to consciously eat less than you want? 
1(unlikely)   2(slightly likely)   3(moderately likely)   4(very likely) 
49. Do you go on eating binges though you are not hungry? 
1(never)   2(rarely)   3(sometimes)   4(at least once a week) 
50. On a scale of 0-5, where 0 means no restraint in eating (eating whatever you 
want, whenever you want it) and 5 means total restraint (constantly limiting food 
intake and never ‘giving in’), what number would you give yourself? 
0 
Eat whatever you want, whenever you want it 
1 
Usually eat whatever you want, whenever you want it 
2 
Often eat whatever you want, whenever you want it 
3 
Often limit food intake, but often ‘give in’ 
4 
Usually limit food intake, rarely ‘give in’ 
5 
Constantly limiting food intake, never ‘give in’ 
 
51. To what extent does this statement describe your eating behaviour? ‘I start 
dieting in the morning, but because of a number of things that happen during the 
day, by evening I have given up and eat what I want, promising myself to start 
dieting again tomorrow.’ 
 
1(not like me)   2(little like me)   3(pretty good description of me) 
4(describes me perfectly) 
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APPENDIX U 
White bread 
Brown bread 
Cheddar cheese 
Ham 
Tuna 
Salted crisps 
Mayonnaise 
Margarine 
Apple 
Banana 
Chocolate rolls (Mini-rolls) 
Muffins (chocolate, chocolate chip) 
Cookies 
Cereal bars (Nutrigrain) 
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